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Summary 
 
This thesis reports the synthesis, the characterization and the biological evaluation of new 
classes of metal-porphyrin conjugates for potential bio-medical applications. 
[Ru([9]aneS3)(N-N)(L)][X]n where N-N = nitrogen chelating ligand such as ethane-1,2-
diamine (en) orbpy, L = S-dmso, Cl and X = CF3SO3 or PF6, n = 2 or 1 respectively),  
[Ru([9]aneN3)(dmso-S)2Cl]Cl, fac-[99mTc (CO)3(H2O)3]+ and [NEt4]2 fac-[ReBr3(CO)3] were 
chosen as metal fragments. 
 
In the first section we describe different synthetic approaches to the preparation of porphyrin 
conjugates with Ru(II) coordination compounds. 
Ru (II) fragments were chosen they have shown a promising anticancer activity both in vitro 
and in vivo, in murine models. 
Water solubility in an important feature for biomedical application but usually porphyrins are 
fairly or not water soluble. The conjugation of a metal fragment to a porphyrin, beside 
increasing the solubility of the porphyrin macrocycle, is an intriguing alternative for making 
water soluble compounds that are expected to combine the cytotoxicity to the metal fragment 
to the phototoxicity of the porphyrins for an additive antitumor effect. 
We varied the number and charge of the peripheral Ru fragments, and described conjugates 
whose total charge ranges from +4 to +8. We showed that the connection can occur through a 
single coordination bond (N(pyridyl)–Ru) or through multiple coordination bond (through a 
chelating bpy unit). 
We demonstrated that meso-pyridylporphyrins (PyPs), besides being synthetically more 
affordable, allow to tune the geometry of the conjugates. 
We showed that in the series of porphyrins with peripheral bpy units at meso positions, it is 
possible to vary the metal fragment and the length and the flexibility of the connectors 
between the bpyAc peripheral moieties and the meso C atoms to obtain compounds with 
different solubility  
Finally some or those conjugates were evaluated as  potential PDT agents. 
Singlet oxygen quantum yield was evaluated for all of them as useful parameter. 
The in vitro cell growth inhibition of some of such conjugates toward MDA-MB-231 human 
breast cancer cells and HBL-100 human non tumorigenic epithelial cells are reported, together 
with their phototoxic effects onMDAMB-231 cells. All conjugates have IC50 values in the low 
micromolar range that decrease by 1 order of magnitude upon irradiation of cell cultures with 
visible light. This make them promising for PDT of cancer. 
In the second section we describe the first example of 99mTc – porphyrins conjugates where 
the connection between the metal fragment and the porphyrins macrocycle occurred at the 
periphery of the cromophore, at meso position. 
In radiopharmaceutical chemistry it is common to compare the retention time in the HPLC in 
the radiochromatogram of the 99mTc conjugate with the UV-vis trace of the corresponding 
non-radioactive Re congener to confirm the success of the labeling and to characterize 
unambiguously the 99mTc-conjugate. 
By an accurate characterization of the water soluble porphyrinic precursors and of the Re(I) 
congeners, we were able to establish, for the first time, that only one [99mTc (CO)3]+ fragment 
is bounded at the periphery of the porphyrins. 
Furthermore, all the 99mTc/Re-porphyrin conjugates were obtained with high purity level and 
reasonable to good yields. The total charge ranges from +1 to +3. 
Stability studies performed by HPLC on the 99mTc-conjugates revealed an high stability under 
air at room temperature, in absence or presence of cells up to 30 minutes to 24 hours. 
Since natural and synthetic porphyrins and metalloporphyrins are the most useful 
photosensitizers for PDT, we decided to evaluate the water soluble porphyrinic precursors and 
the Re(I)-porphyrins conjugates as potential photosensitizers for PDT.  
The in vitro cell uptake, the cell growth inhibition toward HeLa cells are reported, together 
with their phototoxic effects on the same cell line. 
All conjugates revealed a negligible cytotoxicity (IC50 values higher than 100 µM) after 24 h 
of exposure. Those value decrease by 1 order or magnitude upon irradiation with visible light 
(590-700 nm) at mild light doses ( 5 J/cm2). We found that compounds uptake after 24h 
exposure is significantly different, and it does not affect appreciably their cytotoxicity. On the 
contrary, the phototoxicity is directly related to the ability of the compounds to penetrate 
cells. They proved to have from moderate to good singlet oxygen quantum yields and high 
photostability. 
Taken together, those results make them promising for PDT of cancer. 
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1. Introduction 
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1.1. Natural and sythetic water soluble porphyrins 
 
Porphyrins are a very interesting class of molecules, especially for their chemical and 
biological properties. In fact they are currently under investigations in many research fields, 
such as catalysis, 1  conversion of solar energy 2  and spectroscopy. 3  In addition, these 
compounds play key roles in complex biological systems and, as photosynthetic models, 4 
have been studied for their biological and biomedical applications. 
 
From the structural point of view, all the porphyrins are characterized by an heterocyclic 
macrocycle composed of four modified pyrrole subunits interconnected at their α carbon 
atoms via methinebridges (=CH-) (Figure 1). The structure is completely aromatic with high 
conjugation and π electrons delocalization on the ring. The tetradentatemacrocycle defines a 
cavity of dimensions nearly perfect to coordinate strongly, after deprotonation of two protons 
inside, a large number of metal such as Fe(III) or (II), Zn(II), Cu(II) and Co(II). 
Another important feature, for chemical application, is the stability of the porphyrin ring in 
strong acid and basic conditions. Strong bases such as alkoxides remove protons present on 
the inner nitrogen atoms (pKa ~ 16) while pyrrolic nitrogen atoms have a pKb ~ 9 and can be 
easily protonated with acids such as trifluoroacetic acid.5 
The characteristic flatness, demonstrated by X-ray crystallography and the extensive electron 
delocalization in the macrocyclic core are decisive for the chemical activity and biological 
function of macromolecules.6 
 
 
 
 
 
 
 
Figure 1. Schematic drawing of a porphyrins macrocycle. 
 
As a consequence of the extensive electron delocalization, porphyrins typically have very 
intense absorption bands in the visible region and they are deeply colored; in fact the name 
porphyrin comes from a Greek word πορφυρος, purple. 
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In a typical visible absorption spectra, porphyrins usually show an intense Soret band at 
around 400 nm, which results from the delocalized cyclic electronic pathway, and several 
weaker absorption bands (Q bands) between 450 nm and 800 nm, which are responsible for 
the rich color (Figure 2). 
Usually the insertion of peripheral substituent on the porphyrin ring induces relatively little 
changes in the intensity and wavelength of absorption while the protonation of the two inner 
nitrogen atoms or the insertion of a metal ion in the tetradentate cavity significantly change 
the absorption spectrum, with two typical Q-bands between 500 and 700 nm in addition to the 
Soret band. These changes are very useful to characterize metal porphyrins.7 
 
Figure 2.A typical UV-vis spectrum of a porphyrin 
 
Since porphyrins are able to absorb in all the visible region at specific ranges of wavelengths, 
they are considered good chromophores and thus able to induce reversible or irreversible 
chemical changes on the surrounding biological substrates. 
Furthermore, these macrocycles typically show preferential uptake and retention by tumor 
tissues, possibly via receptor-mediated endocytosis of low density lipoproteins (LDL). This 
suggestion is mainly supported by the observation that lipoproteins readily incorporate 
porphyrins, and that tumor cells have been found to exhibit elevated activity of LDL 
receptors.8,9,10 
Since they are good chromophores with a good selectivity for tumor tissues, they are 
promising candidate for PDT. 
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1.2. Photodynamic Therapy in Cancer 
 
1.2.1. General aspects 
 
Photodynamic therapy (PDT) is an approved therapeutic procedure for the treatment of a 
variety of solid tumors and non-malignant lesions. It involves the local or systemic 
administration of a photosensitizer11,12,13(porphyrin-like, chlorophyll-like, or dye compound) 
followed by irradiating the targeted disease site with non-thermal visible light of appropriate 
wavelength(s) (Figure 3).14,15 
 
 
Figure 3. Schematic PDT treatment16 
 
The anticancer effect of PDT is a consequence of a low-to-moderately selective degree of 
photosensitizer (PS) uptake by proliferating malignant cells, direct cytotoxicity of reactive 
oxygen species (ROS, mainly 1O2) and a severe vascular damage that impairs blood supply to 
the treated area.1718 Those biological effects of PDT are limited to the particular areas of 
tissues exposed to light.  
Thanks to Thomas Dougherty’s pioneering work, in 1975 it was demonstrated that the topical 
administration of a photosensitizer namely hematoporphyrin IX, and red light, successfully 
eradicated mammary and bladder tumor in mice. Nowadays PDT has been recognized as an 
experimental tool for treatment of tumors located in skin, lung, gall bladder, esophagous, head 
and neck.19 
PDT as a treatment procedure has been accepted by the United States Food and Drug 
Administration for use in endo-bronchial and endo-esophageal cancer 20  and also as a 
treatment of premalignant and early malignant lesions of skin (actinic keratosis), bladder, 
breast, stomach and oral cavity.21 
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1.2.2. Photosensitizers 
 
Photosensitizers (PS) are the key element in PDT. After the approval of Photofrin for the PDT 
treatment, researchers from all over the world got actively involved in developing efficient 
PSs.  
Generally, a good photosensitizer must possess certain photophysical properties. For example, 
it should be able to produce singlet oxygen with high quantum yield (Φ∆).22 In addition, a 
high molar extinction coefficient in the spectral region of the excitation light, a high triplet 
statequantum yield ΦT, a relatively long triplet state lifetime (τT), and a high triplet-state 
energy are other important factors. The photobleaching of a PS is another important 
parameter. Aphotosensitizer that will photobleach slowly in tissues will be a better agent for 
PDT. Finally the amphiphilicity and water solubility are characteristic desiderable for a good 
PS. 
From biological point of view, it should posses high selectivity in terms of target cells versus 
healthy cells, minimal skin photosensitivity and no dark toxicity.  
Photosensitizers are generally classified as porphyrins or non-porphyrins. In fact, in the 
beginning, the attention has been focused on porphyrins and their analogues because their 
presence in natural systems makes them ideal candidates for use in biological singlet oxygen 
generation. As a result of their biological roles, these photosensitizers generally lack 
cytotoxicity in the absence of light, which proves important in certain applications . 
The porphyrins and their derivatives have the ability to absorb several wavelengths in the UV-
vis range. The long-lived triplet states of many porphyrins allow for high quantum yields. The 
introduction of different substituents on the macrocycle allows the tuning of the porphyrins 
properties. Some photosensitizers approved for clinical PDT treatments in humans are listed 
in Table 1. 
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Chemical 
classification 
Photosensitizer 
tradename/company Type of diseases Country 
 
 
 
 
 
 
 
Hematoporphyrin 
Porfimer Na 
Photofrin 
 
 
Barrett’s displasia 
 
Cervical cancer 
 
Endobronchial cancer 
 
 
 
Esophageal cancer 
 
 
Gastric cancer 
 
Papillary bladder cancer 
 
U.S., Canada, EU, UK 
 
Japan 
 
Canada, Most EU Countries, 
Japan, U.S. 
 
 
Canada, Most EU Countries, 
Japan, U.S. 
 
Japan 
 
Canada 
 
Protoporhyrin 
 
Pro drug (5-
aminolevulinic 
acid - ALA) 
converted 
tophotoactive 
protoporhyrinIX/ 
Levulan, Levulan 
Kerastick (for topical 
use)/Dusa 
Pharmaceuticals) 
Actinic keratosis, 
Basal cell carcinoma U.S., EU 
Temoporfin mTHPC / Foscan Biolitec Pharma Head and neckcancer EU, Norway, Iceland 
Verteporfin Visudyne Age-related Macular Degeneration 
Canada, Most EU Countries, 
Japan, U.S. 
 
Table 1. Photosensitizers approved in human diseases. 
 
Commonly PSs are divided into three generations. First-generation PS are hematoporphyrin, 
its derivatives HpD, and the purified, commercially available and yet largely employed 
Photofrin (Figure 4).  
 
N
NH N
HN
COOHHOOC
H2N
COOH
ON
NH N
HN
COONaNaOOC
O*
*O
nn = 1-9
a b5-ALA
 
Figure 4. Examples of photosensitizers approved for clinical PDT. Photofrin (a) and 5-ALA, as a prodrug of 
Protoporhyrin (IX) (b). 
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Photofrin showed some advantages, such as the absence of intrinsic toxicity, the possibility of 
using small drug doses, the good clearance from normal tissue and the possibility of repeated 
administrations without serious consequences. But the complex composition, the prolonged 
photosensitivity (up to 3 months), the poor selectivity 0.1-3%,23 the slow clearance rate and 
the relatively weak long-wavelength absorption moved the research for new photosensitizes. 
Such photosensitizes belongs to the second generation. They include benzoporphyrin 
derivative, chlorins, phthalocyanines and texaphrins as well as naturally occurring 
compounds, such as hypericin, and 5-aminolevulinic acid (5-ALA) and some of its related 
esters24 that promote the endogenous production of the protoporphyrin IX (PpIX) (Figure 4). 
Now research is moving toward the synthesis of the third generation of photosensitizers, 
where dark toxicity, solubility and tumor selectivity are characteristic under optimization. 
From this point of view, the design of new photosensitizers by using sugar moiety, 25 
peptides,26 and hormones 27or fullerene 28 may afford excellent candidate PDT drugs. 
 
1.2.3. Photochemistry 
 
Upon absorption of a photon, the photosensitizer is activated to an exited single state (S1) and 
then, by intersystem crossing (4), it can converts to an exicited triplet state (T1) (Figure 5). 
 
 
 
 
Figure 5. Jablonski diagramshowing the various modes of excitation and relaxation in a chromophore. 
(1) = exited state, (2) = fluorescence emission (3) = internal conversion, (4) = intersystem crossing, (5) = 
fluorescence emission (6) = internal conversion, (7) = reaction of triplet state with surrounding molecules (8) = 
Type I reactions (9) = spin exchange with oxygen (10) = Type II reactions. 
 
Since phosphorescence is a spin-forbidden decay, the lifetime of the T1 state is longer (from 
10-3 to 10 µs) than that of the S1 state (from 10-9 to 10-6ns). Consequently, the molecule in T1 
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excited state can react with the surrounding molecules, according two types of reactions, 
defined as Types I and II. 
Firstly, in a Type I reaction, the photosensitizer can react directly with the biomolecules, such 
as the cell membrane constituents, and transfer a proton or an electron to form a radical anion 
or cation, respectively. These radicals may further react with oxygen to produce reactive 
oxygen species (ROS). Alternatively in a Type II reaction, the excited PS can transfer its 
energy directly to molecular oxygen to form excited state singlet oxygen that consequently 
induce apoptosis and necrosis of targeted cells and tissues (Type-II PDT).29,30,31 It is highly 
probable that in the presence of molecular oxygen, and as a direct result of the 
photoirradiation of the PS molecule, both Type-I and II pathways play a pivotal role in 
disrupting cellular mechanisms and cellular structure.  
Type I mechanism is favored at high concentration of photosensitizer, hypoxic environment 
or in the presence of others molecules that can be easily oxidized. Nevertheless, there is 
considerable evidence to suggest that the Type-II photo-oxygenation process predominates in 
the induction of cell damage, a consequence of the interaction between the irradiated 
photosensitiser and molecular oxygen.32 
The energy required for the triplet to singlet transition in oxygen is 22 kcal mol-1, which 
corresponds to a wavelength of 1274 nm (infrared light).33 Thus relatively low energy is 
needed to produce singlet oxygen. The latter interaction usually involves energy transfer to 
yield chemically highly active singlet oxygen (1O2) which reacts with many biological 
molecules, including lipids, proteins, and nucleic acids, leading to cancer cell death. 
Singlet oxygen (1O2) is so reactive that it has a lifetime that ranges from 10–100 µs in organic 
solvents. In an aqueous environment single oxygen’s lifetime is reduced to approximately 2 
µs because the energy of oxygen–hydrogen (O–H) stretching in water molecules nearly equals 
the excited-state energies of singlet oxygen. The energy is dissipated as heat by the stretching 
and vibrational motions of water molecules.  
Because singlet oxygen reacts so rapidly, the oxidative damaged is highly localized to regions 
no larger in diameter than the thickness of a cell membrane. The sequence of reactions 
involved in the process is summarized in Figure 6. 
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Figure 6. P = photosensitizer, 3O2 = oxygen  triplet ground state, 1O2 =excited singlet oxygen, S0 and S1 = 
ground state and first excited singlet state, T1 = first triplet excited state, ISC = intersystem crossing. 
 
When the photosensitizer returns from the triplet to the ground state, it can absorb another 
quantum of light and start again with a new cycle. Some photosensitizes undergo rapid 
decomposition in the presence of 1O2 (photobleaching). This can be deleterious since the 
photosensitizer is no longer able to absorb light and thus to cause the phototoxic effect; 
however, it could be an advantage in biological systems where rapid breakdown of the 
photosensitizer after use is necessary. 
The efficiency of production of singlet oxygen is an empirically determined quantity called 
the singlet-oxygen quantum yield (Φ∆). The singlet-oxygen quantum yield describes the 
number of singlet oxygen molecules that are formed per photon of energy absorbed and it 
correlates with triplet-state quantum yield ΦT and with the efficiency of energy transfer . 
 
1.2.4. Light 
 
Selectivity in PDT can also be enhanced by selectively delivering the light to the tumor tissue 
and excluding it as fully as possible from the healthy tissues nearby. Nowadays different laser 
systems and incoherent light sources are used in PDT.34 
A laser beam for its intrinsic characteristics differs from ordinary light, as it is collimated 
(parallel, with very low divergence), coherent (all waves are in phase), monochrome (line 
width 0.01 nmor less). The first feature allows to fix it at the end of a thin quartz fiber and to 
transmit it, by means of optical fibers in a beam of 0.4 to 1 mm diameter. This allows to 
irradiate tumors located internally and not just superficially. 
The monochromatic wavelength allows to use the most appropriate wavelength for the 
absorption of light by the photosensitizer drug and to the maximize light transmission through 
tissues. 
Light upon interaction with a tissue surface can be reflected, scattered, transmitted, or 
absorbed (Figure 7) depending on optical features of the tissue and on the light properties. 
P(S0) P(S1) P(T1)
hν ISC
P(T1) +3O2 P(S0) +1O2
Biomolecules + 1O2 Products
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Light propagation in the tissue is affected by scattering occurring at inhomogenity sites, (e.g. 
membranes, nuclei), and by a number of factors such as the presence of absorbing dyes 
(hemoglobin, melanin) and water.35 In general, light penetration depth is highly dependent on 
the tissue type and its intensity decreases with penetration depth through the tissue surface. 
Since light penetration depth into most biological tissues increases upon increasing the 
wavelength, light of the spectral range called “phototherapeutic window” (620-850 nm) is 
predominantly used in phototherapy. 
Compounds with aromatic systems and with extended conjugation, such as porphyrins, are 
able to absorb light with high efficiency. Although the absorption spectra of porphyrins show 
the Soret band, with higher absorption in the near UV and blue, the activation of the 
porphyrin is obtained with red light using the Q satellite bands. 36, 37 This is mainly due to the 
depth of penetration of light (from 3 to 8 mm) in the range from 630 to 800 nm (Figure 8). 
 
Figure 7. Interactions of light with a tissue. From ref. 35. 
 
Since light penetration depth into most biological tissues increases upon increasing the 
wavelength, light of the spectral range called “phototherapeutic window” (620-850 nm) is 
predominantly used in phototherapy 
Compounds with aromatic systems and with extended conjugation, such as porphyrins, are 
able to absorb light with high efficiency. Although the absorption spectra of porphyrins show 
the Soret band, with higher absorption in the near UV and blue, the activation of the 
11 
 
porphyrin is obtained with red light using the Q satellite bands.1 This is mainly due to the 
depth of penetration of light (from 3 to 8 mm) in the range from 630 to 800 nm (Figure 7). 
 
 
Figure 8. Relative diffusion depth of penetration with light at various wavelengths (assuming the depth of tissue 
penetration at 800 nm is 100%) 37 
 
The light dose administered is expressed in joules per unit of surface (J/cm2). Typically 
fluencies of 10 J/cm2 are applied in therapy for second-generation PSs (e.g. mTHPC),38 and 
this value depends to the extinction coefficient of the photosensitizer. 
The tumors are illuminated with a dose-rate not exceeding 100 mW/cm2 to avoid the 
appearance of thermal effects, being unspecific, that may overlap with those photodynamic. 
The total dose of light given usually depends on the type and size of the tumor. PDT induces 
necrosis of the treated tumors, which appears in two or three days. 
 
1.2.5. Mechanism of Action/Damage and Subcellular Targets 
 
Because of the limited migration of 1O2 from the site of its formation 39, sites of initial cell 
and tissue damage of PDT are closely related to the localization of the sensitizer.40 
The main damages induced by PDT occur where the photosensitizer localize within the cell.42 
Photosensitizers can accumulate almost everywhere within the cell; there they cause specific 
detrimental effects. Nevertheless, plasma and lysosomal membrane, mitochondria and 
endoplasmic reticulum (ER) represent the preferential targets.41 
Due to its electrophilic nature, 1O2 can give cycloaddition and oxidation reactions in various 
biomolecules, all of which are quite disruptive to biological processes.42 
The ideal target includes unsaturated lipids, such as cholesterol, andα-amino acid residues of 
proteins (Scheme 1). Among these, tryptophan is the most reactive,43 but also histidine and 
methionine can react. 
                                                 
1Potter W. R., in Proceedings of SPIE 1989, 1065, 88. 
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Scheme 1. Subcellular targets of 1O2 
 
Hydroperoxide (cholesterol) or endoperoxides (tryptophan) can be easily generated. The fate 
of these organic oxygenated compounds can be different. For example, cholesterol peroxide 
can trigger a massive immune response,44 causing the destruction of the cell,45 or it can be 
detoxified by using a membrane-based glutathione peroxidase to catalyze the two-electron 
reduction and detoxification of lipid hydroperoxides.46 
Since the unsaturated lipids and proteins are essential constituents of biological membranes, 
reactions between singlet oxygen and the components of the membrane cause an alteration of 
the permeability of the membrane that leads to cytolysis, swelling, blistering on the cell 
membrane, release of vesicles containing enzymes, inhibition of enzymes of membrane such 
as Na+, K+-ATPase, destruction of the channels of the Ca2+.47 
For example, in mitochondria these events can lead the release of cytochrome C48and the 
subsequent rapid induction of apoptosis.49,50 According to some authors the variations of 
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intracellular Ca2+ level are responsible for  the increase in mitochondrial membrane 
permeabilization. 
Regarding the ER, it has been reported that, after PDT, different heat shock proteins as well as 
the ER chaperones, GRP78/Bip, calreticulin, calnexin are induced in a time dependent 
manner.51 
These photo-oxidated proteins can sustain the activation of unfolded protein response (UPR) 
that is involved in cell death both in vitroand in vivosystems. Therefore, a more accurate and 
critical evaluation is required. 
Although the effects of cell damage are important for the destruction of tumor tissue, vascular 
damages are responsible of the complete death of tumor effects of PDT. 
After irradiation, in fact, there is a cascade of biological responses, such as the accumulation 
of macrophages and platelets, the release of cytokines and prostaglandins, the platelet 
aggregation with the consequent thrombus formation. The result of these events is the total 
vascular stasis. This hypothesis is supported by some experimental observations. In particular, 
using the porfimer sodium (Photofrin) at 10 and 25 mg/kg in rat caused a dose-related 
constriction of arteriolein the site of application of light.52 
In the PDT vascular stasis is generally irreversible and it is followed by necrosis of the tumor 
tissue.53The apoptotic response may contribute to antitumor effect of PDT, especially if the 
photosensitizer is localized preferentially in the mitochondria, because these organelles are 
capable to induce and control nuclear apoptosis.  
Moreover, since most PDT sensitizers do not accumulate in cell nuclei, PDT has generally a 
low potential of causing DNA damage, mutations, and carcinogenesis 54 thus allowing the 
frequent repetition of phototherapeutic treatments. 
Additionally, PDT leads to activation of tumor directed, systemic immune responses.55,56, 57 
For example it has been demonstrated that PDT causes invasion and leukocyte infiltration of 
the tumor, events that are typical of acute inflammation and immunity. In addition, PDT 
appears to increase the presentation of tumor-derived antigen to T cells. At the same time, 
PDT stimulates the recruitment of host leukocytes, lymphocytes, neutrophils and 
macrophages into tumor tissue, by up-regulating the inflammatory cytokines interleukin IL-6 
and IL-1.58  Once generated by PDT, these cells cause an immune reaction that may be 
important for the eradication of disseminated tumor cells and/or located in metastatic sites. 
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2. Ru-Porphyrins conjugates 
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2.1. Approaches toward the synthesis of water soluble porphyrins  
 
Synthetic porphyrins are of considerable interest in biology, especially for properties such as 
the structural similarity with heme and vitamin B12. Natural porphyrins are present in the 
prosthetic group of hemoglobin and myoglobin which are responsible for oxygen 
transportation in red blood cells and oxygen storage in living tissue, and of some proteins with 
enzymatic activity such as cytochromes, catalases and peroxidases, involved especially in the 
cellular respiration.  
Unfortunately most porphyrins do not have an appreciable solubility in water, at pH close to 
neutrality, to permit biological and biomedical applications. An important goal is therefore to 
increase the water solubility of these structures. Several approaches have been developed to 
synthesize water-soluble porphyrins. A well established strategy involves the attachment of 
either hydrophilic or easily ionisable (or altogether charged) functional groups to the 
periphery of the chromophore, mainly at the meso positions. 
Thus, it is possible to obtain either cationic or anionic water soluble derivatives. Cationic 
porphyrins are commonly derived from meso-tetra(aminophenyl)porphyrin or from meso-
tetrapyridylporphyrin by protonation or alkylation of the pyridyl groups, respectively. Anionic 
porphyrins are prepared by attachment of -OH, -COOH, or -SO3Na functions to the aryl 
groups in meso-tetra-arylporphyrins . 
Other strategies involve the introduction of water-soluble biocompatible polymers such as 
poly(ethyleneglycol) monomethyl ether 59 or sugar units.60 
Some of these water soluble compounds, are of utmost interest for biomedical applications, 
and they have been extensively investigated in several bio-related fields, such as: i.specific 
binding of DNA as intra/extra intercalating agents,61 ii. interactions with quadruplex DNA 
and telomerase inhibition, 62  iii. chemical or photochemical induced DNA cleavage, 63  iv. 
antiviral activity, including HIV-1,64 v. boron neutron capture therapy (BNCT) of tumors,65 vi. 
selective interaction with potassium channels, 66  vii. acetylcholinesterase inhibition, 67  viii. 
antibacterial activity,68 and ix. photodynamic therapy for the treatment of cancer (PDT).69 As 
previously discussed PDT represents a successful application of porphyrins for the treatment 
of cancer for the tumor-targeting properties of the porphyrins and the absorption in the red 
regionof the electromagnetic spectrum. 
The coordination of water-soluble (e.g. charged) metal complexes to peripheral sites of the 
porphyrins is an intriguing alternative to the synthetic strategies described above for making 
water-soluble compounds. Such conjugates might have improved characteristics for 
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biomedical applications: i. if the metal complex possess anantiproliferative activity, they 
might combine the phototoxicity of the porphyrins chromophore and the cytotoxicity of the 
metal fragment for additive antitumour effect; ii. they might behave as carrier ligands for the 
active transport of anticancer metal fragments into cancer cells. Porphyrins show preferential 
uptake and retention by tumor tissues (tumor-localization properties); 70iii.provided that the 
conjugates are sufficiently stable, the fluorescence emission of the chromophore might be 
exploited for tracking the biodistribution of the metal in the extra- and intra-cellular 
environment of malignant cells through fluorescence microscopy. 
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2.2. Metal-based anticancer agents 
 
Platinum complexes 
 
Metal complexes became very attractive as anticancer agents since 1965 when Rosenberg 
observed for the first time the anti-proliferative effects of some chloro-ammino platinum 
complexes. Cisplatin (cis-[PtCl2(NH3)2]) is the parent compound of this class of agents and it 
is still one of the most effective chemotherapeutic agents in clinical use.71 Its ability to inhibit 
tumor growth is related to its efficient binding to nuclear DNA after release of the two 
chloride ions: in other words, cisplatin is a pro-drug that is activated by hydrolysis.  
In over three decades of dedicated efforts to develop cisplatin analogues and Pt complexes 
that break the cisplatin paradigm, only two Pt compounds, namely carboplatin 
([Pt(cbdc)(NH3)2] where cbdc = 1,1-cyclobutane dicarboxylate) 72 and oxaliplatin 
([Pt(ox)(DACH)] where ox = oxalate and DACH = diamino cyclohexane), have been 
approved for worldwide clinical use. Platinum compounds have been the treatment of choice 
for ovarian, testicular, head and neck, and small cell lung cancer for the past 20 years. Despite 
its clinical success, cisplatin has several drawbacks: i. severe toxicity, in particular 
nephrotoxicity, neurotoxicity and emetogenesis; ii. applicability to a relative narrow range of 
tumors; iii. limited solubility in aqueous solution; iv.spontaneous or acquired resistance to 
some tumors.  
 
Ruthenium complexes 
 
The development of drug resistance, the toxic side-effects of cisplatin, and the lack of activity 
of platinum compounds against several types of cancer 73 have prompted the search for new 
metal-based antitumor drugs. Since complexes of transition metals other than platinum may 
exhibit antitumor activity markedly different from that of cisplatin and its analogues, several 
metals have been investigated. Among many transition metal compounds, ruthenium 
complexes have attracted great interest for their potential use as anti-cancer agents and have 
been widely investigated in the past 30 years. 
While Pt(II) complexes are characterized by a the square-planar geometry, Ru(III) and Ru(II) 
(the more common oxidation states in aqueous solution) are usually esacoordinate and with 
octahedrical structure and are often fairly inert to ligand substitution. 
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The two most representative compounds of this class are KP1019 and NAMI-A, developed in 
the 1990s by Keppler 74 and Alessio 75 respectively (Figure 9). 
They both have completed phase I clinical trials with promising results.76 NAMI-A has started 
already a phase II combination study, whereas the sodium salt of KP1019, KP1339, was 
selected for further development because it is about 35-times more water soluble than its 
parent compound. 
Both compounds are moderately cytotoxic in vitro and, in animal models, have activities 
different from established Pt drugs: KP1019 showed excellent activity against platinum 
resistant colorectal tumors,77 whereas NAMI-A was found to be particularly active against the 
development and growth of metastases of solid tumors,78 even in advanced stage.79 
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Figure 9. Schematic structures of NAMI-A (top, left), KP1019 and KP1339 (top, right), RM175 (down, left), 
RAPTA-C (down, right). 
 
In recent years, entirely new classes of organometallic Ru(II)-arene compounds, developed by 
the groups of Sadler, 80  Dyson, 81 Keppler 82 and others, 83 were found to have promising 
anticancer activity both in vitro and, in some cases, also in vivo in murine models. 84 
Interestingly, some of them proved to be active also against cisplatin-resistant xenografts.85 
Representative examples of these organometallic compounds (also called piano-stool 
compounds) are [Ru(η6-arene)Cl(L-L)]n+ (L-L = azotate chelating ligand, n = 1; L-L = oxygen 
anionic chelating ligand, n = 0).  
Among them, active compounds are [Ru(η6-arene)Cl(en)](PF6) (en = etilendiammine, arene = 
benzene, p-cymene (Cym), tetrahydroanthracene (THA), dihydroanthracene (DHA), biphenyl 
(Bip). Representative examples are [(η6-biphenyl)Ru(en)Cl][PF6] (RM175) and [(η6-p-
cymene)- RuCl2(pta)] (RAPTA-C) (Figure 9). 
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Since cytotoxicity of the metal fragment increases with the lipophilicity,86 Prof. Alessio’s 
research group started a structure-activity relationship investigation aimed to establish 
whether the η6–arene fragment of these organometallic half sandwich compounds might be 
effectively replaced with a neutral face-capping ligand while maintaining the other ligands 
unchanged.  
Thus, they developed series of new half sandwich Ru(II) coordination compounds of the 
general formula [Ru([9]aneS3)(chel)L][X]n, 87,88 (where chel = neutral N–N chelating ligand 
such as en, 2,2'-bipyridine (bipy) or substituted bipy, L = Cl n = 1, L = dmso n = 2, [X] = 
CF3SO3-, PF6-), were the aromatic ligand has been replaced by the sulfur macrocyle 1,4,7-
trithiacyclononane ([9]aneS3)or by the corresponding nitrogen macrocycle 1,4,7-
triazacyclononane ([9]aneN3, also known astacn) 89 (Figure 10). 
 
Figure 10. Schematic structures of Ru(II) compounds with aromatic ligands (left) and Ru(II) compounds with 
1,4,7-trithiacyclononane(center), and 1,4,7-triazacyclononane (right) . 
 
In general, they demonstrated that Ru-[9]aneS3 compounds have a cytotoxicity comparable to 
that of the corresponding organometallic analogs. The most cytotoxic complex among this 
class was [Ru([9]aneS3)(en)Cl][OTf], that was found to be ca. 10 times less cytotoxic than the 
corresponding piano-stool organometallic compound RM175 against human breast cancer 
MDA-MB-231 cells. 
Those data suggest that the aromatic fragment of the piano-stool Ru (II) compounds is not an 
essential feature for the in vitro anticancer activity and it might be effectively replaced by 
another face-capping ligand with a low steric demand such as [9]aneS3. 
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2.3. Metal-porphyrin conjugates  
 
The coordination of metal complexes to porphyrin systems for biomedical applications has 
been investigated over the past decade, but only few examples are reported in literature. 
Song et al. reported an increase of the antitumor activity of anionic and cationic porphyrin-
platinum conjugates (Figure 11) compared to the platinum complexes against murine 
leukemia L1210 cell line. 90  They found that the coordination of a Pt(II) fragment in 
peripheral position did not affect the tumor-targeting properties of the porphyrins. 
 
 
 
 
Figure 11. Schematic structure of cationic porphyrin–platinum(II) conjugates.Adapted from ref. 90. 
 
Brunner et al. derivatized asymmetric tetraarylporphyrins 60 and hematoporphyrin 91with a 
platinum(II) fragment (Figure 12). Their aim was to combine the cytostatic activity of 
cisplatin or oxaliplatin and thephotodynamic effect of hematoporphyrin and or asymmetric 
tetraarylporphyrins in the same molecule after irradiation with red light.90, 91 
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This study demonstrated an increase of the antitumor activity of the platinum moiety by an 
additional light-induced toxicity. Some of the most active conjugates of the two series of 
compounds are shown in Figure 12. 
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Figure 12. Schematic drawing of some Pt-porphyrin conjugates, 59, 91 
 
More recently, Guo and co-workers described a dinuclear cisplatin-phthalocyanine conjugate 
that showed a remarkable enhancement of cytotoxicity against tumor cell lines when 
irradiated with red light.92 
Porphyrin units decorated at the periphery with ruthenium complexes have been already 
reported in literature and promising preliminary results were obtained in specific biologic 
assay. 
Therrien and co-workers recently reported that neutral conjugates of meso-3'- and 4'-
pyridylporphyrins with organometallic piano stool [Ru(η6-arene)Cl2] fragments (Figure 13) 
are moderately cytotoxic in the dark against Me300 human melanoma cells, and become 
cytotoxic upon irradiation with visible light. 93 Interestingly, photodynamic studies revealed 
that, 3'-pyridyl photosensitizers were better photosensitizers  than 4'-pyridyl photosensitizers. 
However, due to the very low solubility of the complexes in water, the biological application 
seems to be rather limited. Furthermore, the possible dissociation of the arene moiety in vivo 
leads a substantial risk of toxicity of these compounds. 
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Figure 13. Schematic structure of Ru(η6-arene)-porphyrins. Adapted from ref. 93a. 
 
Swavey and co-workers reported the synthesis and the characterization of new cationic 
fluorinated porphyrins bearing one or two [Ru(bpy)2Cl] fragments (Figure 14). 94 95 The 
ruthenium porphyrin conjugates were able to bind DNA and photocleave supercoiled DNA 
when irradiated with low-energy light. In addition, this complexes showed low dark toxicity 
but initiates apoptosis in melanoma cells upon irradiation in the visible range. 
 
 
Figure 14. Schematic structure of fluorinated Ru-porphyrinsAdapted from refs. 94 and 95 respectively. 
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2.4.Synthesis and Characterization of Ru(II)-porphyrin conjugates 
 
The aim of this work was to synthesize water soluble compounds that are expected to 
combine the cytotoxicity to the metal fragment to the phototoxicity of the porphyrins for an 
additive antitumor effect. 
 
Conjugation strategies  
 
The coordination of a porphyrin to peripheral metal fragments can occur either through a 
single bond or through multiple bonds (i.e. through a chelating moiety). Typically, pyridyl 
rings are used as peripheral ligands for the coordination of late transition metal ions. 96,97,98 
The former synthetic approach has an indubitable advantage: the commercially available, or 
otherwise easily prepared, meso-pyridylporphyrins (PyPs) can be exploited.  
In PyPs, the pyridyl N atoms can be either in 3'(3'PyP) or, more commonly, in 4' position 
(4'PyP). Even though synthetically more demanding, also PyPs in which the pyridyl rings are 
not directly bound at the meso positions, but are connected thorough a spacer, have been used 
occasionally.99 In the case of ruthenium, the vast majority of the conjugates reported in the 
literature involve the symmetrical coordination of four equal Ru fragments to a meso-
tetrapyridylporphyrin (TPyP).100,101In general, relatively few TPyP-(Ru)4 conjugates were 
explicitly prepared for biomedical investigations. In such context, the peripheral Ru fragments 
were typically of the type Ru(chel)2X, where chel is a polypyridyl ligand. 102, 103 The choice of 
rutheniumpolypyridyl complexes was motivated by two main reasons: i. they have a good 
affinity for DNA.104 Thus, similarly to Pt(II) fragments, they might behave as chaperones and 
help localizing the porphyrins photosensitizer close to DNA where the photoinduced 
generation of ROS would be more effective for inducing cell damage. ii. They are potential 
photosensitizers, and some of them were found capable of DNA photooxidation and 
photocleavage. 105 , 106 , 107 Examples of mono- and di-pyridylporphyrins conjugated to Ru 
polypyridyl fragments were also recently reported and their DNA binding properties and 
photocleavage capability described.94, 95,108The residual meso-phenyl groups may be exploited 
for increasingwater solubility (e.g. through appropriate substituents) or forenhancing the 
photophysical properties (e.g. by fluorination). 
Besides the already mentioned compounds by Therrien and coworkers,93 recently, we 
described the preparation and characterization of several new Ru-porphyrin conjugates that 
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bear either negatively charged NAMI-A-type Ru(III) fragments or negatively charged 
ruthenium(II)nitrosyl complexes.109 
Nevertheless, the single-bond conjugates might be insufficiently stable towards aquation 
under in vivo conditions, with consequent loss of the peripheral Ru fragments. Conjugation 
through multiple bonds increases the stability of the adducts but poses the necessity of 
developing affordable synthetic strategies towards porphyrins with peripheral chelating 
moieties. Even though a few examples of such Ru-porphyrin conjugates are known in the 
literature, we are unaware that any of them was explicitly prepared and investigated for 
biomedical purposes so far. 
 
Herein, both coniugation strategies were applied to synthesize Ru–porphyrin conjugates.  
4'PyPs and 3'PyPs were used for the coordination of Ru fragments through a single 
coordination bond (Figure 15a). 
Furthermore we describe the preparation in acceptable yields of a series of porphyrins that 
bear 4 peripheral bipyridinemoieties connected through an amide bond or through a flexible 
linkers of variable length and hydrophilicity. Lately these porphyrins were used for the 
coordination of Ru fragments through a double coordination bonds (Figure 15b).  
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Figure 15. Metal-porphyrins conjugates through single bond (a) or multiple bonds (b). 
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2.4.1. Conjugates with meso 4'-tetrapyridylporphyrin (4'-TPyP). 
 
We performed the coordination of 4'TPyP to half-sandwich Ru(II) fragments.  
Treatment of 4'TPyP with a slight excess of [Ru([9]aneS3)(en)Cl][CF3SO3] (in the presence 
of Ag(CF3SO3) for removing the chlorido ligand) affords the octacationic conjugate 
[4'TPyP{Ru([9]aneS3)(en)}4][CF3SO3]8 (2) in excellent yield (Scheme 2). 
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Scheme 2. Synthesis of [4'TPyP{Ru([9]aneS3)(en)}4][CF3SO3]8 (2) aand 
[4'TPyP{Ru([9]aneS3)(bpy)}4][CF3SO3]4 (3).b 
aReactions and conditions: (a) methanol/chloroform, 4h, reflux (92%). (b) methanol/chloroform, 8h, reflux 
(71%)   
 
Compound 2, besides being soluble in organic solvents such as methanol and nitromethane, is 
also well soluble in aqueous solution and in PBS (pH=7.4).  
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Figure 16.1H NMR spectrum (500 MHz) of 2 in D2O. See Scheme 2 for numbering scheme. 
 
Overall, the 1H NMR spectrum of 2 is consistent with the symmetry of the compound: all 
peripheral Ru fragments are equivalent. All proton resonances are sharp at 20 °C, with the 
exception of the βH signal that is remarkably broad (Figure 16). The four equivalent pyridyl 
rings give two well resolved doublets in the aromatic region of the spectrum. The upfield 
region is similar to that of the precursor Ru complex: in D2O the two pairs of diastereotopic 
protons on the equivalent NH2 groups give two well resolved resonances at δ = 4.17 and 5.09 
(coupled in the H-H COSY spectrum), whereas the CH2 protons of en and of [9]aneS3 
resonate as a series of partially overlapping multiplets between δ = 2.6 and 3.1 (Figure 16). 
Only four aliphatic 13C resonances are observed in the HSQC spectrum (one for the en 
carbons and three for the [9]aneS3 carbons), consistent with a CS symmetry in solution for 
each equivalent Ru fragment, as was found in the precursor.87  
The corresponding conjugate [4'TPyP{Ru([9]aneS3)(bpy)}4][CF3SO3]8, (3) with bpy in the 
place of en, was obtained by treatment of 4'TPyP with[Ru([9]aneS3)(bpy)(dmso-
S)][CF3SO3]2 upon replacement of dmso by the pyridyl groups (Scheme 2). Compound 3 was 
also characterized in the solid state by X-ray crystallography: the tetranuclear cation is 
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composed of four [[Ru([9]aneS3)(bpy)]2+ units bound to the meso pyridyl moieties in a 
centro-symmetric arrangement (Figure 17).  
 
 
 
Figure 17. Molecular structure of the centro-symmetric complex cation of 
[4'TPyP{Ru([9]aneS3)(bpy)}4][CF3SO3]8 (3). 
 
The cation presents a pseudo four fold axis normal to the porphyrin mean plane: the four Ru 
fragments are iso-oriented, with intermetallic side distances of 14.303(4) Å (Ru1···Ru2) and 
14.213(3) Å (Ru1···Ru2'). The Ru centers have a distorted octahedral coordination sphere, 
with Ru−S and Ru−N(bpy) coordination distances that average to 2.17(1) Å 2.373(5) Å, 
respectively (i.e. they are longer by ca. 0.05 and 0.03 Å, respectively, than those found in the 
Ru(II) precursor).88 The two independent meso pyridyl rings N5 and N6 form a dihedral angle 
with the porphyrin mean plane of ca. 68° and deviate slightly from a linear coordination, with 
Ru−N(py)···C(meso) angles significantly narrower than 180° (168.3 and 172.9°, 
respectively). As a consequence, the bpy ligands are considerably canted towards the adjacent 
meso pyridyl rings (dihedral angles between the mean planes of 62.4(4) and 72.8(4)°, Figure 
18). A pyridine ring of each bpy is located approximately in the porphyrin plane (Figure 18), 
at a distance of ca. 4.45 Å from a pyrrole hydrogen atom. This feature, probably dictated by 
packing effects, might be compatible with weak CH···π interactions.  
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Figure 18. Top: side view of the complex cation of 3 along the Ru2·· ·Ru2' direction ([9]aneS3 ligands at Ru2 
ions omitted for clarity). Bottom: top view showing the canting of the bpy ligands towards the pyrrole rings. 
 
Compound 3 is mildly soluble in water and in phosphate buffer at pH 7.4.  
 
Figure 19. 1H NMR spectrum (500 MHz) of 3 in CD3NO2. See Scheme 2 for numbering scheme. 
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As for 2, the 1H NMR spectrum of 3 in CD3NO2(Figure 19) shows sharp signals at 20 °C 
(with the exception of the βH resonance) and is consistent with the symmetry of the molecule 
(Scheme 2). The single set of bpy and pyridyl signals (four and two, respectively) implies that 
all four metal fragments are equivalent and that each of them has a CS symmetry. The 
anisotropic shielding of the bpy rings, that are perpendicular to the plane of the porphyrin, 
more than counteracts the deshielding typically observed upon coordination of 4'PyPs to 
Ru(II) fragments;110as a consequence, the resonances of 4'TPyP are shifted slightly upfield 
compared to 2 (δ H2,6 = 8.63 in 3vs 9.31 in 2;δ H3,5 = 8.14 in 3 vs 8.41 in 2).  
As already mentioned, both 2 and 3 have very broad βH resonances at 20 °C, suggesting the 
occurrence of conformational equilibria. Variable temperature (VT) NMR experiments 
showed that for 2, in CD3NO2 solution, the resonance of the eight pyrrole protons becomes a 
sharp singlet at 65 °C, whereas at -30 °C in CD3OD solution it splits into two equally intense 
sharp singlets (δ= 9.30 and 8.97) that are not correlated in the H-H COSY spectrum. (Figure 
20). 
 
Figure 20. Temperature dependence of the 1H NMR spectrum (downfield region) of 
[4'TPyP{Ru([9]aneS3)(en)}4][CF3SO3]8 (2) in CD3OD. *: impurity. 
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The βH resonance of the bpy derivative 3 has a very similar temperature dependence in 
CD3OD/CD3NO2 (99:1) solution and splits into two equally intense sharp singlets at -40 °C (δ 
= 8.89 and 8.51, Figure 21) 
 
 
Figure 21. Temperature dependence of the 1H NMR spectrum (downfield region) of 
[4'TPyP{Ru([9]aneS3)(bpy)}4][CF3SO3]8 (3) in CD3OD/CD3NO2 (99:1) solution. 
 
The upfield singlet was assigned to the four pyrrole protons that are directly shielded by the 
bpy rings. The βH NMR pattern found for both 2 and 3 at low T is compatible with the 
presence in solution of a frozen conformer with a D2h symmetry, with adjacent Ru fragments 
arranged in a pairwise fashion: en (or bpy) ligands on Ru units at meso positions 5, 10 (and 
15, 20) face each other, while those on the meso positions 5, 20 (and 10, 15) are far apart 
(Figure 20 and Figure 21). The two types of βH protons, a and b, are exchanged by the 
concerted rotation of the four Ru complexes. This geometry is different from that found in the 
solid state for 3(Figure 22), where all Ru fragments are iso-oriented, but is similar to that 
found by us for the Re(I) conjugate [4'TPyP{Re(CO)3(bpy)}4][CF3SO3]4.111 
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Figure 22. Schematic structure of the prevailing conformer of 2 at low T. Dotted lines indicate the two 
symmetry planes. The two sets of equivalent βH protons, responsible for the two singlets in the low t NMR 
spectrum, are labeled a and b. 
 
Both porphyrin conjugates 2 and 3 are very stable in aqueous solution and in phosphate buffer 
at physiological pH: their NMR and visible spectra remain unchanged for hours. This 
behavior is consistent with the substitutionally inert coordination sphere of the Ru(II) 
fragments. 
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2.4.2. Conjugates with meso 3'-tetrapyridylporphyrin (3'-TPyP). 
 
Photodynamic studies by Therrien et al. revealed that 3'-pyridylporphyin photosensitizers are 
more efficient than 4'-pyridylporphyrinanalogs. 93 Starting from these observation, we 
synthesized the 3'-pyridylporphyrin conjugates bearing in peripheral positions the same Ru(II) 
fragments, [Ru([9]aneS3)(en)]2+ and [Ru([9]aneS3)(bpy)]2+, of Ru-4'TPyPs previously 
described. 
The synthesis of 3'TPyP was performed following asynthetic procedure reported in 
literature.112 
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Scheme 3.Synthetic strategy towards the synthesis of [3'TPyP{Ru([9]aneS3)(bpy)}4][PF6]8 (5)a and 
[3'TPyP{Ru([9]aneS3)(en)}4][PF6]8 (6)b. 
aReactions and conditions: (a) methanol/chloroform, 48h, reflux (86%)b methanol/chloroform, 48h, reflux (76%). 
 
Treatment of 3'TPyP with a slight excess of either [Ru([9]aneS3)(bpy)Cl][PF6] or 
[Ru([9]aneS3)(en)(Cl)][PF6] (in the presence of AgPF6 for removing the chlorido ligand) 
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afforded the octacationic conjugates [3'TPyP{Ru([9]aneS3)(bpy)}4][PF6]8 (5) or 
[3'TPyP{Ru([9]aneS3)(en)}4][PF6]8 (6), respectively, in excellent yield (Scheme 4).  
While compound 6 is soluble in water and in PBS, 5 is only mildly soluble in water but it is 
soluble in organic solvents such as methanol and nitromethane. 
 
Compound 5 was characterized in solid state by single crystal X-ray analysis. The structural 
determination evidenced in the crystal the tetranuclear complex beside the PF6– anions and 
two nitromethane molecules per complex unit. 
The complex, composed of four [Ru([9]aneS3)(bpy)]2+ units bound to the meso pyridyl 
moieties, has a fourfold symmetry being located about a crystallographic 4  axis (Figure 23), 
so that the metals are alternatively displaced above and below the porphyrin mean plane. 
 
 
Figure 23.Side view of the complex cation [3'TPyP{Ru([9]aneS3)(bpy)}4][PF6]8 (5) (porphirine moiety in 
black) 
 
The crystallographically independent metal unit is chelated by the nitrogens of bipyridine, by 
the sulfur atoms of the tripodal ligand and complete the distorted octahedral coordination 
sphere through the nitrogen donor of the pyridine unit bound to the meso position of the 
porphyrin. The metals are separated by 12.357 Å, while diagonal distance is 17.034 Å (Figure 
24). 
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Figure 24.Molecular structure of the complex cation of [3'TPyP{Ru([9]aneS3)(bpy)}4][PF6]8 (5) viewed down 
the fourfold symmetry axis. (5). 
 
The Ru-N(bpy) bond distances (of 2.084(8) and 2.080(8) Å) are slightly shorter than those 
relative of Ru-N(pyridine) (2.118(7) Å), while the Ru-S are similar within their esd’s (range 
2.299(3)–2.316(2) Å). The coordination angles provide indication of the distortions in the 
coordination sphere of the metal (coordination cis angles between 78.3 (4) and 97.5 (3)°). The 
geometrical parameters of the coordination sphere are comparable to those measured in the 
corresponding complex [4'-TpyP{Ru([9]aneS3)(bipy)}4]8+. The1H NMR spectrum of 5 in 
CD3NO2 at room temperature is reported in Figure 25. The downfield region is quite 
complex: it shows a manifold of relatively broad and overlapping multiplets suggesting the 
coexistence of several conformers, owing to hindered rotation about the C(meso)–C(pyridyl) 
bond (and perhaps also the N-Ru bond) (Figures 23-24). Thus, no assignment was attempted. 
This behavior has been already observed in the spectrum of the rhenium-
3'tetrapyridylporphyrin derivative 111 
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Figure 25. 1H NMR spectrum of 5 in CD3NO2. 
 
The1H NMR spectrum of 5 in CD3NO2 at room temperature is reported in Figure 25. The 
downfield region is quite complex: it shows a manifold of relatively broad and overlapping 
multiplets suggesting the coexistence of several conformers, owing to hindered rotation about 
the C(meso)–C(pyridyl) bond (and perhaps also about the N−Ru bond). The conformational 
equilibria must be slow on the NMR time scale. This behavior has been already observed for 
similar conjugates of 3'TPyP with rhenium(I) complexes. Even though full assignment was 
not attempted, the most downfield manifold of (at least 5) singlets can be assigned to H2 on 
the pyridyl ring. The number of H2 singlets is not necessarily coincident with the number of 
conformers: this would be the case only if in each conformer the four bpy ligands are made 
equivalent by the symmetry. 
The 1H NMR spectrum of 6 in CD3NO2 (Figure 26) is similar to that of 5, even though 
obviously less crowded in the aromatic region. The resonances were assigned by means of a 
conventional H-H COSY spectrum. 
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Figure 26.H-H COSY spectrum of 6 in CD3NO2. See Scheme 3 for numbering scheme. 
 
All the aromatic resonances are very broad and only the signal at δ 9.70 shows a multiplicity. 
The most upfield signal at δ 8.17, was assigned to the pyridyl proton 5 py, as H-H COSY 
spectrum (Figure 26) displays two strong cross peaks between this resonance and vicinal 
protons 4py (δ 9.37) and 6py (δ 9.01). The resonances of protons 2py and 4py closest to the 
coordinated N atom are the most downfield (δ 9.70 and 9.37 respectively). 
βH and the pyridyl proton 6py (δ 9.02) overlap and are quite broad. The pyridyl proton 2py 
which should resonate as a singlet consists of a multiplet that may reflect the presence of the 
four conformers in solution. 
In the upfield region the spectrum shows, beside the multiplets of [9]aneS3 and the multiplets 
of the CH2 en that resonate together (δ 2.73 –3.02, 64 H), a broad multiplet at (δ 2.73 –3.02) 
for the NH2en that integrates for 8 protons. The resonance of the remaining 8 NH2 en protons 
overlaps with the resonance of residual CH3NO2, as shown in Figure 26. 
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2.4.3. Conjugates with meso-tetra(bpy-phenyl)porphyrin (Bpy4-PP) 
 
We report here the preparation and characterization of a porphyrin that bears 4 peripheral bpy 
moieties at meso positions, meso-tetra(bpy-phenyl)porphyrin (Bpy4-PP) (Figure 13) and its 
conjugates with half-sandwich Ru(II) fragments. Bpy4-PP was obtained in excellent yield by 
direct coupling of meso-(p-aminophenyl)porphyrin, p(NH2)4PP with 4-methyl- 2,2'-
bipyridine-4'-carboxylic acid (bpyAc), obtained in 32% yield starting from 4,4'-dimethyl-
[2,2']-bipyridine by consecutive SeO2 and Ag2O oxidation without isolation of the 
intermediates.  
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Scheme 4.Synthesis of Bpy4-PP (7)a 
aReactions and conditions: (a) EDCI, BpyAc, pyridine, 2h, rt (91%). 
 
The coupling reaction was carried out in pyridine, using, N-(3-dimethylaminopropyl)-N'-
ethylcarbodiimide hydrochloride (EDCI) as coupling reagent. The 1H NMR spectrum of 
Bpy4-PP is show in Figure 27. Assignments, performed through conventional 2D correlation 
spectra, were consistent with those already reported in the literature for Bpy-PP and Bpy2-
cisPP.113,114 
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Figure 27:Downfield region of1H NMR spectrum of 7in CDCl3.See Scheme 4 for numbering scheme. 
 
The six inequivalent bpyAc protons give six resolved resonances (four doublets and two 
singlets). The most downfield of them is typically the H6 doublet, partially overlapped with 
the βH resonance. The chemical shifts of all the aromatic resonances, and that of H3 in 
particular, were found to depend on the concentration probably because of aggregation 
mediated by π-π stacking. The singlet of the methyl group in 4' position, that falls at ca. δ  2.5, 
is correlated in a NOESY spectrum to the resonances of the adjacent H3' and H5' protons. 
This feature, in conjunction with the H-H COSY spectrum, allowed us to distinguish the two 
inequivalent halves of bpyAc. The amidic NH resonance typically falls in the range δ 10– 11 
and rapidly decreases in time due to H/D exchange with the solvent. In Bpy4-PP the eight 
equivalent pyrrole protons resonate as a singlet. 
The Bpy4-PP was treated with a 4.4 amount of the half-sandwich Ru(II) precursor 
[Ru([9]aneS3)(dmso)3][CF3SO3]2 in CHCl3-acetone mixture: replacement of two adjacent 
dmso ligands by the bpy moieties afforded the corresponding conjugate [Bpy4-
PP{Ru([9]aneS3)(dmso-S)}4][CF3SO3]8 (8) in good yield. 
βH+ H6 
H3 
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oPh   mPh 
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Scheme 5. Synthesis of [bpy4-PP{Ru([9]aneS3)(dmso- S)}4][CF3SO3]8(8)  
 
The conjugate has been characterized by mono- and bidimensional NMR spectroscopy (it is 
soluble in CDCl3, CD2Cl2, CD3NO2, dmso but scarcely soluble in water. The model complex 
[Ru([9]aneS3)(bpyAc)(dmso-S)][CF3SO3]2 88 was characterized by NMR spectroscopy and X-
ray crystallography and it was used as reference for NMR assignments. 
In general, all proton NMR resonances of conjugate 8 are slightly broader than those in the 
free porphyrin orin the model complex. 88 The 1H NMR spectrum of [Bpy4- 
PP{Ru([9]aneS3)(dmso-S)}4][CF3SO3]8 (8) (Figure 28) shows in the upfield region, beside 
the multiplets of [9]aneS3 (δ2.9– 3.4), three singlets of equal intensities between δ 2.7 and 
2.9. By analogy with the spectrum of the model complex, 88 the upfield singlet was attributed 
to the methyl on bpyAc (attribution confirmed by the NOESY experiment) and the other two 
to the diastereotopic methyls of dmso-S. In the downfield region, the six resonances of the 
bpyAc protons are shifted downfield of 0.3-0.5 ppm.  
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Figure 28. 1H NMR spectrum (500 MHz) of [Bpy4-PP{Ru([9]aneS3)(dmso-S)}4][CF3SO3]8(12). See Scheme 4 
for numbering scheme. 
 
Optically matched dmso solutions of Bpy4-PP 7 and conjugate 8 showed very similar 
fluorescence spectra upon selective excitation at the Soret band (λex = 425 nm, λem = 656 
nm). The emission intensity of 8 is ca. 20% lower than that of the parent porphyrins as 
expected because of the peripheral heavy atoms.96 
 
Figure 29. Fluorescence spectra (λex = 425 nm, λem = 656 nm) of optically matched dmsosolutions of Bpy4-PP 
(7) (black) and [{Bpy4-PP}{Ru([9]aneS3)(dmso-S)}4][CF3SO3]8 (8) (red) 
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2.4.4. Conjugates with (TetbpyPP) and (TedabpyPP)  
 
Basically the same multi-step synthetic route was followed to obtain the two new extended-
arms porphyrins, TetbpyPP (9) and TedabpyPP (10) (Scheme 6), that bear four peripheral bpy 
fragments at the meso positions.  
 
Scheme 6. Synthetic route to 9 and 10.a 
a Reactions and conditions: (a) propionic acid, reflux, 1.5 h (21%); (b) KOH aq 40%, THF/CH3OH 2:1, 40 °C, 
1 h (93%); (c) EDCI/HOBt/DMAP, NH2CH2CH2OCH2CH2OCH2CH2NHBoc (72%) DMF, rt, 24 h or 
EDCI/HOBt, NH2CH2CH2NHBoc, DMF, rt, 2.5 h; then TFA, rt, 2 h (100%); (d) EDCI/HOBt/DMAP, bpyAc, 
DMF, rt, 24 h (96% and 74%).  
 
First, the condensation of pyrrole and methyl 4-formyl benzoate 115 followed by hydrolysis in 
basic conditions in THF/MeOH, gave the meso-4'-tetracarboxyphenylporphyrin, TCPP. The 
hydroxybenzotriazole (HOBt) ester of TCPP was then coupled with either N-Boc-2,2′-
 diethylamine (yield 60%) or 
These intermediates (TetNHBocPP and 
deprotected using TFA in CH
conditions, giving 9 (74%) or 
were characterized by UV
electrospray mass spectrometry
Both porphyrins are well soluble i
biological tests could not be performed. 
The 1H NMR spectra of 9 and
The chemical shifts of all the 
spectra (Figure 30 and 31) and by comparison with the bpy
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Figure 31. H-H COSY NMR spectrum of TedabpyPP 10 in CD2Cl2.  
 
For each porphyrin the six inequivalent bpyAc protons give six resolved resonances (four 
doublets and two singlets) equally spaced in both spectra. Herin the NMR and ESI-MS 
characterization of 10 is described (Figure 31). 
The H-HCOSY spectrum of 10 shows a strong cross peak between the doublet of the H6 (δ 
8.62) and the doublet of the H5 (δ 7.66). The proton H5' resonates as a doublet at δ 6.96 and it 
is coupled with the doublet at δ 8.35, attributed to the adjacent proton H6'. The singlet at δ 
8.74 integrating for 8H refers to βH pyrrolic protons. The two doublets at δ 8.11 and 8.18 are 
related to the o/m Ph protons. In the H-H COSY spectrum of 10 this resonance at higher fields 
overlaps with the resonance of the proton H3' and integrates for 12H. The two broadened 
triplets at δ 7.21 and 7.31 were attributed to the resonances of the amide protons by HSQC 
experiments. 
In the upfield region the methyl protons of the bpy resonate as a singlet at δ 2.21 (12H). The 
aliphatic CH2 protons resonate as multiplets of low intensity between δ 3.65 and 3.88. They 
both display a strong cross peak with the amide protons in the H-HCOSY spectrum. Finally, 
the pyrrole NH protons resonate at δ -3.00 as a broad singlet. 
H5' H5 
mPh  oPh + H3' 
CONH 
H3 CH2spacer 
βH 
H6' H6 
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Compound 10 was also characterized by spectrometry ESI-MS. The spectrum reported in 
Figure 32 displays the molecular peak MH +at m/z 2096.7 together with the peaks M+Na+ 
(m/z 2118.6), M+K+ (m/z 2134.5) and M+Na++K+ (m/z 2158.5). 
 
 
Figure 32.ESI-MS spectrum of 10. 
 
Treatment of either porphyrins 9 and 10 with four equivalents of the neutral Ru (II) precursor 
[Ru([9]aneS3)(dmso)Cl2] in refluxing CH2Cl2/MeOH mixtures afforded − upon replacement 
of the dmso and a chloride ligand by the bpy moieties −the corresponding tetraruthenated 
compounds in excellent yield: [TedabpyPP{Ru([9]aneS3)Cl}4]Cl4 (11) (Scheme 7) or 
[TetbpyPP{Ru([9]aneS3)Cl}4]Cl4 (12), respectively.  
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Scheme 7.Schematic structure of the ruthenium-porphyrin conjugate 11a. 
aReactions and conditions: (a) methanol/diclometane, 24h, reflux (92%) 
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Figure 33. H-H COSY NMR spectrum of 11 in dmso-d6.  
 
Herein the more polar conjugate 11 is described (Figure 33). Even though compound 11 has a 
good solubility in water, its proton NMR spectrum in D2O presents only broad peaks, possibly 
due to aggregation occurring at NMR concentrations as previously observed with other Ru-
porphyrin conjugates.116 For this reason the NMR spectra of both compounds were recorded 
in dmso-d6, where only sharp resonances are observed. In general, the NMR spectra of both 
conjugates are consistent with their expected four-fold symmetry, i.e. all peripheral Ru 
fragments are equivalent.  The 1H NMR spectrum of 11 in the upfield region shows, beside 
the multiplets of [9]aneS3 (δ 2.40 – 2.85), a singlet at δ 2.53 for the methyl on bpyAc, and the 
multiplets of the aliphatic spacer (δ 3.55 – 3.70). The two internal NH pyrrole protons appear 
as a broad singlet at δ ≈ -2.9. In the downfield region, the six resonances of the bpyAc protons 
maintain the same relative pattern as in the free TedabpyPP except for H3 and H6 (even 
though, as typical for these compounds, they are slightly broader than those in the free 
porphyrins). While the resonances of H5,5' (see Scheme 7 for numbering scheme) are 
scarcely affected by coordination to Ru, those of H6,6' and H3,3' are shifted downfield by ca. 
0.5 ppm. Also the two triplets of the amide NH protons are remarkably shifted downfield (ca. 
2 ppm compared to free TedabpyPP), but this effect is most likely due to the change of 
CONH H6 H3 
H5        H5' 
CONH 
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CH3 bpy 
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solvent (dmso-d6vs CD2Cl2). The correlation H-H COSY spectrum of 11 displays two strong 
cross peaks between vicinal bipyridyl protons (H5 and H6, H5' and H6'), and two weaker 
peaks between the multiplets for the CH2 protons of the spacer and the NH amide protons 
(Figure 33). We attributed the most downfield NH resonance to the amide group close to the 
bpy moiety. The 1H NMR spectrum of 12 displays several overlapping resonances of the 
bpyAc protons, and only those of H5,5' are well resolved (Figure 34). Owing to its very low 
solubility in water, compound 12 was not investigated further. 
 
Figure 34. 1H NMR spectrum of 12 in dmso-d6in the aromatic region. 
 
Consistent with what observed already for compound 8, the fluorescence spectrum of 11 is 
very similar to that of the parent porphyrin 10 except for the ca. 25% quenching of the 
emission intensity attributed to the peripheral heavy atoms (Figure 35).  
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Figure 35: Emission spectra of 0.2 A solutions of 10indmso (red), 11 in dmso (pink)  and  in water (cyan). λex  
421 nm, λem 648 nm. 
 
The fluorescence properties of porphyrins are useful to study their aggregation behavior in 
solution. In fact porphyrins in their monomeric form usually show intense fluorescence 
emissions, which are partially or completely quenched upon aggregation in solution.61 The 
fluorescence spectra of 0.2 A solutions of 11 in dmso and in water upon excitation of the 
Soret band showed an emission band at 648 nm; the significant reduction in emission 
intensity on going from dmso to H2O (≈ 60 %) suggests that the ruthenium-porphyrin 
conjugate aggregates in water (Figure 35). This finding is consistent with the very low 
resolution of the 1H NMR spectrum in D2O. The time course of UV-vis absorbance spectrum 
of 11 in aqueous solution was recorded at 25 °C. The Soret band absorbance gradually 
increased (≈ 14 %) until an almost constant value was reached after 3 h (Figure 36a and b).  
ab 
 
Figure 36: (a) UV-vis spectra of 11 (0.2 A solution in water) recorded at 10 min (0 – 40 min), 20 min (40 min 
- 60 min), 30 min (1 h – 2 h), 60 min (2 h – 6 h) intervals. (b) Boltzmann fitting of absorbance data. 
No shape modification or shift of the Soret band were observed, suggesting that no major 
chemical modification of the porphyrin structure is occurring and that the minor absorbance 
increase might be due to chloride hydrolysis and formation of the Ru-aquo species (Figure 
36).87 
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[TedabpyPP{Ru([9]anoN3)(dmso-S)}4](Cl)8 (13) 
 
We showed before that TedabpyPP is a good precursor for the efficient preparation of the 
octacationic porphyrin conjugate 11 bearing the sulphur macrocycle 1,4,7-tritiocyclononane 
([9]aneS3). 
To extend the structure-relationship investigations we synthesized a new Ru-porphyrin 
conjugate in which tritiocyclononane is replaced by the nitrogen macrocycle 1,4,7-
triazacyclononane ([9]aneN3, tacn). 
With this aim we used the complex [Ru([9]aneN3)(dmso-S)2Cl]Cl as metal precursor to 
obtain the conjugate[TedabpyPP{Ru([9]aneN3)(dmso-S)}4](Cl)8(13) (Scheme 8). For the 
synthesis of 13 it was necessary to vary the reaction conditions previously described to 
synthesize 11, increasing the reaction time from 24 to 48h and using a 1:5 ratioporphyrin / Ru 
in dichloromethane/methanol 1:3. 
At reaction completion, the solution was concentrated and treated with diethyl ether to 
precipitate the product. After filtering and washing with diethyl ether and diclorometane, the 
porphyrins conjugate 13 was obtained in 79% yield. 
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Scheme 8. Synthetic route to [TedabpyPP{Ru([9]aneN3)(dmso-S)}4](Cl)8 (13).a 
aReactions and conditions: (a) methanol/diclometane, 48h, reflux (79%) 
 
The ottacationic ruthenium conjugate 13 was characterized by mono- and bidimensional 1H 
NMR spectroscopy. 
All the resonances were assigned by means of conventional H-H COSY spectra and by 
comparison with the bpy-porphyrins previously prepared. 
The H-H COSY spectrum of 13 recorded in dmso-d6 at room temperature shows in the 
downfield region (Figure 37) a cross peak between the two well resolved doublets at δ 7.62 
and 8.10 attributed to the bipyridil protons H5' and H6'and between protons H5 and H6 at δ 
7.62 and 9.16 respectively. The protons of [9]aneN3, resonate as two boad multiplets at δ 6.06 
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(4H) and 7.22 (8H), respectively. Those assignations were confirmed by HSQC experiments 
(Figure 38a). The o/mPh (16H) protons resonate in a multiplet at δ 8.31. 
The two broad triplets at δ 8.99 and 9.49 were attributed to the resonances of the amide 
protons by HSQC experiments (Figure 38a). The βH and H3' (δ 8.85), and the bipyridyl 
protons H6' and H3 (δ 9.16) overlap and are quite broad. 
 
 
Figure37. H-H COSY NMR spectrum of 13 in dmso-d6 in the downfield region. 
 
The HSQC spectrum of the porphyrin 13 in dmso-d6 in the downfield region shows only CH 
groups (Figure 38a). In particular, this experiment confirms the assignment of the NH of the 
[9]aneN3 at δ 6.06 and at 7.22 and of the CONH at δ 8.49 and 8.99 (for the absence of cross 
peaks). Furthermore it shows the overlap of two CH resonances at δ 8.30 (o/mPh) and 9.17 
(H6'and H3). 
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Figure 38a. HSQC spectrum of 13 in dmso-d6in the downfield region. Read peaks: CH/CH3 groups. 
 
 
 
Figura 38b. HSQC spectrum of 18 in dmso-d6in the upfield region. Blue peaks: CH2 groups; read peaks: 
CH/CH3 groups. *:impurity. 
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In the upfield region the HSQC shows the blue cross-peaks of CH2 group of the spacer. The 
red cross peak of the CH3 bypiridil at δ 2.56 correlates with a carbon that resonates at about δ 
20. 
The protons of the methyl groups of the ruthenium-bonded dmso correlate with carbon atoms 
that resonates at about δ 45. One of the two diastereotopic methyl groups resonates at δ 2.61, 
the other overlaps with the resonance of the solvent. 
Compound 13, besides being soluble in organic solvents such as methanol, is also well 
soluble in aqueous solution and in PBS at pH=7.4. 
 
2.2.5. Conclusions 
 
In this part we have described different synthetic approaches to the preparation of porphyrin 
conjugates with Ru(II) coordination compounds. We have varied the number and charge of 
the peripheral Ru fragments, and described conjugates whose total charge ranges from +4 to 
+8. The connection can occur through a single N(pyridyl)–Ru bond or through a chelating 
bpy unit. The Ru compounds can either contain one labile ligand or be coordinatively 
saturated and substitutionally inert. 
Meso-pyridylporphyrins (PyPs), beside being synthetically more affordable, allow to tune the 
geometry of the conjugates. We have shown that when 3'PyPs, instead of 4'PyPs, are used, the 
peripheral metal fragments typically lay both above and below the plane of the chromophore, 
thus giving access to diverse shapes and geometries. 
In the first serie of porphyrins with peripheral bpy units at mesopositions described in this 
work, bpy4-PPs, the linker is relatively short and rigid.  
Due to the mild solubility of these compounds, we developed two novel “extended-
arms”versatile porphyrins, namely TetbpyPP and TedabpyPP, with a multistep approach and 
reasonable overall yield. These porphyrins are particularly suited for the strong coordination 
of peripheral metal fragments. 
In general we demonstrated that all the porphyrins can effectively bind four half-sandwich 
Ru(II) coordination compounds to give the cationic conjugates in excellent yields. 
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2.5. Determination of Singlet oxygen Quantum Yield (Φ∆)  
 
The singlet oxygen quantum yield (Φ∆) is a key property of a photosensitising agent. 
Since the most common mechanism of action of the PDT photosensitizers involves the 
production of singlet oxygen upon photo-excitation (Type II mechanism), Φ∆ was measured 
for the conjugates previously described Most PDT photosensitizers clinically used typically 
have Φ∆values of ca. 0.5.117 
The singlet oxygen generation by the Ru(II)-porphyrin conjugates was measured using 9,10-
dimethylanthracene (DMA) as a substrate. This compound reacts with 1O2 and is converted to 
the non-fluorescent 9,10-endoperoxide with 100% efficiency (no physical quenching). 118 
The amount of photogenerated 1O2 was calculated by measuring the residual DMA 
concentration as a function of the irradiation time.119 
In a typical experiment, 3 ml of an ethanol solution containing 1,5 ml of 20 µM DMA and 1,5 
ml of a porphyrin solution of absorbance A = 0.4 were placed in a quartz cuvette of 1 cm 
optical path and gently stirred during exposure to the Teclas lamp (100 mW/cm2) at a 
temperature of 20 ±2 °C. 
The results obtained using compound 2 as a substrate are reported here as an example. The 
spectophotofluorimetric analysis to determine the DMA content was performed at 5-s 
intervals up to a total irradiation time of 25 min. The unirradiated and the irradiated DMA 
solutions were excited at 360 nm and the fluorescence emission was observed in the 380 – 
550 nm wavelength range (Figure 39). The DMA photooxidation follows the first order 
kinetic: thus, the rate constant of the photoprocess was obtained from the slope of semilog 
plot (Figure 40) and has been converted into quantum yield of singlet oxygen generation by 
comparison with the rate constant for DMA photooxidation by hematoporphyrin (Hp) (Ф∆ 
0.65 in ethanol).120 
 
56 
 
 
Figure 39. Photobleaching of an ethanol solution of DMA by 2 upon irradiation with a Teclas lamp (590–700 
nm) at 100 mW/cm2. 
 
Figure 40. Photooxidation of 10 µM DMA in ethanol solution sensitized by 2. k is the first-order rate vs constant 
for the photoprocess as deduced from the slope of the semilog plot. 
 
Exposure of the porphyrins to the clinically useful red light (590-700 nm) for up 30 min using 
the experimental condition specified before caused a negligible decrease in the intensity of the 
visible absorption bands. This process, generally defined as photobleaching, is usually related 
to irreversible destruction of the tetrapyrrolic macrocycle.  
All the compounds appeared to photosensitize the oxidation of the DMA according to first-
order kinetics; a behavior typically observed for most photodynamically active 
photosensitizers.  
k = 2.50801 (s-1) 
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For each porphyrin, the photokinetic experiments were performed in ethanol. The results are 
showed in Table 2. 
 
photosensitizer 
k× 10s-1 
in ethanol 
Ф∆ in 
ethanol 
Hp 2.5716  0.65a 
4'TPyP (1) 1.95290 0.49 
[4'TPyP{Ru([9]aneS3)(en)}4][CF3SO3]8(2) 2.50801  0.63 
[4'TPyP{Ru([9]aneS3)(bpy)}4][CF3SO3]4 (3) 3.31698 0.84 
3'TPyP(4) 1.71403  0.43 
[3'TPyP{Ru([9]aneS3)(en)}4][PF6]8(6) 1.68385  0.43 
[3'TPyP{Ru([9]aneS3)(bpy)}4][PF6]8(5) 3.48938  0.88 
Bpy4-PP (7) 1.50587  0.38 
[Bpy4-PP{Ru([9]aneS3)(dmso-S)}4][CF3SO3]8(8) 1.39556  0.37 
TedabpyPP(10) 1.5846  0.40 
[TedabpyPP{Ru([9]aneS3)Cl}4]Cl4(11) 1.40215  0.35 
[TedabpyPP{Ru([9]aneN3)(dmso-S)}4](Cl)8(13) 1.0330  0.26 
 
Table 2. Quantum yield of production of singlet molecular oxygen (Ф∆) and order rate vs constant for the 
photoprocess in ethanol upon irradiation with a Teclas lamp (590–700 nm) at 100 mW/cm2. 
a: from reference 120 
 
The investigated Ru-porphyrin conjugates have from moderate (Φ∆ = 0.35 and 0.26 for 11 
and 13, respectively) to good (Φ∆ =0.84and 0.88 for 3 and 5, respectively) singlet oxygen 
quantum yield. In general Ru(II)-porphyrins conjugates through single coordination bond 
show Φ∆ values higher than conjugates through two coordination bonds. Ru(II)-porphyrins 
conjugates through two coordination bonds have moderate singlet oxygen quantum yields (Φ∆ 
= 0.37 and 0.35 for 8 and 11, respectively). These Φ∆ values are not significantly different 
from those of the corresponding parent porphyrins (0.38, 0.40 for the precursors of 7 and 10, 
respectively).  
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2.6. Cell culture studies 
 
Out of the above-mentioned porphyrin-Ru conjugates, we selected the four cationic 
compounds described in Figure 41, representative of both types of connections, for biological 
tests. 
Compounds 2 and 3 bear coordinatively saturated Ru compounds, whereas 8 and 11 have 
half-sandwich Ru fragments with a relatively labile dmso or Cl ligands and are therefore, in 
principle, more prone to coordination to biological targets. All conjugates are either soluble in 
water or in dmso; those conjugates that are not well soluble in aqueous solution usually 
become moderately soluble in phosphate buffer at physiological pH or upon addition of small 
amounts of dmso.109 
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Figure 41. Schematic structures of ruthenium-porphyrin conjugates 2, 3, 8 and11. 
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2.6.1. Cytotoxicity 
 
The cytotoxicity of conjugates 2, 3, 8 and 11– in the dark –was evaluated by Dr. Alberta 
Bergamo in the human breast cancer cells MDA-MB-231 and in the non tumorigenic 
epithelial cells HBL-100, after an exposure of 72 h. The IC50 values are reported in Table 3 
and are compared with those obtained by treating cells with two half-sandwich Ru(II) 
complexes that closely mimic the peripheral fragments on the conjugates: 
[Ru([9]aneS3)(bpy)Cl][CF3SO3] (14) and [Ru([9]aneS3)(en)Cl][CF3SO3] (15) (Figure 42). 
 
Table 3. IC50 values of porphyrins 2,3,8 and 11,and complexes14 and 15on MDA-MB-231 and HBL-100 cells 
after 72 h. (in the Dark)a 
 
 IC50 [µM] 
 MDA-MB-231 HBL-100 
2 4 ± 1 2 ± 1 
3 5 ÷ 5 4 ÷ 5 
8 4 ÷ 6 10 ÷10 
11 12 ± 2 26 ± 2 
[Ru([9]aneS3)(bpy)Cl][CF3SO3] (14) > 300* n.d. 
[Ru([9]aneS3)(en)Cl][CF3SO3] (15) 146 ÷ 177* 175** 
 
aMDA-MB-231 cells grown in multi-well plates are treated with compounds 2- 11 at 0.1 µM ÷ 30 µM for 72 
h, then cell cytotoxicity was detected by MTT. IC50 are the mean ± S.D. calculated from values obtained in three 
separated experiments (compounds 2, 11) or the values obtained in two separate experiments (compounds 3, 8). 
Statistics: unpaired t test.*from ref. 88. **from ref. 87 
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Figure 42. Schematic structures of [Ru([9]aneS3)(bpy)Cl][CF3SO3] (14), [Ru([9]aneS3)(en)Cl][CF3SO3] (15) 
and [Ru([9]aneS3)(bpyAc)(dmso-S)][CF3SO3]2(16). 
 
While the reference Ru complexes are either mildly (15) or not cytotoxic at all (14), the Ru-
porphyrin conjugates 2, 3 and 8 show IC50 values in the low micromolar range (2 ÷ 10 µM), 
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i.e. up to two orders of magnitude lower than those measured for 14. Compound 11 is slightly 
less active in reducing cell proliferation as it shows, in both cell lines, IC50 values statistically 
higher than those of the other conjugates. Taken together, these results show that, even when 
the cell growth inhibition per Ru fragment is considered, conjugates remain remarkably more 
cytotoxic compared to the reference Ru complexes. In addition, their cytotoxic activity seems 
to be scarcely dependent on the type of porphyrin-Ru connection on the total positive charge 
of the adduct, and on the solubility in water (only 2 and 11 are well soluble). These 
observations suggest that the increase of cytotoxic potency of the porphyrin conjugates with 
respect to the Ru complexes might derive from an improved uptake in cancer cells.121 In 
addition, the cell growth inhibition, which is apparently independent on the presence of 
substitutionally-labile ligands on the ruthenium fragments (compare 2 and 3 vs 8 and11), 
probably does not involve direct coordination of the conjugates to biological targets. The 
finding of cytotoxic activity in substitutionally inert metal complexes, which apparently 
contradicts the paradigms established for anticancer Pt compounds, is becomingly an 
increasingly common feature in modern inorganic anticancer research.122 
Whereas for 2 and 3 the IC50 values are substantially independent of the cell line being 
treated, compounds 8 and 11 are ca. two times more active against the highly invasive tumour 
MDA-MB-231 cells than against the non tumorigenic HBL-100 cells, with IC50 values of 
approximately 5 µM and 10 µM for compound 8 (p = 0.0283 for MDA-MB-231 vs HBL-
100), and of 12 µM and 26 µM for compound 11 (p = 0.0009 for MDA-MB-231 vs HBL-
100), respectively. Despite what might be a first-sight impression, the half-sandwich Ru 
fragments of compounds 8 and 11 are remarkably similar: the investigation performed on the 
reference complexes [Ru([9]aneS3)(bpy)Cl][CF3SO3] (14) and 
[Ru([9]aneS3)(bpyAc)(dmso)][CF3SO3]2 (16) showed both dmso and Cl are relatively labile 
ligands that are released in aqueous solution.67 Thus both 8 and 11, under in vivo conditions, 
are likely to generate the same peripheral [Ru([9]aneS3)(bpy-PP)(H2O)]2+fragments. Thus, the 
main structural difference of 11 compared to 8 are the flexible hydrophilic spacers between 
the chromophore and the peripheral Ru fragments. Apparently, this feature makes 11 less 
cytotoxic but preserves its capability to distinguish between the non tumorigenic HBL-100 
and the highly invasive MDA-MB-231 cell line showing selectivity against this latter. This 
finding suggests that compounds 8 and 11 might have a specific interaction with a target 
differently expressed by the two cell lines. 
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2.6.2. Phototoxicity 
 
Conjugates 2, 8 and 11 were selected for performing a detailed investigation of their cytotoxic 
activity against MDA-MB-231 human breast cancer cells under irradiation with visible red 
light (phototoxicity). These compounds, besides being soluble in dmso, are also well (2 and 
11), or at least appreciably (8), soluble in water, and represent three types of porphyrins with 
increasing structural complexity and both types of porphyrin-Ru connections. The cells 
cultures were exposed for 24 h at concentrations of the conjugates ranging from 0.1 µM to 10 
µM, then were irradiated at 590-700 nm with a fluence rate of 25 mW/cm2 and light doses 
from 1 to 10 J/cm2. The exposure of control cells to these total doses does not induce an 
inhibition of cell proliferation as reported in Figure 43. 
Dark 1 J/cm2 5 J/cm2 10 J/cm2
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
O
.
D.
 
(57
0 
n
m
)
 
Figure 43. Cell viability of control cells exposed or not to different total light doses. MDA-MB-231 human 
breast cancer cells were irradiated or not (Dark), at a fluence rate of 25 mW/cm2 and total light doses ranging 
from 1 J/cm2 to 10 J/cm2. Cell cytotoxicity was determined 24 h after the end of irradiation by MTT test. Bars 
represent the mean ± S.D. of optical density values obtained in a representative experiment performed in 
quadruplicate. 
 
Cell cytotoxicity was determined using the MTT test 24 h after the end of the irradiation. 
Cells treated with the same concentrations of the test compounds, but kept in the dark, were 
used as controls for photo-cytotoxicity, whereas cells not exposed to drugs neither to light 
were used as controls for cytotoxicity. The optimal total light dose was determined in a 
preliminary series of experiments using 11 as representative ruthenium-porphyrin conjugate 
(Figure 44). By irradiating the tumour cells at increasing total light doses from 1 to 30 J/cm2, 
the dose-response curve shifts to the left and the IC50 value correspondingly decreases. Light 
doses greater than 10 J/cm2 were discarded as induced to excessive toxicity. 
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Figure 44. Light dose-effect curves for 11 as representative ruthenium-porphyrin conjugate. MDA-MB-231 
human breast cancer cells were exposed to 1 µM to 10 µM for 24 h, then cells were irradiated at a fluence rate of 
25 mW/cm2 and total light doses ranging from 1 J/cm2 to 30 J/cm2. Cell cytotoxicity was determined 24 h after 
the end of irradiation by MTT test. The dotted line corresponds to 50% inhibition of cell proliferation. 
 
The phototoxicity of compounds 2, 8 and 11 against MDA-MB-231 cells at increasing total 
light doses is shown in Table 4. IC50 values are compared to those calculated from cell 
cultures similarly treated with the Ru-porphyrin conjugates but kept in the dark. For example, 
compound 2 has an IC50of 3.34 µM in the dark, that becomes 1.73 µM, 0.29 µM (p< 0.05 vs 
dark) and 0.13 µM (p< 0.05 vs dark) when cells are exposed to 1 J/cm2, 5 J/cm2 and 10 J/cm2, 
respectively. Similar results were observed for compound 11, whose IC50 drops from 2.09 µM 
(dark) to 0.10 µM (10 J/cm2, p < 0.01 vs dark). Under these experimental conditions, 
compound 8 is slightly less active than the others when cells are kept in the dark (IC50 = 24.62 
µM) but, after light exposure its IC50 value decreases by one order of magnitude, similarly to 
the other two compounds: 1.71 µM at 10 J/cm2 (p < 0.001 vs dark, and p < 0.05 vs 1 J/cm2). 
 
Table 4. IC50 values of compounds 2, 8 and 11 in MDA-MB-231 cells treated for 24 h and then exposed to 
increasing doses of visible light (590-700 nm).a 
 
 IC50 [µM] 
 Dark 1 J/cm2 5 J/cm2 10 J/cm2 
2 3.34 ±1.87 1.73 ± 1.10 0.29 ± 0.02 0.13 ± 0.04 
8 24.62 ± 6.38 10.64 ± 1.61 3.93 ± 1.24 1.71 ± 0.64 
11 2.09 ± 0.78 0.56 ± 0.12 0.24 ± 0.10 0.10 ± 0.04 
a MDA-MB-231 cells grown in multi-well plates were treated with compounds 2, 8 and 11 at 0.1 µM ÷ 10 µM 
for 24 h, then cells were irradiated with visible light (590-700 nm) at 25 mW/cm2fluence rate and total light 
doses of either 1 J/cm2, 5 J/cm2 or 10 J/cm2. Cell cytotoxicity was detected by MTT test 24 h after irradiation. 
Statistics: ANOVA Analysis of variance and Tukey-Kramer post test. 
 
It should be noted that the experimental conditions used in these experiments for determining 
the cytotoxicity in the dark (i.e. 24 h of cell challenge with each compound followed by 
further 24 h in a drug free medium and evaluation by the MTT test) are different from those 
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described above (i.e. 72 h continuous drug treatment followed by the MTT test). The two 
schedules do not affect the IC50 of 2 but yield moderately different values for 8 and 11: 8 is 
ca. 5 times more active after a continuative 72 h exposure, whereas the opposite result – i.e. a 
ca. 5-fold decrease of the cytotoxic activity – is found for compound 11 when cell treatment is 
prolonged from 24 h to 72 h.  
Most interestingly, compounds 2, 8 and 11 are all good candidates for being used in PDT 
because they are effective at mild light doses (10 J/cm2), and show IC50 values one order of 
magnitude lower than those calculated in the dark in the same experimental conditions. 
Compounds 2 and 11 are the most potent and most promising since they already cause a 
significant reduction of tumour cells growth at a treatment dose as low as 1 J/cm2.  
 
2.6.3. Intracellular localization 
 
The intracellular localization in MDA-MB-231 cells of compounds 2, 8 and 11 was 
determined after 16 h of exposure using fluorescence microscopy; the results for compound 
11 are reported in Figure 45. The porphyrin-associated fluorescence revealed that 11 
accumulates in the cytoplasm of the breast cancer cells (Figure 45B), yielding red emission 
spots, but not in the nucleus as demonstrated by the overlay with the blue fluorescence of 
DAPI (Figure 45C), a compound that selectively stains the nucleus (Figure 45A). Compound 
11 apparently accumulates in not yet identified granular structures of the cytoplasm. Similar 
results were obtained with compounds 2 and 8 (data not shown). DAPI staining, several hours 
after treatment, did not show morphological changes at nuclear level typical of apoptosis. On 
the basis of this observation the most likely mechanism of cell death seems to be necrosis, 
consistent with literature data showing that both death mechanisms are possible in PDT, 
depending on the characteristics of the photosensitising agent 123, on the cell lines used 124and 
on the treatment schedule used125. 
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Figure 45. Evaluation of the intracellular localization of 11 in MDA-MB-231 human breast cancer cells by 
fluorescence microscopy. MDA-MB-231 cells were grown on histological glass slides and exposed to 11 (10 
µM) for 16 h in the dark. Cells were fixed in 4% buffered formol, stained with DAPI and examined 
(magnification 200×). (A) DAPI (excitation at 365 nm), (B) compound 11 (excitation at 535 nm), (C) overlay of 
excitation at 365 nm for DAPI staining of cell nuclei (blue) and excitation at 535 nm, indicating accumulation of 
11 (red spots) in the cytoplasm of the cells. 
 
2.6.4. Ruthenium cell uptake 
 
The uptake of compound 8 by MDA-MB-231 and  HBL-100 cells was measured by atomic 
absorption spectroscopy after treatment for 1 h, 2 h, 4 h and 24 h. Two concentrations (4.5 
µM and 10 µM) were used for each cell line, that represent the IC50 values calculated for this 
compound in MDA-MB-231 and HBL-100 cells after a 72 h exposure, respectively. Figure 46 
shows the µg of ruthenium/106 cells as a function of the time of treatment: in both cell lines 
the ruthenium associated to cells increases proportionally to the duration of the treatment 
reaching approximately the same maximum value of 0.1 µg/106 cells in both cell lines (after 
24 h at the concentration of 10 µM), although the accumulation kinetic seems slower in the 
human breast cancer cells in comparison to the non tumorigenic cells. 
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Figure 46. Ruthenium uptake in MDA-MB-231 and HBL-100 cells treated with compound 8. Cells grown in 
multi-well plates were treated with compound 8 at 4.5 µM or 10 µM for 1, 2, 4 or 24 h. At the end of the 
treatment ruthenium content was measured with atomic absorption spectroscopy.  
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Thus, the large positive charge of the conjugate does not seem to inhibit its cellular uptake. 
Indeed, it has been demonstrated that highly charged metal complexes are capable of crossing 
cell membranes even better than neutral or low-positively charged complexes 126. 
 
2.6.5. Conclusions 
 
Compound 11, together with the three other cationic Ru-porphyrin conjugates 2, 3, 8 were 
investigated for in vitro cell growth inhibition toward MDA-MB-231 human breast cancer 
cells and HBL-100 human non tumorigenic epithelial cells. In the dark, all compounds 
showed IC50 values in the low micromolar range, i.e. at least 2 orders of magnitude lower than 
the corresponding Ru complexes. 
Their cytotoxic activity is scarcely dependent on the type of porphyrin and of Ru fragment. In 
other words, conjugation of the Ru(II) half-sandwich compounds to the porphyrin led to a 
remarkable increase of cytotoxicity, possibly due to improved uptake (see above).  
Three compounds were selected for investigating their phototoxic effects on MDA-MB-231 
human breast cancer cells upon illumination. Conjugates 2, 8, and 11 became ca. 10 times 
more cytotoxic after irradiation with visible light (590-700 nm) and proved to have from 
moderate to good singlet oxygen quantum yields. According to fluorescence microscopy 
experiments, they accumulate in the cytoplasm of the breast cancer cells but do not penetrate 
significantly into the nucleus. The most potent compounds 2 and 11 were active at nanomolar 
concentration and very low light dose (1 J/cm2), making them promising sensitizers for the 
PDT of tumors 
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2.7. Experimental Section 
 
Mono and bidimensional (H-H COSY) 1H NMR spectra were recorded at 400 or 500 MHz, 
respectively, on a JEOL Eclipse 400FT or on a Varian 500 spectrometer. All spectra were run 
at ambient temperature. 1H chemical shifts in D2O were referenced to the internal standard 
2,2-dimethyl-2,2-silapentane-5-sulfonate (DSS) at δ = 0.00. In other solvents chemical shifts 
were referenced to the peak of residual non-deuterated solvent (δ = 7.26 for CDCl3, 5.32  for 
CD2Cl2, 3.31 for CD3OD, 2.50 for dmso-d6). UV-vis spectra were obtained at T = 25 °C on a 
Jasco V-500 UV-vis spectrophotometer equipped with a Peltier temperature controller, using 
1.0 cm path-length quartz cuvettes (3.0 mL). Electrospray mass spectra were recorded in the 
positive ion mode on a Bruker Esquire ESI-MS instrument. Fluorescence spectra were 
recorded on a F-4550 Hitachi spectrofluorimeter. 
 
Column chromatography was performed on silica gel 60 Å (Merck, 230-400 mesh ASTM), 
eluting with chloroform/ethanol mixtures as specified below. 
All chemicals were purchased from Sigma-Aldrich and used without further purification 
unless otherwise specified. 
The porphyrin-Ru conjugates precipitate with variable amounts of crystallization solvent, that 
depends on the batch. For this reason elemental analysis of such conjugates did not afford 
reliable and reproducible results and the values are not reported here (typically, some of the 
elemental analysis values, especially for C, differ from calculated values by > 0.5%). 
Nevertheless, the proposed formulas are all consistent with the 1H NMR and ESI spectra. 
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Conjugates with 4'TpyP  
 
[4'TPyP{Ru([9]aneS3)(en)}4][CF3SO3]8 (2). 
 
A 46.5 mg amount of [Ru([9]aneS3)(en)Cl](CF3SO3) (0.14 mmol) dissolved in 2 ml of 
MeOH was added to a suspension of 4'TPyP (20 mg, 0.032 mmol) in 15 ml of CHCl3. After 
addition of AgCF3SO3 (35.7 mg, 0.14 mmol), the reaction mixture was heated to reflux for 4 
h. The reaction was monitored by TLC analysis (silica gel, CH2Cl2/EtOH 90:10). The dark 
suspension was concentrated in vacuo to ca. 10 ml and a few drops of diethyl ether were 
added. A purple solid formed upon standing, which was removed by filtration and vacuum 
dried. The solid was redissolved in 10 ml of MeOH and centrifuged to eliminate AgCl. The 
solution was evaporated to dryness under reduced pressure to obtain the title compound. 
Yield: 59 mg (92%).  
 
1H NMR(D2O, δ, see Scheme 2for numberingscheme): 2.6 – 3.1 (m, 64H, CH2 [9]aneS3 + 
en), 4.17 (m, 8H, NH2), 5.09 (m, 8H, NH2), 8.52 (d, 8H, J = 5.67, H3,5), 9.11 (v br s, 8H, 
βH), 9.36 (d, 8H, J = 5.71, H2,6). δH (CD3OD, 25 °C, see Scheme 2 for numbering scheme): 
2.5 – 3.1 (m, 64H, [9]aneS3 + en), 4.38 (br m, 8H , NH2), 5.32 (m, 8H , NH2),8.42 (d, 8H, J = 
6.48, H3,5), 9.04 (v br, 8H, βH), 9.33 (d, 8H, J = 6.34, H2,6). δH (CD3OD, -15 °C): 2.5 – 3.1 
(m, 64H, [9]aneS3 + en), 4.46 (m, 8H , NH2), 5.43 (m, 8H , NH2), 8.42 (d, 8H, J = 6.21, 
H3,5), 8.97 (s, 4H, βH), 9.30 (s, 4H, βH ), 9.34 (d, 8H,  J = 6.18, H2,6). UV-
vis(CH3OH)λmax,nm (relative intensity, %): 419 (100), 513 (7.7), 549 (4.0), 589 (2.8), 646 
(1.8). 
 
[4'TPyP{Ru([9]aneS3)(bpy)}4][CF3SO3]8 (3). 
 
A 89.5 mg amount of [Ru([9]aneS3)(bpy)(dmso-S)][CF3SO3]2 (0.11 mmol) dissolved in 2 ml 
of methanol was added to a suspension of 4'TPyP (15.5 mg, 0.025 mmol) in 15 ml of CHCl3. 
The mixture was heated to reflux for 8 h, until disappearance of the spot of unreacted 
porphyrin according to TLC analysis (silica gel, CHCl3/EtOH 90:10). Dropwise addition of 
diethyl ether to the solution induced the precipitation of a purple solid, that was removed by 
filtration and washed with diethyl ether and dried under vacuum at r.t. Yield: 70 mg (78%).  
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1H NMR (CD3NO2 , δ): -3.35 (s, 2H, NH), 3.5 – 2.7 (m, 48H, CH2 [9]aneS3), 7.92 (t, 8H, 
H5,5'), 8.13 (d, 8H, H3,5), 8.33 (t, 2H, H4,4'), 8.63 (m, 16H, βH + H2,6), 9.22 (d, 2H, H3,3'), 
9.48 (d, 2H, H6,6'). UV-vis(CH3NO2)λmax, nm (relative intensity, %): 425 (100), 518 (8.8), 
553 (5.4), 590 (4.2), 646 (2.8). 
 
Table 5. Crystallographic data and details of structure refinements for compounds 3. 
 
4·4(CH3NO2) 10 
Empirical formula  C116H118F24N20O32Ru4S20 C22H28F6N2O9RuS6 
Formula weight 3805.78 871.89 
Crystal system Monoclinic Monoclinic 
Space group P 21/c P 21/c 
a (Å) 23.157(5) 10.026(3) 
b (Å) 16.581(4) 23.075(4) 
c (Å) 20.833(5) 14.057(3) 
β (°) 97.01(3) 96.40(2) 
Volume (Å3) 7939(3) 3231.8(13) 
Z 2 4 
Dcalcd (g cm–3) 1.592 1.792 
µ(mm–1) 0.890 0.958 
F(000) 3844 1760 
θmax (°) 25.52 28.28 
Reflns collected 49860 35958 
Unique reflections 4833 7081 
Rint 0.0404 0.0532 
Observed I> 2σ (I) 3965 4120 
Parameters 733 418 
Goodness of fit 1.117 0.870 
R1 (I> 2 σ(I)) [a] 0.0844 0.0427 
wR2 [a] 0.2515 0.1043 
∆ρ (e/Å3) 1.161[b] –0.831 0.420 –0.425 
 
[a]R1 = ΣFo–Fc / ΣFo, wR2 = [Σw(Fo2 – Fc2)2/ Σw(Fo2)2]½ 
[b]
 residual peak close to a triflate anion. 
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Table 6. Selected coordination bond lengths (Å) and angles (°) for compound 3. 
 
Ru(1)−N(1) 2.175(12) Ru(2)−N(3) 2.152(12) 
Ru(1)−N(2) 2.165(12) Ru(2)−N(4) 2.163(12) 
Ru(1)−N(5) 2.194(11) Ru(2)−N(6) 2.212(12) 
Ru(1)−S(1) 2.376(4) Ru(2)−S(4) 2.381(5) 
Ru(1)−S(2) 2.378(5) Ru(2)−S(5) 2.361(4) 
Ru(1)−S(3) 2.376(4) Ru(2)−S(6) 2.365(5) 
 
N(1)−Ru(1)−N(5)  87.4(4) N(3)−Ru(2)−N(6) 88.2(4) 
N(1)−Ru(1)−S(1) 175.6(4) N(3)−Ru(2)−S(4) 96.8(4) 
N(1)−Ru(1)−S(2) 96.6(4) N(3)−Ru(2)−S(5) 175.7(4) 
N(1)−Ru(1)−S(3) 92.7(3) N(3)−Ru(2)−S(6) 91.7(3) 
N(2)−Ru(1)−N(5) 84.5(4) N(4)−Ru(2)−N(6) 87.0(5) 
N(2)−Ru(1)−S(1) 99.1(4) N(4)−Ru(2)−S(4) 174.9(4) 
N(2)−Ru(1)−S(2) 172.2(4) N(4)−Ru(2)−S(5) 97.4(4) 
N(2)−Ru(1)−S(3) 95.3(3) N(4)−Ru(2)−S(6) 94.0(4) 
N(5)−Ru(1)−S(1) 91.6(3) N(6)−Ru(2)−S(4) 91.1(3) 
N(5)−Ru(1)−S(2) 91.4(3) N(6)−Ru(2)−S(5) 91.0(3) 
N(5)−Ru(1)−S(3) 179.8(4) N(6)−Ru(2)−S(6) 179.0(4) 
S(1)−Ru(1)−S(2) 87.70(16) S(4)−Ru(2)−S(5) 87.43(16) 
S(1)−Ru(1)−S(3) 88.32(15) S(4)−Ru(2)−S(6) 87.91(17) 
S(2)−Ru(1)−S(3) 88.83(16) S(5)−Ru(2)−S(6) 89.12(16) 
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Conjugates with 3'TpyP  
 
[3'TPyP{Ru([9]aneS3)(bpy)}4][PF6]8 (5) 
 
A 44.0 mg amount of [Ru([9]aneS3)(bpy)Cl](PF6) (0.07 mmol) was dissolved in 10 ml of 
MeOH. After addition of AgPF6 (17.7 mg, 0.07 mmol), the reaction mixture was heated to 
reflux for 1 h. After removal of AgCl by filtration, the yellow solution was concentrated in 
vacuo to ca. 5 mL and it was added to a solution of 3'TPyP (10 mg, 0.016 mmol) in 5 ml of 
CHCl3. The mixture was heated to reflux for 48 h, until disappearance of unreacted porphyrin 
according to TLC analysis (silica gel, CHCl3/EtOH 90:10). Dropwise addition of diethyl ether 
to the solution induced the precipitation of a purple solid, that was removed by filtration, 
washed with diethyl ether and dried under vacuum at r.t. Yield: 48 mg (86%).  
 
UV-vis (EtOH) λmax, nm (ε× 10-3, dm3 mol-1cm-1): 418 (82), 513 (10.9), 546 (8.7), 587 (7.7), 
643 (5.2). 
 
Table7. Selected coordination bond lengths (Å) and angles (°) for compound 5. 
Ru(1)-N(1) 2.084(8) Ru(1)-S(1) 2.316(2) 
Ru(1)-N(2) 2.080(8) Ru(1)-S(2) 2.308(2) 
Ru(1)-N(3) 2.118(7) Ru(1)-S(3) 2.299(3) 
 
N(2)-Ru-N(1) 78.3(4) N(1)-Ru-S(2) 97.5(3) 
N(2)-Ru-N(3) 90.6(3) N(3)-Ru-S(2) 91.6(2) 
N(1)-Ru-N(3) 88.7(3) S(3)-Ru-S(2) 87.69(9) 
N(2)-Ru-S(3) 96.6(3) N(2)-Ru-S(1) 89.9(2) 
N(1)-Ru-S(3) 174.7(3) N(1)-Ru-S(1) 93.0(2) 
N(3)-Ru-S(3) 89.9(2) N(3)-Ru-S(1) 178.3(2) 
N(2)-Ru-S(2) 175.2(3) S(3)-Ru-S(1) 88.44(9) 
  S(2)-Ru-S(1) 88.01(8) 
 
 
[3'TPyP{Ru([9]aneS3)(en)}4][PF6]8(6) 
 
To a 37.1 mg amount of [Ru([9]aneS3)(en)Cl](PF6) (0.07 mmol) dissolved in 10 ml of MeOH 
a 17.8 mg amount of AgPF6(0.07 mmol) was added and the reaction mixture was heated to 
reflux for 1 h. After removal of AgCl by filtration, the yellow solution was concentrated in 
vacuo to ca. 5 mL and it was added to a solution of 3'TPyP (10.0 mg, 0.016 mmol) in 5 ml of 
CHCl3. The mixture was heated to reflux for 48 h, until disappearance of the unreacted 
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porphyrin according to TLC analysis (silica gel, CHCl3/EtOH 90:10). Dropwise addition of 
diethyl ether to the solution induced the precipitation of a purple solid, that was removed by 
filtration and washed with chloroform and diethyl ether and dried under vacuum at r.t. The 
solidwas recrystallized from methanol/diethyl ether. Yield: 38 mg (76%).  
 
1H NMR (CD3NO2, δ, see Scheme 3 for numbering scheme): -2.92 (s, 2H, NH), 2.73 – 3.02 
(m, 64H, CH2 [9]aneS3 + en), 3.60 (m, 8H, NH2), 5.09 (m, 8H, NH2), 8.17 (t, 4H, H5), 8.94 – 
9.02 (d, 12H, βH + H6), 9.37 (t, 4H, H4), 9.64 – 9.75 (m, 4H, H2). 
UV-vis (EtOH) λmax, nm (ε× 10-3, dm3 mol-1cm-1): 421 (221), 513 (16.4), 546 (6.8), 587 (7.3), 
643 (3.9). 
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meso-tetra(bpy-phenyl)porphyrin (Bpy4-PP) (7) 
 
A 42.0 mg amount of bpyAc (0.196 mmol, 4.4 equiv.) and 58.8 mg of ECDI (0.274 mmol) 
were dissolved in 4 ml of pyridine. The solution was stirred for 30 min, then a 30.0 mg 
amount of p(NH2)4PP (0.045 mmol) was added and stirring was continued at r.t. The reaction 
was monitored by TLC (silica gel, CHCl3/EtOH 90:10). After 3h, water (20 ml) was added to 
the reaction mixture. The purple precipitate was removed by filtration, washed with water (80 
ml) and vacuum dried at r.t. Yield: 60 mg (91%).  
1H NMR (CDCl3, δ see Scheme 4 for numberingscheme): -2.76 (br s, 2H, NH), 2.52 (s, 12H, 
CH3), 7.26 (d, 4H, H5' overlapped with the resonance of residual CHCl3), 8.03 (dd, 4H, J= 
0.7, 4.1 Hz, H5), 8.13 (d, 8H, J = 8.3 Hz, mbg), 8.28 (m, 8H, J = 8.2 Hz,obg), 8.38 (s, 4H, 
H3'), 8.55 (s, 4H, H3), 8.64 (d, 4H, J = 5.0, H6'), 8.95 (m, 12H, βH + H6). UV-
vis(CHCl3)λmax, nm: 424, 518, 556, 594, 651. ESI-MS: m/z 1481.5 [M+Na+]. 
  
[Bpy4-PP{Ru([9]aneS3)(dmso-S)}4][CF3SO3]8 (8). 
 
A 20.0 mg amount of Bpy4-PP (0.014 mmol) dissolved in 10 ml of CHCl3 was added to a 
solution of [Ru([9]aneS3)(dmso)3][CF3SO3]2 (47.5 mg, 0.058 mmol) dissolved in 45 ml of 
acetone. The resulting solution was heated to reflux for 2 h, during which time a purple 
precipitate formed. The solution was concentrated under vacuum to ca. 15 ml. The solid was 
removed by filtration, washed with diethyl ether and dried under vacuum. Yield: 46 mg 
(81%).  
1H NMR (CD3NO2, δ, see Scheme 5 for numberingscheme): -2.72 (br s, 2H, NH), 2.75 (s, 
12H, CH3), 2.81 (s, 12H, dmso-S), 2.89 (s, 12H, dmso-S), 2.65 – 3.50 (m, 12H, CH2 
[9]aneS3), 7.76 (d, 4H, J = 5.4 Hz, H5'), 8.35 (m, 20H, H5 + mbg + obg), 8.75 (s, 4H, H3'), 
8.98 (d, 4H, J = 5.8 Hz, H6'), 9.08 (m, 8H, βH), 9.13 (s, 4H, H3), 9.33 (d, 4H, J = 5.6 Hz, 
H6), 9.92 (br s, 4H, CONH). UV-vis(dmso)λmax, nm (relative intensity, %): 424 (100), 519 
(5.9), 557 (4.8), 593 (2.1), 651 (2.6). 
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Conjugates with TetBpyPP and with TedabpyPP 
 
4-formyl benzoate  
 
HCl (g) was bubbled for 30 min in a solution of 4-formylbenzoic acid (5 g, 0.33 mmol) 
dissolved in 250 ml of methanol and cooled in an ice bath. The mixture was heated to reflux 
for 30 min and evaporated to dryness under reduced pressure to obtain a white solid that was 
recrystallized from petroleum ether to obtain the title compound. Yield 4.17 g (77%). Mp = 60 
°C (lit. 60 °C).  
 
1H NMR (CDCl3, δ): 3.97 (s, 3H, CH3), 7.96 (d, H3,5, J = 8.3 Hz), 8.20 (d, H2,6, J = 8.2 Hz), 
10.11 (s, CHO).  
 
meso-4'-tetracarboxymethylphenylporphyrin (4'-TCMePP)  
 
A 2.30 g amount of methyl 4-formyl benzoate (14 mmol) in propionic acid (50 ml) was 
heated at 120 °C. Freshly distilled pyrrole (1.0 ml, 14 mmol) was added and the mixture was 
refluxed for 1.5 h, then stored at –18 °C for 12 h. The purple precipitate was removed by 
filtration, thoroughly washedwith cold methanol and dried in vacuo at room temperature. 
Yield 0.63 g (21%).  
 
1H NMR (CDCl3, δ): -2.81 (br s, 2H, NH), 4.12 (s, 12H, CH3), 8.30 (d, 8H, oPh,  J = 8.1 Hz), 
8.45 (d, 8H, mPh, J = 8.1 Hz ), 8.82 (s, 8H, Hβ). UV-vis (CH2Cl2, 25°C) λmax, nm (relative 
intensity, %): 420 (100), 515 (4.0), 550 (2.0), 590 (1.4), 646 (1.0). Selected IR (KBr, cm-1): 
3313 (NH),1723 (s, C=O),1276 e 1020 (C-O). 
 
meso-4'-tetracarboxyphenylporphyrin (4'-TCPP)  
 
A 12 ml amount of a 40% KOH aqueous solution was added to a 200 mg amount of 4'-
TCMePP (0.236 mmol) dissolved in 200 ml of a 2:1 THF/MeOH mixture. The reaction 
mixture was stirred at 40 °C for 1 h, acidified with conc. HCl (pH 5) and extracted with 
THF/CH2Cl2 1:1 (4 × 50 ml). The organic fraction was evaporated under reduced pressure 
affording 174 mg of the desired purple product. Yield: 93%.  
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1H NMR (dmso-d6, δ): - 2.94 (s, 2H, NH),  8.40 (m, 16H, mPh + oPh), 8.87 (s, 8H, βH), 13.32 
(s, 4H, COOH). UV-vis (EtOH) λmax, nm (relative intensity, %) 416 (100), 513 (4.2), 548 
(2.1), 590 (1.3), 646 (0.9).  
 
TedaNHBocPP  
 
A 146 mg amount of EDCI (0.76 mmol) and a 103 mg amount of HOBt (0.76 mmol) were 
added to a solution of 4'-TCPP (100 mg, 0.126 mmol) dissolved in 4 ml of anhydrous DMF. 
To this solution, after  stirring for 30 min, a 138 mg amount of N-Boc-2,2′-
(ethylenedioxy)diethylamine (0.56 mmol) 168 and a 68 mg amount of dimethylaminopyridine 
(DMAP) (0.56 mmol) dissolved in 1 ml of anhydrous DMF were added. The reaction mixture 
was shielded from light and stirred at room temperature for 24 h, then the solvent was 
removed on a rotary evaporator to yield a dark semi-solid. A 1:1 THF/CH2Cl2 mixture (100 
ml) was added and the organic layer was washed with water (40 ml × 3) and dried over 
anhydrous Na2SO4. The organic fraction was evaporated to dryness under vacuum and the 
resulting solid was dissolved in 3 ml of CH2Cl2 and purified by column chromatography (4 × 
20 cm) using CH2Cl2/EtOH (90:10) as eluent.  The work-up afforded 153 mg of the product 
as a purple solid (yield 72%).  
 
1H NMR (CDCl3, δ): -2.83 (br s, 2H, NH), 1.38 (s, 36H, CH3 Boc), 3.35 (m, 8H, CH2spacer), 
3.61 (t, 8H, CH2spacer), 3.73 (m, 16H, CH2spacer), 3.84 (m, 16H, CH2spacer), 5.04 (br s, 
4H, NHCO), 8.24 (dd, 16H, 8H mPh + 8H oPh), 8.81 (s, 8H, βH). 
 
TetNHBocPP 
 
A procedure similar to that described above was used, with the following parameters: 170 mg 
of 4'-TCPP (0.215 mmol) in 10 ml of anhydrous DMF, 247.3 mg of EDCI (1.29 mmol) and 
174 mg of HOBt (1.29 mmol). To this solution a 275 mg amount of N-Boc-ethylenediamine 
127
 (1.72 mmol) was added and the reaction mixture stirred for 2.5 h at r.t. Yield 176 mg 
(60%).  
 
1H NMR (CDCl3, δ): -2.84 (br s, 2H, NH), 1.48 (s, 36H, CH3 Boc), 3.56 (m, 8H, CH2NHCO), 
3.74 (m, 8H, CH2NHBoc), 5.09 (m, 4H, NHBoc), 7.57 (m, 8H, CH2NHCO) 8.24 (dd, 16H, 
8H mPh + 8H oPh, J = 8.22, 19.53 Hz ), 8.79 (s, 8H, βH). 
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TedaNH2PP·4CF3COOH 
 
A 6 ml amount of trifluoroacetic acid (TFA) was added to a solution of TedaNHBocPP (153 
mg, 0.096 mmol) dissolved in 9 ml of anhydrous CH2Cl2. The mixture was shielded from 
light and stirred at room temperature for 2 h, after which the solvent was completely removed 
on a rotary evaporator to give a dark green semi-solid of the title porphyrin as triflate salt. A 
small amount (20 mg ca.) was neutralized with triethylamine (2 drops), dissolved in methanol 
(2 ml), precipitated with diethyl ether, filtered and thoroughly washed with diethyl ether for 
characterization. The remaining product was used in the following step without further 
purification. 
 
 
1H NMR (free base) (CD3OD, δ): 3.17 (t, 8H, CH2NH2), 3.80 (m, 40H, CH2spacer), 8.32 (dd, 
16H, mPh + oPh), 8.90 (br s, 8H, βH). UV-vis (MeOH) λmax, nm (ε × 10-3, dm3mol-1cm-1) : 
415 (479), 513 (20), 546 (11), 587 (7.1), 645 (5.9). ESI-MS m/z: 1312.7 (MH+), 
1334.6(M+Na+), 1350.6 (M+K+). 
 
TetNH2PP·4CF3COOH 
 
The same procedure as above was used, with the following parameters: 189 mg of 
TetNHBocPP (0.14 mmol) in 10 ml of anhydrous dichloromethane and 5 ml of TFA.  
 
1H NMR (free base) (dmso-d6, δ): -2.93 (s, 2H, NH), 3.13 (d, 8H, CH2NH2), 3.63 (d, 8H, 
NHCH2), 8.35 (dd, 16H, mPh + oPh), 8.84 (m, 8H, βH), 9.11 (m, 4H, NHCO). ESI-MS (m/z): 
959.4 (MH+), 981.4 (M+Na+), 
 
TedabpyPP (10) 
 
A 115 mg amount of bpyAc (0.54 mmol), a 155 mg amount of EDCI (0.81 mmol), and a 109 
mg amount of HOBt (0.81 mmol) were dissolved in 5 ml of anhydrous DMF. After stirring 
for 30 min at room temperature, a solution of TedaNH2PP (0.090 mmol) and 110 mg of 
DMAP (0.90 mmol) in 5 ml of anhydrous DMF was added. The reaction mixture was stirred 
for 24 h in the dark. At reaction completion (TLC: aluminium oxide, CH2Cl2/EtOH 90:10) the 
solvent was evaporated under vacuum and the resulting solid was triturated with  diethyl 
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ether, filtered, thoroughly washed with diethyl ether and dried in vacuum. Yield: 180 mg 
(96%). 
 
1H-NMR (CD2Cl2, δ): -3.00 (s, 2H, NH), 2.21 (s, 12H, CH3bpy), 3.68-3.83 (m, 48H, CH2 
spacer), 6.96 (d, 4H, J = 4.72 Hz, H5'), 7.21 (t, 4H, NHCO bpy), 7.31(t, 4H, NHCO), 7.66 
(dd, 4H, J = 1.64, 4.96 Hz, H5), 8.10 (s, 4H, H3'), 8.10 (d, 8H, J = 7.95 Hz, oPh), 8.18 (d, 8H, 
J = 7.95 Hz, mPh), 8.35 (d, 4H, J = 4.96 Hz, H6'), 8.62 (d, 4H, J = 4.96 Hz, H6), 8.65 (s, 4H, 
H3), 8.74 (s, 8H, βH). ESI-MS m/z: 2096.7 (MH+)2118.6 (M+Na+), 2134.5 (M+K+). UV-vis 
(MeOH) λmax, nm (relative intensity, %): 418 (100), 514 (4.7), 549 (2.4), 590 (1.5), 646 (1.1).  
 
TetbpyPP (9) 
 
The same synthetic procedure as above was used, with the following parameters: 191 mg of 
bpyAc (0.89 mmol), 218 mg of EDCI (1.14 mmol) and 159 mg of HOBt (1.17 mmol) in 13 
ml of anhydrous DMF. TetNH2PP (0.14 mmol), 154 mg of DMAP (1.26 mmol) in 7 ml of 
anhydrous DMF. Yield: 181 mg (74%). 
 
1H-NMR (dmso-d6, δ): -2.94 (br s, 2H, NH), 2.40 (s, 12H, CH3), 3.64 (m, 16H, CH2), 7.28 (d, 
4H, H5'), 7.87 (d, 4H, H5), 8.26 (s, 4H, H3'), 8.31 (m, 16H, oPh + mPh), 8.57 (d, 4H, H6'), 
8.84 (m, 16H, βH+H6+H3), 9.00 (t, 4H, CONH), 9.16 (t, 4H, CONH). ESI-MS m/z: 1744.7 
(MH+), 1766.7 (M+Na+), 1782.6 (M+K+). UV-vis (MeOH + 5% dmso) λmax, nm (ε×10-3, dm3 
mol-1cm-1): 416 (237), 512 (13), 547 (7.1), 589 (5.1), 645 (3.8). 
 
[TedabpyPP{Ru([9]aneS3)Cl}4][Cl]4 (11) 
 
A 50 mg amount of TedabpyPP (0.024 mmoli) was dissolved in a mixture of MeOH (6 ml) 
and CH2Cl2 (2.5 ml). To this solution a 41 mg amount of [Ru([9]aneS3)(dmso)Cl2] (0.095 
mmol) dissolved in 16 ml of hot MeOH was added. The mixture was refluxed for 24 h and its 
colour turned deep red. After reaction completion (TLC: aluminium oxide, CH2Cl2/EtOH 
90:10) the solvent was evaporated under vacuum and the residue redissolved in a few drops of 
methanol. Dropwise addition of diethyl ether to the purple-brown solution induced the 
precipitation of a purple solid, that was removed by filtration and washed repeatedly with 
diethyl ether and dried under vacuum at r.t. Yield: 79 mg (92%).  
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1H NMR (dmso-d6, δ): -2.93 (s, 2H, NH), 2.40 – 2.85 (m, 48H, CH2 [9]aneS3), 2.53 (s, 12H, 
CH3 bpy), 3.55 – 3.70 (m, 48H, CH2 spacer) 7.50 (d, 4H, J = 5.03 Hz, H5'), 7.95 (d, 4H, J = 
5.12 Hz, H5), 8.30 (s, 16H, oPh + mPh) 8.65 (s, 4H, H3'), 8.82 (d, 4H, J = 5.75 Hz, H6'), 8.84 
(s, 8H, βH), 8.93 (t, 4H, CONH), 9.01 (s, 4H, H3), 9.11 (d, 4H, J = 5.74 Hz, H6), 9.27 (t, 4H, 
CONH).ESI-MS m/z: 841.5 (MH+). UV-vis (MeOH) λmax, nm (relative intensity, %): 417 
(100), 513 (5.5), 549(2.9), 590 (1.5), 645 (1.0). 
 
[TetbpyPP{Ru([9]aneS3)Cl]4}][Cl]4 (12) 
 
The same synthetic procedure as above was used, with the following parameters: 25 mg of 
TetbpyPP (0.014 mmol) in 25 ml of MeOH. 27 mg of [Ru([9]aneS3)(dmso)Cl2] (0.063 
mmol). Yield: 39 mg (92%).  
 
1H NMR (dmso-d6, δ): -2.94 (br s, 2H, NH), 2.5 – 2.9 (m, 48H, CH2 [9]aneS3), 7.49 (d, H5'), 
8.03 (d, H5), 8.34 (dd, 16H, oPh + mPh) 8.78 (s, H3'). 8.84 (m, 16H, βH + H6'), 9.17 (m, 
12H,  CONH + H3), 9.52 (m, 4H, CONH).UV-vis (MeOH) λmax, nm (relative intensity, %): 
417 (100), 513 (8.1), 548 (3.9), 589 (2.6), 645 (1.8).  
 
[TedabpyPP{Ru([9]aneN3)(dmso-S)]4}][Cl]4 (13) 
 
A 30.0 mg amount of TedabpyPP (0.014 mmol) was dissolved in a mixture of MeOH (10 
ml) and CH2Cl2 (3 ml). To this solution a 39.3 mg amount of [Ru([9]aneN3)(dmso)2Cl] 
(0.086 mmol) dissolved in 7 ml of hot MeOH was added. The mixture was refluxed for 48 h 
and its colour turned deep red. After reaction completion (TLC: aluminium oxide, 
CH2Cl2/EtOH 90:10) the solvent was evaporated under vacuum and the residue dissolved in a 
few drops of methanol. Dropwise addition of diethyl ether to the purple-brown solution 
induced the precipitation of a purple solid, that was removed by filtration and washed 
repeatedly with diethyl ether, diclorometane and dried under vacuum at r.t. Yield: 36.8 mg 
(79%). 
 
1H NMR (dmso-d6, δ) T = 25 °C: -2.94 (s, 2H, NH), 2.56 (s, 12H, CH3 bpy), 2.61 (s, 12H, 
CH3 dmso), , 2.62 – 3.23 (m, 48H, CH2 [9]anoN3), 3.53 – 3.75 (m, 48H, CH2 spacer), 6.06 (s, 
4H, NH tacn), 7.22 (m, 8H, NHtacn), 7.62 (d, 4H, J = 5.05 Hz,  H5'), 8.10 (d, 4H, J = 4.95 
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Hz, H5), 8.31 (m, 16H, oPh + mPh) 8.85 (m, 12H, βH + H3'), 8.99 (m, 4H, CONH), 9.16 (d, 
8H, H6' + H3), 9.49 (m, 8H, H6 + CONH). 
1H NMR (dmso-d6, δ) T = 50 °C: -2.87 (s, 2H, NH), 2.57 (s, 12H, CH3bpy), 2.61 (s, 12H, CH3 
dmso), 2.60 – 2.90 (m, 48H, CH2 [9]anoS3), 3.53 – 3.75 (m, 48H, CH2 spacer), 6.04 (s, 4H, 
NH tacn), 7.19 (m, 8H, NH tacn), 7.61 (d, 4H, J = 5.05 Hz,  H5'), 8.09 (d, 4H, J = 4.95 Hz, 
H5), 8.30 (m, 16H, oPh + mPh) 8.81 (s, 4H, H3'), 8.85 (m, 12H, βH + CONH), 9.16 (m, 8H, 
H6' + H3), 9.41 (m, 4H, CONH), 9.50 (d, 4H, H6).  
UV-vis (MeOH) λmax, nm (relative intensity, %): 416 (100), 513 (6.2), 547 (3.7), 588 (2.3), 
645 (1.4). 
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Tumour cell lines for in vitro tests 
 
The MDA-MB-231 – highly invasive – human breast cancer cell line was kindly supplied by 
Dr. P. Spessotto (Cro, Aviano, Italy), and maintained in Dulbecco’s modified Eagle’s medium 
(EuroClone®, Devon, UK) supplemented with 10% fetal bovine serum (FBS, Gibco, 
Invitrogen™, Paisley, Scotland, UK), 2 mM L-glutamine (EuroClone®, Devon, UK), 1% non-
essential aminoacids, and 100 IU/ml penicillin and 100 µg/ml streptomycin (EuroClone®, 
Devon, UK). 
The HBL-100 human non-tumorigenic epithelial cell line was kindly supplied by Dr. G. 
Decorti (Department of Biomedical Sciences, University of Trieste, Italy), and maintained in 
McCoy’s 5A medium supplemented with 10% FBS, 2 mM L-glutamine, and 100 IU/ml 
penicillin and 100 µg/ml streptomycin. 
All cell lines were kept in a CO2 incubator with 5% CO2 and 100% relative humidity at 37 °C. 
Cells from a confluent monolayer were removed from flasks by a trypsin-EDTA solution. 
Cell viability was determined by the trypan blue dye exclusion test. For experimental 
purposes cells were sown in multiwall culture clusters. 
 
Determination of cell cytotoxicity 
 
Cell growth inhibition was determined by the MTT viability test [29]. Cellssown on 96-well 
plates were incubated 24 h later with concentrations from 0.1 µM to 30 µM of the appropriate 
compound, prepared by dissolving it in a medium containing 5% of serum, for 72 h. Solutions 
of the conjugates 2 – 11 were prepared by diluting a freshly prepared stock solution (10-2 M) 
of each compound in dimethylsulfoxide (dmso) (Sigma, St. Louis, MO, USA). Maximum 
dmso concentration in the cell incubation medium was ≤ 0.3% v/v. Cell toxicity analysis was 
performed at the end of the incubation time. Briefly, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) dissolved in PBS (5 mg ml-1) was added (10 µl per 100 µl of 
medium) to all wells and the plates were then incubated at 37°C with 5% CO2 and 100% 
relative humidity for 4 h. After this time, the medium was discarded and 200 µl of dmso were 
added to each well according to the method of Alley et al. 128. Optical density was measured 
at 570 nm on a SpectraCount Packard (Meriden, CT) instrument. IC50 values were calculated 
from dose-effect curves with GraphPad Prism version 4.03 for Windows (GraphPad Software, 
San Diego, CA, USA) 
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Determination of cell phototoxicity 
 
Cells grown in 96-well cell culture plates were incubated 24 h later with concentrations from 
0.1 µM to 10 µM of compounds 2,8 and 11, prepared by dissolving them in a medium 
containing 5% of serum, for 24 h. Stock dmso solutions of each conjugate were prepared as 
described above. Maximum dmso concentration in the cell incubation medium was ≤ 0.1% 
v/v. Thereafter the media containing compounds were replaced with drug-free medium 
containing 5% of serum and cells were irradiated at 590-700 nm at a fluence rate of 25 
mW/cm2 and light doses ranging from 1 J/cm2 to 10 J/cm2. This wavelength interval was 
isolated from the emission of a halogen lamp (Teclas, Lugano, Switzerland) by the insertion 
of broadband optical filters. A plate similarly treated but not exposed to light was used as 
reference for the dark cytotoxicity in the same experimental conditions. Experiments were 
conducted in quadruplicate and repeated trice. Analysis of cell phototoxicity using the MTT 
assay as described above was performed after a further incubation of 24 h after irradiation and 
compared to the values of control cells without light irradiation. 
 
Determination of the quantum yield for singlet oxygen generation 
 
The quantum yield (Φ∆) of singlet oxygen generated by compounds 2,8 and 11 upon 
photoexcitationwas measured using 9,10-dimethylanthracene (DMA) as substrate [31]. 
Typically, 1.5 ml of a 20 µM ethanol solution of DMA and 1.5 ml solution of the porphyrin 
(0.4 A at Soret band maximum, ≈ 10-6 M) in ethanol were placed in a quartz cuvette of 1 cm 
optical path and irradiated with 590–700 nm light for different periods of time at 20 ± 2 °C 
under gentle magnetic stirring. The fluence-rate was 100 mW/cm2. The DMA fluorescence 
emission was recorded in the 380–550 nm wavelength range with excitation at 360 nm. The 
first-order rate constant of the photo-oxidation of DMA by 1O2 was obtained by plotting 
lnF0/F as a function of the irradiation time t, where F0 and F represent the fluorescence 
intensity at time 0 and at time t, respectively. The rate constant was then converted into 1O2 
quantum yield by comparison with the rate constant for DMA photo-oxidation sensitized by 
haematoporphyrin (Hp), for which Φ∆ was shown to be 0.65 120 
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Microscopy experiments 
 
MDA-MB-231 cells were grown on histological slides in complete medium until 75% 
confluence was reached and exposed to compounds 2, 8 and 11 (10 µM) for 16 h in the dark. 
At the end of the treatment, after discarding the medium containing the compound and 
washing, cells were fixed for 10 min in buffered formol, and nuclei were stained with 4',6-
diamino-2-phenylindolyl hydrochloride (DAPI, Molecular Probes, Invitrogen, Italy) 
according to the manufacturer’s instructions. Then slides were mounted with 20% PBS-
glicerol and analyzed under a fluorescence microscope (Leica, DM 2000, Italy) with filters set 
at 365 ± 5 nm excitation light (BP 340/380, FT 400, LP 425) for DAPI, and 535 ± 25 nm 
excitation light (BP 515-560, FT 580, LP 590) for porphyrins. 
 
Determination of ruthenium cell uptake  
 
Ruthenium cell uptake was determined by atomic absorption spectroscopy (AAS) on 
samples processed with a modification of the procedure by Tamura and Arai. 129 MDA-MB-
231 and HBL-100 cells were seeded in complete medium containing 5% of serum in a 6-well 
plate. When cells reached 75% confluence they were incubated with 4.5 µM or 10 µM of 
compound 8 for 1, 2, 4 or 24 h at 37 °C. At the end of the treatment the wells were washed 
three times with PBS, the cells collected by a trypsin/EDTA solution, counted with the trypan 
blue exclusion test and the intracellular concentration of ruthenium was determined. The cells 
were dried in Nalgene® cryogenic vials (a first drying step was performed overnight at 80 °C 
and a second step at 105 °C until the samples reached a constant weight). The dried cells were 
decomposed by the addition of an aliquot of tetramethylammonium hydroxide (25% in water) 
(Aldrich) and of milliQ water at a ratio of 1:1 directly in each vial at room temperature under 
shaking. Final volumes were adjusted to 1 ml with milliQ water. The concentration of 
ruthenium in treated cells was measured by flameless atomic absorption spectroscopy using a 
Zeeman graphite tube atomizer, model SpectrAA-300, equipped with a specific ruthenium 
emission lamp (hollow cathode lamp P/N 56-101447-00, Varian, Mulgrave, Victoria, 
Australia). Quantification of ruthenium was carried out in 10 µl samples at 349.9 nm with an 
atomizing temperature of 2500°C, using argon as carrier gas at a flow rate of 3.0 l/min. 
Before each analysis, a five-point calibration curve was obtained to check the range of 
linearity using ruthenium custom-grade standard 998 mg/ml (InorganicVentures, Lakewood, 
N.J.). 
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Statistical analysis 
 
Data obtained in the experiments were subjected to Statistical Analysis of Variance 
(ANOVA) and Tukey-Kramer post-test, or to Unpaired t-test performed using 
GraphPadInStat version 3.06 for Windows (GraphPad Software, San Diego, CA, USA).  
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3. 99mTc/Re-Porphyrins conjugates 
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3.1. Approaches towards the synthesis of target specific radiopharmaceuticals 
 
99mTc is the ‘workhorse’ of diagnostic nuclear medicine and it is used in some chemical form 
in the majority of diagnostic scans conducted each year in hospitals worldwide.130 
Several oxidation states are available for Tc, with remarkably different chemical features. In 
recent years the organometallic Tc(I) fragment fac-[99mTc(CO)3]+ has attracted considerable 
interest in the design of novel 99mTc radiopharmaceuticals.131 This core offers a number of 
attractive features: i. The synthetic precursor fac-[99mTc(CO)3(H2O)3]+ can be readily obtained 
in aqueous solution from the pertechnetate salt under reducing conditions as developed by 
Alberto et al. 132  Nowadays GMP-produced kits for preparing [99mTc(H2O)3(CO)3]+ are 
commercially available, ii. fac-[99mTc(CO)3(H2O)3]+ is water-soluble and the aqua ligands are 
readily exchanged, in particular by chelating ligands. iii. The fac-[99mTc(CO)3]+ core is 
chemically robust and maintains its integrity under the most forcing conditions (in addition, as 
the Tc(I) ion has a low spin d6 electronic configuration, its complexes are typically inert), iv. 
the core is lipophilic and organometallic in nature, making the chelation more covalent in 
character, v. it is relatively easy to characterize the 99mTc(I) adducts using the “cold” non-
radioactive (and diamagnetic) Re(I) analogue, which can be prepared on the macroscopic 
level and thoroughly characterized. To confirm the identity of the 99mTc-labelled compound, it 
is common in radiopharmaceutical chemistry to compareits retention time in the HPLC 
radiochromatogram with the UV-vis trace of the corresponding non-radioactive Re congener: 
if the two retention times are coincident, identity – and therefore – characterization of the 
99mTc adduct is confirmed. vi. Finally, since Re has twoβ-emitting isotopes suitable for 
therapeutic applications,186Re (t1/2=3.8 d, Emax=1.07MeV) and 188Re (t1/2=0.7 
d,Emax=2.12MeV), the possibility for combined diagnosis (99mTc) and radiotherapy (Re) 
emerges as an attractive concept for further exploration. 
In the last decade, the research in the area of 99mTc radiopharmaceutical has been mainly 
focused towards developing radiotracers that preferentially localize in neoplastic tissues. In 
these 2nd generation radiopharmaceuticals the “vehicle” that carries the radionuclide to the 
diseased tissue is often a “targeting biomolecule” that must accumulate in tumor tissues with 
high affinity and specificity. It is this high receptor binding affinity and specificity that makes 
receptor imaging (often called “molecular imaging”) advantageous over traditional 
scintigraphic imaging using simple Tc complex radiopharmaceuticals or other imaging 
modalities such as X-ray computed tomography (CT), ultrasound (US), and nuclear magnetic 
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resonance imaging (MRI).Thus, the labelling of biologically active molecules with 99mTc is a 
field of intense research133,134,135,136 
Typically, the design of receptor/site-specific 99mTc compounds follows the ‘conjugate’ or 
‘pendant’ method, in which a 99mTc-chelate moiety is attached to a molecule that has a high 
binding affinity/selectivity for tumor tissues. 
Bifunctional chelates, such as that schematically illustrated in Figure 47, provide an effective 
strategy for binding the radioactive metal cation tothe biologically targeting molecule.137,138,139 
The linker is important because it is able to influence the lipo- or hydrophilicity of the 
radiopharmaceutical and because it separates the bioactive part from the metal-complex 
minimizing steric effects. Usually this strategy ensures an appropriate accumulation of the 
radiotracer in the diseased tissues. 
 
 
Figure47. Principle of bifunctionalchelator (BFC) and bioconjugate ready to be labelled in akit formulation.1 
 
Many biomolecules, including monoclonal antibodies, antibody fragments and small peptides, 
have been studied for as‘‘carriers’’ for radionuclides.  
Nowadays, due to the intense efforts, several molecules are under developments. Table 8 lists 
selected commercial 99mTc-target-specific radiopharmaceuticals and their medical 
applications. 
 
Radiopharmaceutical Trade name Primary uses 
99mTc-Apcitide AcuTect1 Synthetic peptide for imaging DVT (deep vein thrombosis) 
99mTc-Arcitumomab Neotect1 Monoclonal antibody for colorectal cancer 
99mTc-Depreotide Zevalin Somatostatin receptor-bearing pulmonary masses 
 
Table 8. Selected target-specific diagnostic radiopharmaceuticals. 140 
 
As targeting molecule we choose water-soluble porphyrins, as these macrocycles typically 
show preferential uptake and retention by tumor tissues, possibly via receptor-mediated 
endocytosis of low density lipoproteins (LDL). This suggestion is mainly supported by the 
observation that lipoproteins readily incorporate porphyrins, and that tumor cells have been 
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found to exhibit elevated activity of LDL receptors. 8, 9, 10 Thus, porphyrins might behave as 
carrier ligands for the active transport of metal compounds into cancer cells. 
Porphyrins can bind metal ions either inside the macrocycle (metalloporphyrins) or through 
accurately designed peripheral binding sites (metal-porphyrin conjugates). Both 
metalloporphyrins and metal-porphyrin conjugates have been investigated by us 141 and by 
others 142  as potential cytotoxic and photo-cytotoxic agents. For example, the in vitro 
anticancer activity of the gold(I)-porphyrins developed by Che143  and co-workers is well 
established, and several Ru(II)-porphyrin conjugates developed in particular by some of us 142 
and by Therrien 94 and co-workers possess a promising phototoxicity induced by visible light. 
Furthermore, provided that the metal-porphyrin conjugates are sufficiently stable, the 
fluorescence emission of the chromophorecan be exploited for tracking the biodistribution of 
the metal in the extra- and intra-cellular environment of malignant cells through fluorescence 
microscopy. Notably, for porphyrin compounds investigated for bio-medical purposes, water 
solubility is an essential requisite.  
There are relatively few examples of 99mTc labelled porphyrins/porphyrins adducts, mainly 
concerning 99mTc(V). An earlier attempt in 1983 was made to label hematoporphyrin 
derivative (HpD, a complex mixture of hematoporphyrindiacetate, monoacetate, vinyl 
porphyrins, deuteroporphyrins and other analogs) with [99mTcO4]-ion. The labeling 
mechanism was unclear and it presumably occurred at the carboxylic chain of the 
porphyrin.144 Although 99mTc exhibited a high binding efficiency for HpD, the heterogeneous 
chemical composition of HpD caused the formation of two major labeled species. Thus it was 
not possible to determine the chemical nature of these species and the fraction responsible for 
accumulatlon in tumour tissue was never identified. Even though the 99mTc-HpD conjugate 
was shown to accumulate in mammary adenocarcinomas of mice, owing to the unclear 
composition its utility was rather limited. 
Following a similar approach to obtain tumour specific imaging agents, Shetty et al. in 1996 
tried to overcome those problems by a [99mTcO4]-complexation with the water soluble 
porphyrins meso-tetrakis[3,4-bis(carboxymethyleneoxy)phenylporphyrin (T4CPP) and meso-
5,10,15,20-tetrakis[3,4-bis(carboxymethyleneoxy)phenyl]porphyrin (T3,4BCPP) (Figure 48) 
in buffered saline (pH = 7). Also in this case the labelling of T4CPP and T3,4BCPP with the 
99mTc(V) ion seemed to occur at the peripheral –OCH2CO2-groups.145. The authors do not 
specify how many 99mTc-atom are bound to the porphyrins. They reported a mono-99mTc-
T3,4BCPP (Figure 48), but they stated that three more could be potentially chelated.146 
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Figure 48: Schematic structure of the porphyrins T4CPP and T3,4BCPP and  of 99mTc-5,10,15,20-tetrakis[3,4-
bis(carboxymethyleneoxy)phenyl] porphyrin (T3,4BCPP). From ref. 145 and 146. 
 
The labelled products remained stable for more than 4 hours at 25 °C and showed a selective 
accumulation in abdominal 120-sarcoma (Swiss mice) 145 and in mammary tumor (rats).147 
Since T/M (tumor to muscle) ratio in nuclear medicine is a in an important parameter to 
evaluate the accumulation and the efficacy of an imaging agent, T/M ratio was evaluated for 
99mTc-T3,4BCPP in mammary tumor CH3H/J mice, in rat mammary tumor and in rat C6-
glioma and it was compared with those obtained with the known tumor-seeking 
radiopharmaceuticals 99mTc(V)-DMSA (DMSA = dimercaptosuccinic acid), 99mTc-citrate and 
201TlCl. 145 In the case of C6-gliomas, the ratios were 4.2 for T3,4BCPP and 2.2, 4.0 and 3.0 
for the others compounds while in the case of C3H/J mammary tumor, the ratios were 9.4, 8.8, 
8.1 and 8.5, respectively. 
Since an ideal agent should localize in the target tissue with a target to non-target ratio greater 
than 3.0, 148 those data validate the hypothesis that this porphyrin can be good candidate for 
tumor localizing agent. Furthermore 99mTc-T3,4BCPP appeared promising as a tumor imaging 
agent because it showed T/M ratios higher than those evaluated for the wellknown tumor-
seeking radiopharmaceuticals. 
The chlorin analog of T3,4BCPC (Figure 49) was also labelled with 99mTc and investigated as 
tumor imaging agent149.  
In vivo biodistribution studies of the labeled compound were carried out in rodent and murine 
tumor models in comparison with 99mTc(V)-DMSA, 99mTc-citrate and 201TlCl using a gamma 
camera computer system. 
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Also in this case they found T/M values of 9.5 in C3H/J mammary tumor bearing rats, 6.0 in 
NMU-mammary tumor rats and 4.4 in C -glioma rats, in general appreciably higher than those 
obtained with the well known tumor-seeking radiopharmaceuticals. 
 
Trying to improve the stability of such conjugates, more recently the same group labeled a 
new water-soluble cyclam acid porphyrin (CAP), 5,10,15,20-tetrakis [4-{4',8',11'-
tris(carboxymethyl)-1'-(1',4',8',11'-tetraazacyclotetradecane)amidomethyleneoxy}phenyl] 
(Figure 49) with 99mTc, using the tetraazacyclotetradecane as tetradentate ligand for 
99mTc.150In vivo distribution studies were performed in mammary tumour and C6-glioma 
tumour-bearing rats.  
Also in this case tumour to muscle (T/M) ratio was determined and compared with 99mTc(V)-
DMSA, 99mTc-Citrate and 201TlCl. In the case of mammary tumour rats the ratios were 6.93 
for the porphyrins and 1.97, 5.30 and 3.29 for the others radiopharmaceuticals. In the case of 
C6-gliomas the ratios were 5.58 for the porphyrin, 2.18, 3.96 and 3.02 for the others 
compounds. 
 
Figure 49: Schematic structureof 5,10,15,20-tetrakis[3,4bis(carboxymethyleneoxy)phenyl]chlorin (T3,4BCPC) 
(from ref. 148) and cyclam acid porphyrin (CAP) bound to themacrocyclic ligands 1,4,8,11-
tetraazacyclotetradecane (from ref. 148). 
 
In general those studies revealed a promising potential for detection of cancer by 99mTc-
porphyrin conjugates but they also evidenced that chemical purity and stability of such 
conjugates can be problematic.  
The exploitation of other 99mTc oxidation states, such as Tc(I), with different core geometries 
would allow to use new chelators and targeting strategies. Surprisingly only very few papers 
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describe the coordination of the [M(I)(CO)3]+(M = Tc or Re) fragment to a porphyrin.(I). In 
all cases the coordination seems to occur inside the porphyrinic macrocyle. 
Tsutsuiet al. reported in 1975 the unusual structures of [Tc(I)(CO)3]2-tetraphenylporphyrin 
(TPP) (with the long-lived 99Tc isotope) and  [Re(I)(CO)3]2-TPP (Figure 50), obtained by 
reacting TPP with either Tc2(CO)10 orRe2(CO)10in refluxing decaline.151 Both the rhenium and 
technetium homodinuclear porphyrins were centro symmetric complexes having two metals 
bonded to the porphyrin, one above and one below the plane of the macrocycle while the 
porphyrins macrocycle was highly distorted. 
 
 
Figure 50. The structure of [Re(I)(CO)3]2-TPP. From ref. 151 
 
More than 25 years later, in 2011, Yang at al reported the preparation of a metalloporphyrin 
by the reaction of [99mTc(CO)3(H2O)3]+ with the meso-tetrakis(4-
sulfonatophenyl)porphyrin(TPPS4) (Figure51). 152 
 
Figure 51. Optimized 3D structure of  99mTc(CO)3-TPPS4, From ref 152  
 
91 
 
Despite the excellent labeling yield (more than 90% at pH = 7–8) and the fairly chemical 
stability achieved over a range of time, pH and temperatures, the 99mTc(CO)3-TPPS4conjugate 
showed very poor uptake or little retention in Hep2 tumor cells and transplanted hepatoma 
tissue. Thus, its potential biological application seems to be rather limited. 
For the reasons detailed above and for the possibility of new developments, it is of great 
interest to study the coordination of long-lived [99Tc(CO)3]+ to porphyrins. 
We have a considerable experience in the synthesis of metal-porphyrin conjugates. Recently, 
we described the preparation for biomedical purposesof several new Ru-porphyrin conjugates 
that bear from one to four either negatively or positively charged half-sandwich Ru(II) 
coordination compounds at the periphery of the cromophore, at meso position.109, 141  
Since the concentration of 99mTc formulations in the blood 153 is typically in the picomolar 
range, in this work we focused our attention on porphyrins capable of binding only one 
[99mTc(CO)3]+ fragment. Here we describe the synthesis and characterization of two new 
water soluble meso-substituted porphyrins that have in peripheral position either a 
diethylenetriamine unit for tridentate coordination (18) or a bipyridyl bidentate chelator 
connected to the macrocycle through a flexible and hydrophilic linker (23) (Figure 52). 
Furthermore we report the synthesis and characterization of their water-soluble conjugates 
that bear in peripheral position either one fac-[Re(CO)3]+ (19 and 24, respectively) or one fac-
[99mTc(CO)3]+ fragment (19a and 24a, respectively) (Figure 52), prepared in Zürich by Prof. 
Alberto’s research group.  
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Figure 52. Schematic structures of the new porphyrins and of their [Re(CO)3]+/[99mTc(CO)3]+ conjugates. 
 
3.2. Synthesis and Characterization 
 
3.2.1. Water soluble porphyrins 
 
According to our experience in porphyrin-metal conjugates, good solubility in water is 
difficult to achieve. Typically, it requires that the metal fragments are highly hydrophilic (e.g. 
they are charged and contain ligands capable of hydrogen bonding, such as NH3 or en) and/or 
the porphyrin itself bears hydrophilic moieties. As our aim was to bind to the porphyrin one 
fac-[M(CO)3]+ fragment (M = Re or 99mTc), which is typically quite hydrophobic, we 
reasoned that – for ensuring sufficient water solubility to the conjugates – we had to rely on 
appropriate functionalization of the chromophore. Thus, we designed two new porphyrins 
with polydentate binding fragments in peripheral position via functionalization of the 
carboxylic group of 5,10,15-tris(4'-pyridyl)-20-(4'-carboxyphenyl)porphyrin (15, Scheme 9). 
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In one case (porphyrins 18) a diethylenetriamine unit was attached for tridentate coordination, 
affording at the same time excellent water solubility. In the other (porphyrins 23) a bipyridyl 
bidentate fragment was connected to the macrocycle. In this case, despite the presence of a 
flexible and hydrophilic linker, the aqueous solubility of the porphyrin turned out to be 
insufficient; good solubility was obtained by methylation of the three pyridyl N atoms, which 
provided three extra positive charges. 
The starting material (14) was obtained (as the methyl ester) by condensation of 4-
pyridylcarboxyaldehyde, methyl 4-formyl benzoateand pyrrole in a 3:1:4 molar ratio under 
Adler–Longo conditions, followed by accurate chromatographic separation of the statistic 
mixture of the six isomeric porphyrins (having from zero to four 4'-pyridyl rings in the meso 
positions).115 Hydrolysis of the ester group in THF/CH3OH under basic conditions gave 
porphyrin 15 that was used for the synthesis of both porphyrins 18 and 23 (Scheme 9). 
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Scheme 9.Synthetic routes toporphyrins 18 and 23.a 
a Reactions and conditions: (a) EDCI/HOBt/DMAP, NH2CH2CH2(NBocCH2CH2N)2NHBoc, DMF, rt, 24 
h(83%); (b) TFA, rt, 2 h (100%).(c) EDCI/HOBt/DMAP, NH2CH2CH2OCH2CH2OCH2CH2NHBoc DMF, rt, 24 
h(89%); (d) CH3I, DMF 90 °C, 2 h (97%); (e) TFA, CH2Cl2, rt, 2 h (100%); (f) CDMT/NMM, DMF, from 0 °C 
to rt, 24 h (78%). 
 
The first step to porphyrin 18 was the coupling reaction (activated by EDCI, HOBt, DMAP in 
DMF under nitrogen) between the primary amine group of (2-Aminoethyl)-(2-(tert-
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butoxycarbonyl-(2-tert-butoxycarbonylaminoethyl)amino)ethyl)carbamic acid tert-butyl ester 
(16) and the carboxylic acid of 15. 154 After purification by column chromatography, the Boc-
protected intermediate 17 was obtained in high yield. Its NMR characterization was 
unambiguous (see Figures 2 - 4); we notice that the resonances of the two equivalent pyridyl 
rings trans to one another are indistinguishable from those of the third ring. Similarly, the 8 
pyrrole protons (βH) give a single unresolved multiplet (four doublets would be expected, 
based on the symmetry). 
 
 
Figure 53a. 1HNMR spectrum of 17 in CDCl3 (see Figure 52 for numbering scheme). *: impurities; **: diethyl 
ether.  
 
Figure 53b. 1HNMR spectrum of 17 in CDCl3downfield region (see Figure 52 for numbering scheme) 
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Figure 54. HSQC spectrum of 17  in CDCl3.Blue peaks:CH2 groups; read peaks:CH/CH3 groups.(see Figure 52 
for numbering scheme)*: impurities; **: diethyl ether. 
 
Deprotection of porphyrins 17 using TFA in CH2Cl2, afforded 18 as TFA salt in good yield 
and purity (as confirmed by the ESI-MS positive spectrum, Figure 55). 
We were unable to establish the charge of 18, i.e. how many amino groups were – on average 
– protonated. The purple color of the porphyrin clearly indicates that the internal pyrrole rings 
are not protonated (in that case the color turns green). An NMR spectrum in CD3OD showed 
that the pyridyl protons have chemical shifts that are similar to those of the precursor 17, 
suggesting that the pyridyl N atoms are not protonated (protonation would be expected to 
induce a consistent downfield shift of the resonance of H 2,6). We expect to have 1-2 TFA 
molecules for each porphyrin. As the exact charge of 18 was unrelevant to its subsequent 
coordination to the Re/Tc fragment, and the amounts available were always small, we did not 
pursue its characterization further.  
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Figure 55. ESI-MS spectrum of 18: m/z 812.5 (M + Na+).  
 
The procedure for obtaining the bipy-substituted porphyrins 23 involved coupling of 15, as 
the hydroxybenzotriazole (HOBt) ester, with N-Boc-2,2'-(ethylenedioxy)-diethylamine in 
DMF (Scheme 9). Methylation of this intermediate with excess methyl iodide in DMF gave 
the tricationic porphyrins 21 (as iodide salt) in almost quantitative yield. After deprotection 
with an excess of TFA in CH2Cl2, the mono-aminoporphyrin intermediate was coupled with 
4-methyl-2,2'-bipyridine-4'-carboxylic acid (bpyAc) 155  by using 2-chloro-4,6-dimethoxy-
1,3,5-triazine (CDMT or Kaminski’s reagent)and N-methylmorpholine (NMM). 156  The 
desidered product 23 (as trifluoroacetate salt) was conveniently purified by Soxhlet 
extraction. 
The two porphyrins, as well as their intermediates, were characterized by mono- and 
bidimensional1H NMR spectroscopy and by electrospray mass spectrometry (Figures 56 - 58). 
Both 18 and 23, beside being soluble in organic solvents such as methanol, are also well 
soluble in aqueous solution and in phosphate buffer (PBS) at pH 7.4. As mentioned above, the 
downfield region of the 1H NMR spectrum of 18 in CD3OD is similar to that of its precursor 
17, except that all resonances are broader. The 1H NMR spectrum of porphyrins 23 in CD3OD 
is similar to those already reported for other bipy-substituted phenyl porphyrins109, 141 and is 
consistent with the geometry of the compound. Assignments were performed through 
conventional 2D correlation spectra (Figure 56). All proton resonances are sharp at 20 °C, 
with the exception of the βH resonance that is remarkably broad (Figure 56). In the upfield 
region the spectrum shows a singlet for the methyl of bpyAc at δ 1.52, and the multiplets of 
the aliphatic spacer (δ 3.55 –3.70). The resonances of the methyl groups on the pyridyl rings 
are hidden by the intense resonance of H2O. In the downfield region, beside the two doublets 
for the pyridyl protons atδ 9.39 (H2,6) and 8.98 (H3,5) and the multiplet of the o,m-phenyl 
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protons at δ 8.24, the spectrum shows six resolved resonances, i.e. four doublets and two 
singlets, for the bpyAc protons.The H-H COSY spectrum of 23 (Figure 57) displays, beside 
the expected cross peaks, also two long range weak correlation peaks between the CH3 
resonance of bpyAc and those of the H3' and H5' protons that allowed the unambiguous 
assignment of the bpyAc resonances. 
 
 
Figure 56.1HNMR spectrum of 23 in CD3OD (see Figure 52 for numbering scheme).*: impurity. 
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Figure 57. H-H COSY NMR spectrum of 23 in CD3OD (see Figure 52 for numbering scheme).*: impurity. 
 
 
Figure 58. ESI-MS spectrum of 23: m/z 1032.5 (M+); m/z (z = 2) 516.3. 
 
The water soluble porphyrins 18 and 23 were used as ligands for tridentate or bidentate 
coordination to the fac-[M(CO)3]+ moiety (M=Re, 99mTc) (Figure 52). As a first step, the 
“cold” Re(CO)3 conjugates were synthesized and accurately characterized. 
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3.2.2. Re(I)-porphyrin conjugates 
 
Porphyrin 18 was treated with a slight excess of [NEt4]2fac-[ReBr3(CO)3] in a MeOH/PBS 
mixture at 70 °C, affording conjugate 19 in good yield (61%) and purity (as confirmed by the 
ESI-MS positive spectrum, Figure 59) after HPLC purification (Figure 60). Conjugate 19 
gives a single HPLC peak, with a retention time distinctly higher than the parent porphirin 18; 
according to HPLC analysis, a solution of 19 in PBS is stable at least up to 24 h. The 1H NMR 
spectrum of 18 is not significantly different from that of 19 (Figure 61). 
 
Figure 59.ESI-MSspectrum of 19: m/z 1060.4 (M+); m/z1099.4 (M + K+). 
 
Figure 60.Comparison of HPLC traces of 18 and 19. Gradient A, See Experimental Section. 
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Figure 61.1H NMR spectrum of 19 in CD3OD in the downfield region (see Figure 52 for numbering scheme). 
 
Whereas porphyrin 18 bears a tridentate N-ligand capable of replacing all three (relatively) 
labile Br- ligands in fac-[ReBr3(CO)3]2-, 23 has only a bidentate chelator and its reaction with 
the Re(I) precursor is expected to afford fac-[ReBr(CO)3(23)](TFA)3. However, we found 
that, during HPLC purification, this derivative originated a complex mixture of products, 
presumably because the bromide ligand is still quite labile and it partially exchanges with 
water, methanol, and with TFA (present in the medium). A similar behaviour had been 
previously observed by Alberto and co-workers with another Re(I) bioconjugate: in that case, 
replacement of Br with I afforded a single, stable product.157After several attempts, we found 
that in our case prolonged heating of 23 with a slight excess of [NEt4]2fac-[ReBr3(CO)3] and 
KSCN in a MeOH/PBS mixture afforded a product with a satisfactorily HPLC analysis (see 
below). Thus, conjugate 24 (formulated as fac-[Re(CO)3(23)(SCN-κN)](TFA)3) was obtained 
in good yield (65%) and purity after HPLC purification. IR analysis of 23 showed (beside the 
CO stretching bands typical of the Re(CO)3 fragment) the presence of a band at 2098 cm-1 
attributed to the CN stretching mode of the SCN-κN ligand by analogy with the known model 
complex fac-[Re(bpy)(CO)3(SCN-κN)] – whose X-ray structure was also determined. 158 
Whereas the ESI-MS spectrum of 24 has a quite complicated pattern due to the 3+ charge 
(Figure 62), its NMR spectra were highly informative (Figure 63). As in the model complex, 
2,6py                                    βH                                                      o,mPh      3,5py 
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coordination of the fac-[Re(CO)3(SCN)] fragment strongly affects the six resonances of the 
bpy protons, that are shifted downfield by 0.5 − 1.0 ppm compared to the parentporphyrin 23. 
Indeed, the NMR spectrum of 24 in CD3OD shows, immediately after dissolution, the patterns 
of one major (24a) and one minor (24b) species; very slowly the initially more abundant 24a 
species converts into 24b, so that the 24a/24b ratio goes from 1:5 at t = 0 to 6:1 after 3 days at 
ambient temperature. A similar behavior had been observed by Probst 159 for the model 
complex fac-[Re(bpy)(CO)3(SCN-κN)] in dmso solution and had been attributed to the-κNto -
κS isomerization of the SCN- ligand. This linkage isomerization has been observed also with 
other metals (e.g. in Ru(II) complexes). 160  
 
 
Figure 62.ESI-MS spectrum of 24: m/z 1359.5 (M+); m/z(z = 2) 680.5 
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Figure 63: 1H NMR spectra of 24 in CD3OD in the aromatic region at different times: t1 = 0; t2 = 24 h;  t3 =48 h; 
t4 = 72 h. 
 
The electronic absorption (Table 9) and emission spectra of conjugates 19 and 24 were not 
significantly different from those of the parent porphyrins 18 and 23, respectively.  
 
Compound Soret Q Band IV Q band III Q band II Q band I 
18 412 (100) 510 (4.8) 543 (1.6) 587 (1.5) 642 (0.6) 
19 413 (100) 511 (4.8) 543 (1.6) 588 (1.4) 642 (0.7) 
23 426 (100) 518 (7.2) 555 (3.7) 591 (2.8) 647 (1.0) 
24 427 (100) 518 (11.7) 555 (6.9) 591 (4.6) 647 (2.0) 
 
Table9. UV–Visible and Absorption Maxima (Relative Intensity) determined in MeOH for all compounds. 
 
The fluorescence properties of porphyrins are useful to study their aggregation behavior in 
solution. In fact, porphyrins in their monomeric form usually show intense fluorescence 
emissions, which are partially or completely quenched upon aggregation in solution. 
Whereas in PBS solution a moderate decrease of the emission intensity with time was 
observed for 19 (ca. 30% after 24 h, Figure 64a), a significant reduction was observed for 24 
(ca. 80% after 24 h, Figure 64b), suggesting that conjugate 24 has a stronger tendence to 
aggregate in PBS.161 
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Figure 64.(a)Emission spectra of a ca. 10 µM solution of 19 in PBS at t=0 (black), t=5 h (red),and t=24 h 
(blue);λex 413 nm, λem651 nm.(b)Emission spectra of a ca. 10 µM solution of 11 in PBS at t=0 (black), t=5 h 
(red),and t=24 h(blue); λex427 nm, λem658 nm 
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3.2.3. 99mTc(I)-porphyrin conjugates 
 
The corresponding99mTc –porphyrinconjugates 19a and 24a (Figure 52) were prepared at 
trace level by ligand exchange reaction employing a solution of fac-[99mTc(CO)3(H2O)3]+ 
prepared from [99mTcO4]- according to literature procedures or with the commercially 
available Isolink kit (Covidien, Tyco-Mallinckrodt Med. B.V. Petten, NL).132, 162 The 
concentration of fac-[99mTc(CO)3(OH2)3]+ was determined by the generator eluate and was 
typically in the range 10−6 – 10−7 M depending on the “age” of the 99Mo/99mTc generator. The 
solution was then buffered with 0.1 M phosphate buffer to pH 7.4. The experimental 
conditions for obtaining the two 99mTc conjugates were optimized by testing different reaction 
times, concentrations and temperatures. HPLC analysis with γ-detection was performed to 
quantify the conversion of the 99mTc precursor. Typically, as mild as possible conditions are 
preferable for the preparation of 99mTc-bioconjugates as some biomolecules are not thermally 
stable. 
We found that, when the reactions were performed at 50 °C, the peak of fac-
[99mTc(CO)3(H2O)3]+ in the radiochromatograms disappeared within 30 min after the addition 
of the porphyrins (at a concentration of ca. 10-4 M for 18, and 10-5 M for 23) (Figure 65a and 
66a, dashed line). In both cases the formation of a single new peak was observed (Figure 65a 
and 66a, solid line). According to HPLC, the labelling yield was quantitative for both 
porphyrins. The retention times for the parent porphyrins, the “cold” Re conjugates and the 
corresponding 99mTc labelled porphyrins are given in Table 10.  
First of all, the comparable retention times of the corresponding Re(CO)3 and 
99mTc(CO)3conjugates confirmed the identity of the 99mTc compounds 19a and 24a (Figure 
65b and 66b). The differences between Re(CO)3 and 99mTc(CO)3 conjugates are explained by 
the separation (void volume) between the UV-vis and the radiodetector. It should be noted, 
however, that we formulated the Re conjugate 24 as the SCN derivative, whereas the 
corresponding 99mTc conjugate 24a has either an aquo or a clorido ligand in the place of SCN- 
(i.e.fac-[Re(CO)3(23)(SCN-κN)]3+vsfac-[99mTc(CO)3(23)(H2O)]4+ or fac-
[Re(CO)3(23)(Cl)]3+). 
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(a)                                                                                               b) 
Figure 65. (a)Radioactive HPLC traces of [99mTc(H2O)(CO)3]+ (dashed line) and of the 99mTc-porphyrin 
conjugate19a (solid line). (b) HPLC traces of porphyrin 18 (black line), of the99mTc-porphyrin conjugate 19a(red 
line), and of the Re-porphyrin conjugate 19 (blue line). 
 
(a)                                                                                               b) 
 
Figure 66.(a)Radioactive HPLC trace of [99mTc(H2O)(CO)3]+ (dashed line) and of the 99mTc-porphyrin conjugate 
24a (solid line). (b) HPLC traces of porphyrin 23(black line),of the99mTc-porphyrin conjugate 24a (red line), and 
of the Re-porphyrin conjugate 24(blue line). 
 
Table 10.Retention times for porphyrins18 and 23 and for their Re and 99mTc conjugates. Elution conditions: C-8 
column, buffer 0,1 % TFA, Gradient A(standard TFA labelling gradient, See experimental section). 
 
Porphyrin Retention time 
(min) 
Conjugate with 
Re(CO)3 
Retention time 
(min) 
Conjugate with 
99mTc(CO)3 
Retention time 
(min) 
18 9.72 19 11.70 19a 11.12 
23 9.95 24 10.27 24a 10.46 
 
 
 
 
 
 
 
 
 
19a  
99mTc(CO)3 
24a  
99mTc(CO)3 
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3.2.4. Stability of Tc conjugates in aqueous solution 
 
The stability of both technetium conjugates 19a and 24a was assessed by HPLC analysis 
under a variety of conditions. After the determination of the formation of the technetium 
conjugates by HPLC, 99mTc conjugates were left at ambient temperature under air and the 
stability was confirmed by injecting the same volume of the radioactive mixture. 19a and 24a 
were both chemically stable for a period of at least 24 h at room temperature in their 
preparation reaction mixture and in cell culture medium in the absence and presence of HeLa 
cells. 
The chromatograms obtained for 19a and 24a from 30 min to 24h are shown in Figure 67 and 
68. The slightly differences between the retention times depends from the high sensitivity of 
the technique used. 
 
Figure 67. Radioactive HPLC traces of the99mTc-porphyrin conjugate 19a at t=30 min (green line), 1h (purple 
line), 2h (blue line), and 4h (red line), 24h (black line). Elution conditions: C-8 column, buffer 0,1 % TFA, 
Gradient A(standard TFA labelling gradient, See experimental section). 
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Figure 68. Radioactive HPLC traces of the 99mTc-porphyrin conjugate 24a at t=30 min (green line), 1h (purple 
line), 2h (blue line), and 4h (red line), 24h (black line). Elution conditions: C-8 column, buffer 0,1 % TFA, 
Gradient A(standard TFA labelling gradient, See experimental section). 
 
3.2.5. Conclusions 
 
We synthesized and accurately characterized two water soluble porphyrins, bearing a 
tridentate and a bidentate chelator to evaluate the possibility of labeling with [99mTc/Re(I) 
(CO)3]+ fragment at the periphery of the cromophore. 
By an accurate characterization of the conjugates bearing the [Re(I)(CO)3]+ fragment, we 
were able to demonstrate that the connection between the metal fragment and the porphyrin 
macrocyle occured at the periphery of the cromophore. All the conjugates were obtained with 
high purity level and reasonable to good yields. The total charge ranges from +1 to +3. 
The same porphyrinic precursors were than labeled with [99mTc(I)(CO)3]+ fragments. 
By comparison of the HPLC traces of the 99mTc conjugates (radiodetection) and the Re 
analogues (UV detection) we were able to confirm unambiguously the success of the labeling, 
the identity of such compounds and  the purity of the 99mTc-conjugates. 
Stability studies performed by HPLC on the 99mTc-conjugates revealed an high stability under 
air at room temperature, in absence or presence of cells up to 30 minutes to 24 hours. 
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3.3. Porphyrins and Re(I)-porphyrins as PDT agent 
 
Since natural and synthetic porphyrins and metalloporphyrins are the most useful 
photosensitizers for PDT163, we decided to evaluate the porphyrins 18 and 23 and the Re(I)-
porphyrins 23 and 19 (Figure 52) as potential PS for PDT.  
The uptake and in vitro cell growth inhibition of the Re(I)-porphyrins 19 and24and ofthe 
parent porphyrins 18 and 23 and was evaluated in HeLa cells. 
Finally, the phototoxic effectsof the previously mentioned porphyrins on HeLa cells upon 
irradiation with red light (590-700 nm) have been studied. 
 
3.3.1. Cell Uptake 
 
The time- and concentration-dependent uptake of the water soluble porphyrins 18 and 23 and 
of the Re(I)-porphyrins 19 and 24 by HeLacells was investigated and the results are shown in 
Figure 69.  
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Figure 69. Time- and concentration-dependent uptake of the unlabeled porphyrins18 and 23, and of the Re(I)-
porphyrins19 and 24 at 0.1 µM up to 100 µM by HeLa cells. HeLa cells grown in multi-well plates were treated 
with compounds 18, 23, 19, and 24 at 0.1 – 100 µM for 1, 2, 4, 8, or 24 h. At the end of the incubation the 
medium was removed, cells were washed with PBS and solubilized using 0.25% Triton X-100 
Finally fluorescence emission was read at 430/670 nm (excitation/emission). Data reported in figure are the 
mean ± S.D. calculated from values obtained in three separate experiments. 
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The uptake is time- and concentration-dependent, low at 0.1 µM and 1.0 µM concentrations 
for all the tested compounds, also prolonging the cell exposure until 24 h. A different ability 
by the compounds to penetrate HeLa cells can be singled out for treatments carried out at 10.0 
µM and 100.0 µM concentrations. The porphyrins 18 is readily and effectively taken up by 
cells, its fluorescence signal constantly increases over time at 10.0 µM, and at 100.0 µM the 
maximal uptake is reached already after 8 h of treatment. The porphyrins 23 shows a much 
lower ability to accumulate in treated cells, never reaching fluorescence levels comparable to 
those of 18. At the highest concentration tested the rate of cell uptake is fast, and the maximal 
fluorescence is achieved after 2 h of exposure, after which it lasts practically unaltered. The 
uptake of Re-porphyrin 19 shows a trend similar to that of its unconjugate counterpart 18, 
although its accumulation in treated cells is quantitatively slightly lower comparing the same 
treatment concentrations and time points. On the contrary, whether the metal fragment is 
bound to the unlabeled porphyrins 23 to obtain the Re-derivative 24, the ability to enter HeLa 
cells is clearly increased, overall at the 100.0 µM concentration. Considering the kinetic of 
cell uptake, the comparison of the behavior of 19 and 24 indicates the first compound still 
actively taken up at 24 h, and the attainment of steady state levels after 4-8 h of treatment in 
the case of Re-porphyrin 4. 
 
3.3.2.Cytotoxicity 
 
The organometallic porphyrin complexes were investigated in vitro as potential drug 
candidates for cancer therapy by evaluating the growth inhibition of human HeLa cells. 
The experiments were carried out with the water-soluble compounds 19 and 24, and with the 
parent water-soluble porphyrins 18 and 23. The effects of these compounds on the cell growth 
were evaluated after treatment for 1 h, 2 h, 4 h and 24 h. Cell viability was determined of the 
MTT assay, which measures mitochondrial dehydrogenase activity. (Table 11) 
Representative concentration–effect curves of all the porphyrins after 24 h of exposure are 
shown in Figure 70. 
All tested compounds affect tumor cell growth only marginally and display IC50 values higher 
than 100 µM, the maximal concentration used in this experimental setting. Only in the case of 
porphyrins 18 it was possible to calculate an IC50 value of 74 uM. Considering, however, that 
such value could only be obtained using the highest concentration of compound (i.e., 100 µM) 
for 24h, this is insufficient to define this compound as a cytotoxic agent. 
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Provided that Re(I) and Tc(I) form analogous conjugates with very similar physical and 
chemical properties that are expected to have the same pharmacokinetic behavior,164and 
considering that no cytotoxicity for the Re-conjugates was revealed at 0.01 µM even after 24h 
of exposure, the Tc(I) porphyrins conjugates are expected to display any toxicity.133 
 
Table 11. IC50 values of compounds 18, 23,19, and24 in HeLa cells treated for 1 h, 2h, 4h and 24h. 
 
  IC50 [µM] 
 1h 2h 4h 24h 
18 > 100 > 100 > 100 74.1 ± 33.6 
23 > 100 > 100 > 100 > 100 
19 > 100 > 100 > 100 > 100 
24 > 100 > 100 > 100 > 100 
HeLa cells grown in multi-well plates were treated with and with the water soluble porphyrins18and 23 and the 
Re-conjugates 19 and 24. Cell cytotoxicity was detected by MTT test at at 0.1 – 100 µM for 1, 2, 4, 8, or 24 h. 
IC50 are the mean ± S.D. calculated from values obtained in three separate experiments. 
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Figure 70. (a) and (b).Antiproliferative activity on HeLacells exposed for 24 h to the Re-porphyrins19 and 24 
and to the parent porphyrins18 and 23. 
 
3.3.3. Phototoxicity 
 
The porphyrins18 and 23, and the Re(I)-conjugates 19 and 24 have been studied to assess 
their cytotoxic activity against HeLa cells under irradiation with visible light (phototoxicity). 
To this end, cells were exposed for 24 h to compound concentrations ranging from 0.1 to 100 
µM, followed by irradiation at 590-700 nm with a fluence rate of 9 mW/cm2 and light doses 
from 1 to 10 J/cm2. Cell cytotoxicity was determined using the MTT test 24 h post-irradiation. 
Exposure of control cells to identical light doses not induce inhibition of cell proliferation as 
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reported in Figure 71. Cells treated with the same concentrations of the test compounds, but 
kept in the dark, were used as controls for photocytotoxicity. 
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Figure 71. Effects of the exposure to light on the proliferation of untreated control cells. HeLa cells grown in 
multi-well plates were kept in the dark or irradiated with visible light (590 – 700 nm) at 9 mW/cm2fluence rate 
and total light doses of 1 J/cm2, 5 J/cm2 or 10 J/cm2. Cell cytotoxicity was detected by MTT test 24 h after 
irradiation. IC50 are the mean ± S.D. calculated from values obtained in four separate experiments. 
 
All tested compounds show no cytotoxicity in HeLa cells kept in the dark, as indicated by the 
IC50 values reported in Table 12 These values are higher than 100 µM, except for the Re(I)-
porphyrin conjugate 19 for which an IC50 value of 20 µM was calculated. All compounds 
become more cytotoxic after the exposure to light and the photocytotoxicity is directly 
proportional to the total light dose applied, as clearly showed by the dose-effect curves 
reported in Figure 72. The most potent compound is the unconjugated porphyrins 18 for 
which the IC50 value drops from > 100 in the dark to 2.0 µM at the lowest light dose used in 
our experimental setting, i.e. 1 J/cm2. 
The conjugation of Re(I) to porphyrins 18 slightly modifies the phototoxic features of the 
molecule, as confirmed by the fact the compound 19 shows IC50 values higher than 18, 
although this difference tends to diminish with increasing light doses. On the contrary, the 
bonding of Re to porphyrins 23 improves the phototoxic properties of the compound in itself 
much less active in comparison to 18. 
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Table 12. IC50 values of compounds 18, 23, 19, and 24 in HeLa cells treated for 24 h and then exposed to 
increasing doses of visible light (590-700 nm). 
 
 IC50 [µM] 
 dark 1 J/cm2 5 J/cm2 10 J/cm2 
18 > 100 2.0 ± 1.3 0.5 ± 0.1 0.2 ± 0.1 
23 > 100 > 100 24.0 ± 6.5 5.8 ± 1.0 
19 20.5 ± 7.2 10.9 ± 2.7 1.9 ± 1.1 0.9 ± 0.1 
24 > 100 41.1 ± 13.0 4.0 ± 2.8 3.3 ± 2.3 
 
HeLa cells grown in multi-well plates were treated with compounds 18, 23, 19, and 24 at 0.1 – 100 µM for 24 h, 
then cells were irradiated with visible light (590 – 700 nm) at 9 mW/cm2fluence rate and total light doses of 
either 1 J/cm2, 5 J/cm2 or 10 J/cm2. Cell cytotoxicity was detected by MTT test 24 h after irradiation. IC50 are the 
mean ± S.D. calculated from values obtained in three or four separate experiments. 
 
Comparing the results obtained in the phototoxicity experiments performed in the dark with 
those of the preliminary cytotoxicity determination (Table 12), compounds 18 and 19 seem to 
behave in an opposite way. The nonconjugate porphyrins 18 has an IC50 of 74 µM after a 24 h 
treatment (Table 11), and > 100 µM after a further 24 h wash out period, a value that is 
similar to that obtained in phototoxicity studies performed in the dark. It is likely that the 24 h 
of wash out after time that follows treatment allows cells recovering from the insult that was 
detectable at the end of the treatment. 
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Figure 72. Light dose- and concentration-dependent effect curves of unconjugated  porphyrins18 and 23, and of 
the Re(I)-conjugates 19and 24. HeLa human cervix cancer cells were exposed to compounds at 0.1 – 100 µM 
18 19 
23 24 
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concentrations for 24 h, then cells were irradiated at a fluence rate of 9 mW/cm2 and total light doses ranging 
from 1 to 10 J/cm2. Cell cytotoxicity was determined 24 h after the irradiation by MTT test. 
 
An opposite consideration can be formulated for the Re(I)-porphyrin19 for which no 
cytotoxicity could be detected immediately after the end of the 24 h treatment (Table 11), but 
which become cytotoxic after a further 24 h wash out period (Table 12). It is assumable that 
19 induces cell damage that needs some time to be detected. 
Compounds uptake after 24h exposure is significantly different, as reported in Figure 69, but 
it does not affect appreciably their cytotoxicity. On the contrary, the phototoxicity is directly 
related to the ability of the compounds to penetrate cells. In fact, the unconjugated porphyrins 
18 and 23, for which the greatest and the lowest uptake was measured, are respectively the 
most and the least phototoxic compounds. The influence of the different uptake of the 
compounds on the phototoxicity fades by increasing the light doses. 
 
Trying to draw some structure-activity relationships it seems reasonable state that: 
1. cytotoxicity is not affected by whatever change made on the porphyrin core (presence 
of diethylenetriamine or bipyridylbidentatechelator, conjugation with the Re(I)).  
2. The presence of bipyridylbidentate chelator in comparison to the diethylenetriamine, 
as ligand on the porphyrin core or the presence of the positive charge on the pyridil 
ring of the porphyrin lowers the cell uptake and, consequently the phototoxicity of the 
compound. 
3. The addition of Re on porphyrins 18 marginally affects the compound uptake and 
consequently weakly modify its phototoxocity. 
4. On the contrary the addition of Re on porphyrins 23 improves the HeLa cell 
penetration giving a compound with more advantageous phototoxic features. 
 
3.3.4. Singlet oxygen quantum yield(Φ∆)  
 
Since the most common mechanism of action of the photosensitizers used in PDT (Type II 
mechanism) involves the production of singlet oxygen upon photoexcitation, the 1O2 quantum 
yield (Φ∆) was measured for of the unconjugated porphyrins 18 and 23 and of the Re(I)-
porphyrins 19 and 24 using the red light (600-700 nm) following the procedure reported 
before. 
Here the spectophotofluorimetric data obtained using 23 as a substrate are reported. 
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Figure 73.Photobleaching of an ethanol solution of DMA by 23 upon irradiation with a Teclas lamp (590–700 
nm) at 100 mW/cm2. 
 
 
Figure 74. Photo-oxidation of 10 µM DMA in ethanol solution sensitized by 23 (■)DMA is stable in the absence 
of 23 (□). k is the first-order rate vs constant for the photoprocess as deduced from the slope of the semilog plot. 
 
 
Compound Φ∆ 
18 0.33 
23 0.66 
19 0.36 
24 0.62 
 
Table 13. Singlet oxygen quantum yield (Φ∆)for the photosensitizers 18, 19, 23 and 24. 
 
k = 3,30758 10-4 (s-1) 
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The investigated Re-porphyrin conjugates showed moderate (Φ∆ = 0.36 for 19) to good (Φ∆ = 
0.62 for 24) singlet oxygen quantum yields. Interestingly these Φ∆ values are not significantly 
different from those of the corresponding parent porphyrins (Φ∆ = 0.33 and Φ∆ = 0.66 for the 
precursors of 18 and 23 respectively) (Table 13). Those data suggest that the peripheral Re 
moieties do not affect by the Φ∆ significantly. 
However the phototoxicity of the investigated porphyrins does not seem to be directly related 
to this parameter. In fact, 18 shows the higher potency in the phototoxic assay at low light 
doses, despite 18 has a lower singlet oxygen quantum yield. 
On the contrary, 23 displays the opposite behavior, in fact it shows the higher value of singlet 
oxygen quantum yield and at the same time the lower potency in the phototoxic assay at low 
light doses. 
It is worth noting that Φ∆ values are determined in ethanol solution and that most likely other 
parameters (e.g., hydrophobicity, cell uptake, ...) play a more significant role in determining 
the phototoxic activity of these conjugates under in vitro conditions. 
 
3.3.5. Photostability of Compounds 
 
The photostability of the various porphyrin derivatives is shown in Table 14. In all cases, 
exposure of the porphyrins to red light caused a modest decrease in the intensity of the visible 
absorption bands, which is indicative of a photobleaching process.165 The data in Table 14 
clearly suggest that all compounds have a high photostability under the conditions used for 
the PDT tests. Furthermore the absorbance decrease involved all the envelope of visible bands 
of the compounds indicating that the photoprocess induces a destruction of the aromatic 
macrocycle with no formation of new visible light-absorbing products. 
The reduced extent of photodegradation exhibited by compounds 18, 23, and 19 and 24 would 
guarantee that the concentration of the photoactive principle undergoes no important changes 
during the required irradiation time in case of phototherapeutic applications. 
 
 irradiation time (min)  
Cmp 0 1 2 5 10 15 20 30 
18 100 100 100 99 99 99 99 98 
23 100 100 100 100 99 99 99 99 
19 100 100 99 99 98 98 97 93 
24 100 100 100 98 97 97 97 96 
 
Table 14. Photostability percentage of the photosensitizers after irradiation with red light (590-700 nm) for 
different period of time. 
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3.3.6. Conclusions 
 
The water soluble porphyrins 18, 19, 23 and 24 previously synthesized were investigated as 
potential PDT agents. 
Uptake studies time- and concentration-dependent on HeLa cells revealed that for Re(I)-
porphyrin 19 and for its parent compound 18 the uptake at 10µM -100 µM is comparable after 
24h. Interestingly, the uptake of Re(I)-porphyrin (24) is 4 times higher compared to its parent 
porphyrin 23, suggesting a different mechanism of biological interaction under in vitro 
conditions. 
In vitro cell growth inhibition toward HeLa cells revealed no cytotoxicity. In fact they showed 
IC50 values higher than 100 µM, the maximal concentration used in this experimental setting 
after 24 h of exposure. 
Then the phototoxic effects on HeLa cells was evaluated upon illumination. Conjugates 18, 
19, 23 and 24 became ca. 10 times more cytotoxic after irradiation with visible light (590-700 
nm) at mild light doses ( 5 J/cm2) and proved to have from moderate to good singlet oxygen 
quantum yields. The most potent compounds 18 and 19 were active at micromolar 
concentration and very low light dose (1 J/cm2), Taken together, those results suggest that 
those porphyrins are promising sensitizers for the PDT of tumors. 
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3.4. Expermental Section 
 
All chemicals and solvents were of reagent grade and were used without purification unless 
stated otherwise. 
The organometallic precursor [Re(CO)3(Br)2][Et4N]2was prepared according to a published 
method. 166  The radioactive synthon [99mTc(CO)3(H2O)3]+ was prepared as described 
elsewhere 133 or using the Mallinckrodt IsoLink kit. Na99mTcO4 in saline solution was eluted 
from a 99Mo/99mTc generator Ultra-Techne Kow from Mallinckrodt in 0.9% saline solution. 
4-Methyl-2,2'-bipyridine-4'-carboxylic acid (bpyAc),155 4-formyl benzoate 141 and N-Boc-
ethylenediamine 167 were prepared according to the published procedures. 
Mono and bidimensional NMR spectra were recorded on a Varian 500 spectrometer or on a 
Bruker 400 and 500 spectrometers at 400/500 respectively. All spectra were run at ambient 
temperature. In all the solvents chemical shifts were referenced to the peak of residual 
nondeuterated solvent (δ =7.26 for CDCl3, 3.31 for CD3OD, 2.50 fordmso-d6). UV-vis spectra 
were obtained at T = 25°C on aJasco V-500 UV-vis spectrophotometer equipped with a 
Peltiertemperature controller, using 1.0 cm path-length quartz cuvettes (3.0 mL). Electrospray 
ionisation mass spectra (ESI-MS) were recorded on a Merck Hitachi M-8000 spectrometer in 
the positive ion mode using methanol as the solvent. Fluorescence spectra were recorded on a 
Perkin-Elmer LS50B fluorescence spectrometer. 
Column chromatography was performed on silica gel 60 Ǻ (Merck, 230-400 mesh ASTM), 
eluting with dichloromethane/methanol mixtures as specified below. 
RP-HPLC analyses were performed on a Perkin-Elmer system (LCPump, Series 200) coupled 
to a UV–visdetector (LC 290; Perkin-Elmer) and a γ detector (LB 507 or LB 509; Berthold, 
Germany) for the99mTc compounds. Analytical separations were performed on Macherey-
Nagel EC 250/3 Nucleodur C18 Gravity (7 µm particle size, 100 Å pore size, 40 × 250 mm) 
or Waters XTerra RP8 columns (5 µm particle size, 1 × 100 mm) with a flow rate of 0.5 
mLmin-1. 
The gradients used for analyses were as follows: 
Gradient A (MeOH): 0-3 min 85% A, 3.1-13 min 85-0% A, 13-20 min 0% A, 20-25 min 0-
85% A 25-30 min 85% A, flow rate 0.5 mLmin-1; Gradient B (MeOH): 0–3 min, 100% A; 3–
3.1 min, 100-75% A; 3.1–9 min, 75% A;9.1-20 min, 75-0% A, 20–25 min, 0%A; 25–25.1 
min 0-100% A; 25.1–30 min 100% A, flow rate 0.5 mLmin-1. Gradient C (MeCN): 0-3 min 
85% A, 3.1-13 min 85-0% A, 13-20 min 0% A, 20-25 min 0-85% A 25-30 min 85% A, flow 
rate 0.5 mLmin-1. 
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HPLC solvents were 0.1% trifluoroacetic acid (solvent A) and MeOH  HPLCgrade (solvent 
B).  
Preparative HPLC was performed on a Varian ProStar system by using a Macherey-Nagel VP 
250/40Nucleosil RP C18 HD 100 Å column and a flow rate of 40 mLmin-1. The solvents were 
0.1% trifluoroaceticacid (solvent A) and methanol or acetonitrile (solvent B). 
 
Synthesis of Compounds. 
 
meso-5-(4'-Methoxyphenyl)-10,15,20-tris(4'-pyridyl)porphyrins or4'TrPyMeP (14) 
 
In a 250 ml round-bottom flask, equipped with an efficient mechanical stirrer, were placed 
consecutively: propionic acid (120 mL), methyl 4-formylbenzoate (1.13 g, 6.88 mmol, 1 
equiv.) and 4-pyridinecarboxaldehyde (2.03 mL, 20.65 mmol, 3equiv.). After the dissolution 
of the methyl 4-formylbenzoate, pyrrole (1.94 mL, 27.53mmol, 4 equiv.) was added dropwise 
(ca. 4 min) to the mixture. The reaction mixture was then refluxed for 2 h in the dark. The 
solvent was partially distilled under reduced pressure to 40 ml. After the addition of a mixture 
of ethylene glycol and methanol (60 mL, 1:1), it was stored at -18°C for 12 h.The purple 
precipitate was removed by filtration, thoroughly washed with coldmethanol, and dried in 
vacuo at room temperature.Yield 0.91g (18%). 
Thin-layer chromatography of the crude product (dichloromethane/methanol 98:2) showed it 
to be a mixture of the six possible porphyrin isomers: 4'-TMeP (Rf = 0.95),4'-MPyTrMeP(Rf= 
0.77), 4'-transDPyDMeP (Rf = 0.55), 4'-cisDPyDMeP (Rf = 0.43), 4'-TrPyMMeP (Rf = 0.33) 
and 4'-TPyP (Rf = 0.13).115 
The isomers were separated using two columns chromatography in series.(, 
dichloromethane/methanol 98:2). The fifth eluted band was identifiedby TLC as 5,10,15,20-
tetrakis(4'-pyridyl)porphyrin (194 mg, 8%). 
The identifications of the porphyrin was confirmed by comparing its Rf value with those of 
the crude mixture and by 1H NMR spectroscopy. 
 
1HNMR (CDCl3, δ): -2.89 (br s, 2H, NH), 4.12 (s, 3H, CH3), 8.17 (d, 6H, J = 5.6 Hz, 
H3,5Py), 8.32 (d, 2H,oPh, J=8.1 Hz), 8.45 (d, 2H,mPh, J=8.1Hz), 8.86 (s, 8H, βH), 9.05 (d, 
6H, J = 5.6 Hz, H2,6Py). 
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5-(4'-Carboxyphenyl)-10,15,20-tris(4'-pyridyl)porphyrin(4'TrPyMOHP) (15) 
 
A 2.4 mLamount of a 40% KOH aqueous solution was added to a40 mg amount of 14 
(0.051mmol) dissolved in 40mL of a 2:1 THF/CH3OH mixture. The reaction mixture was 
shielded from light andstirred at 40 °C for 1 h.At reaction completion (TLC, CH2Cl2/MeOH 
90:10), the mixture was acidified with conc. HCl (pH 5), and extracted with THF/CH2Cl21:1 
(4 ×50 mL). After the evaporation of the organic fraction, the solid was washed with 
petroleum ether, collected by filtration and vacuum dried. Yield: 38.4 mg, 98%.  
 
1HNMR(dmso-d6,δ): -3.00 (s, 2H, NH), 8.27 (d, 6H, J = 5.6 Hz, H3,5Py), 8.37(m,4H,mPh + 
oPh), 8.90 (d, J = 2.4 Hz, 8H, βH), 9.05 (d, 6H, J = 5.6 Hz, H2,6Py).  
RP-HPLC Waters XTerra RP8 (Gradient A): 13.59 min;ESI-MS m/z: 661.5 (MH)+.TLC: 
Rf=0.28 (CH2Cl2/MeOH 90:10). 
 
(2-Aminoethyl)-(2-(tert-butoxycarbonyl-(2-tert-
butoxycarbonylaminoethyl)amino)ethyl)carbamic acid tert-butyl ester (16) 
 
A procedure similar to that described in literature 168was used with the following parameters: 
2-acetyl-5,5-dimethyl-cyclohexane-1,3-dione (Dde) (300mg,1.65 mmol) in EtOH (5 mL) was 
slowly added to an ice-cooled solution of N,N'-bis-(2-aminoethyl)-ethane-1,2-diamine 
(482mg,491 µL, 3.29 mmol) dissolved in EtOH (5 mL). The reaction mixture was stirred 
overnight at rt.  
At reaction completion (TLC, CH2Cl2/MeOH 80:20), the solvent was distilled under reduced 
pressure and the resulting oil was stored at -18°C for 12 h. 
The crude product (2.06 g) was dissolved in EtOH (10 mL) and cooled to 0°C. Di-tert-butyl-
pyrocarbonate((BOC)2O, 3.55 g) in EtOH (10 mL) was then slowly addedto the reaction 
mixture, which was subsequently stirred overnight at rt. Excess of (BOC)2O was quenched 
with H2O (1 mL) and the mixture was stirred at 50°C for 30 min. A 25% aqueous hydrazine 
solution (3.8 mL) was then added to the reaction mixture and stirring was continued for 4 hat 
rt.  
The solvent was removed in vacuo. The resulting oil was purified by column chromatography 
using two columns chromatography in series (dichloromethane/methanol/NH4OH 100:10:1) 
to yield a colorless oil (118mg, yield: 16% based on the amountof Dde). 
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1H NMR (CDCl3, δ): 1.42 (s, 9H, Boc); 1.46 (s, 18H, Boc), 2.23 (br s, 2H, NH2), 2.83 (t, 2H, 
CH2NH2), 3.32 (br, 10H, CH2), 4.88 (br s, 1H, NHCO), 5.05 (br s, 2H, NHCO). 
RP-HPLC Waters XTerra RP8 (Gradient A): 11.41 min.TLC: Rf=0.19 (CH2Cl2/MeOH/25% 
NH4OH, 100:10:1). 
 
(17) 
 
A 17.4 mg amount of EDCI (0.090mmol, 1.5 equiv.) and a 12.3 mg amount of HOBt 
(0.090mmol, 1.5 equiv.) were added to a solution under nitrogen of TrPyMOHP 15 (40mg, 
0.060mmol) dissolved in 4 mLof anhydrous DMF. To this solution, after stirring for 45 min, a 
40.2 mg amount of 16 (0.090mmol) and a 8.0mg amount of dimethylaminopyridine (DMAP) 
(0.066mmol, 1.1 equiv.) dissolved in 2 mL of anhydrous DMF were added. The reaction 
mixture was shielded from light and stirred at rt for 24 h. At reaction completion (TLC, 
CH2Cl2/MeOH 90:10), the solvent was distilled under reduced pressure. The resulting dark 
semisolid was dissolved in 3 mL of CH2Cl2 and purified by column chromatography using 
CH2Cl2/MeOH (90:10) as eluent. The workup afforded 62.55 mg of the product as a purple 
solid (yield95%). 
 
1H NMR (CDCl3, δ): -2.89 (br s, 2H, NH), 1.47 (m, 27H, CH3 Boc), 3.56 (m, 12H,CH2), 4.78 
(br s, 1H, NHCO), 4.98 (br s, 1H, NHCO), 5.51 (br s, 1H, NHCO), 8.16 (d, 6H, J = 5.1 Hz, 
H3,5Py), 8.25(s,4H, mPh + oPh), 8.86 (s,8H, βH), 9.06 (d, 6H, J = 5.1 Hz, H2,6Py). 
RP-HPLC WatersXTerra RP8 (Gradient A): 12.62 min. ESI-MS m/z: 1090.6 (MH)+.TLC: 
Rf=0.56 (CH2Cl2/MeOH 90:10). 
 
(18) 
 
A 300 µL amount of trifluoroaceticacid (TFA) was added to a solution of 17 (63.45 mg, 
0.058mmol) dissolved in 5 mL of anhydrous CH2Cl2. The mixture was stirred at room 
temperature for 3h in the dark. At reaction completion (TLC, CH2Cl2/MeOH 90:10), the 
solvent was completely removed on a rotary evaporator to give a purple solid of the title 
porphyrin as trifluoroacetic salt. The product was used in the following step without further 
purifications. 
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1H NMR (trifluoroacetic salt) (CD3OD, δ):3.09 – 3.49 (m, 10H,CH2), 3.93 (m, 2H, CH2NH2), 
8.41 (s, 4H, mPh + oPh), 8.66 (m, 6H, H 3,5Py), 9.05 (b s, 8H, βH), 9.26 (m, 6H, H 2,6Py). 
RP-HPLC Waters XTerra RP8 (Gradient A): 9.72 min.  
ESI-MS m/z: 789.4 (M)+ , 812.5 (M + Na+). 
TLC: Rf=0.65 (CH2Cl2/MeOH 90:10).UV-vis (CH3OH) λmax, nm (relative intensity): 412 
(100), 510(4.8), 543 (1.6), 587 (1.5), 642 (0.6). 
 
(19) 
 
A 20 mg amount of 18 (0.020mmol) was dissolved in a mixture of CH3OH (6 mL) and PBS 
(2 mL).To this solution a 18.2mg amount of [NEt4]2[ReBr3(CO)3] (0.023mmol) dissolved in 6 
mL of PBS (pH = 7.4).was added. After stirring at 70°C under nitrogen for 12h in the dark, 
RP-HPLC(Waters XTerra RP8, gradient A) showed the formation of the product. 
The solvent was evaporated under vacuum and the residue was redissolved in 8 mL of 
methanol. 
The crude material was purified by preparative HPLC (Nucleosil RP C18 HD 100 Å, gradient 
C) to afford 9 mg (61%) of compound 19 as a purple solid. 
 
1H NMR (CD3OD, δ): 3.42 – 3.67 (m, 8H, CH2), 3.83 – 3.90 (m, 2H, CH2), 4.04 – 4.12 (m, 
2H, CH2), 5.60 (m, 1H, CONH), 8.31 (dd, 6H, J = 5.0 Hz, H 3,5Py), 8.39 (d, 2H, J = 7.8 Hz, 
oPh), 8.32 (d, 2H, J = 7.8 Hz, mPh), 8.81 (br s, 8H, βH), 9.02 (dd, 6H, J = 5.0 Hz, H 2,6Py). 
RP-HPLC Waters XTerra RP8 (Gradient A): 11.70 min. 
ESI-MS m/z: 1060.4 (M)+ , 1099.4 (M + K+). 
UV-vis (CH3OH) λmax, nm (relative intensity): 413 (96), 511 (4.8), 543 (1.6), 588 (1.4), 642 
(0.7).  
 
(20) 
 
A procedure similar to that described above was used, with the following parameters: 30 mg 
of TrPyMOHP (15) (0.045mmol) in 3 mL of anhydrous DMF, 13.04 mg of EDCI (0.068 
mmol, 1.5 equiv.), and 9.19 mg of HOBt (0.068mmol, 1.5 equiv.). To this solution, a 16.9 mg 
amount of N-Boc-ethylenediamine (0.068mmol, 1.5 equiv.) and a 6.1 mg amount of 
dimethylaminopyridine (DMAP) (0.049 mmol, 1.1 equiv.) were added and the reaction 
mixture shielded from light and stirred for 12 h at rt. 
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The resulting solid was washed with water, dissolved in 3 mL of CH2Cl2 and purified by 
column chromatography using CH2Cl2/MeOH (90:10) as eluent. The workup afforded 35 mg 
of the product as a purple solid (yield 89%).  
 
1H NMR (CDCl3, δ): -2.90 (br s, 2H, NH), 1.40 (s, 9H, CH3Boc), 3.35 (m, 2H, CH2 spacer), 
3.63 (t, 2H,CH2 spacer), 3.74 (m, 4H, CH2 spacer), 3.85 (m, 4H, CH2 spacer), 5.04(br s, 1H, 
NHBoc), 7.06 (br s, 1H, NHBoc), 8.16 (d, 6H, J = 5.6 Hz, H 3,5Py), 8.27 (dd, 4H, mPh + 
oPh), 8.86 (br s, 8H, βH), 9.06 (d, 6H, J = 5.6 Hz, H 2,6Py). TLC: Rf=0.75 (CH2Cl2/MeOH 
90:10). 
 
(21) 
 
A 22 mg amount of 4'TrPyMetNHBocPP (20) (0.024mmol) was dissolved in DMF (3 mL). 
Subsequently CH3I (77µL, 1.23mmol, 50 equiv.) was added to the solution and the mixture 
was heated under reflux for 2 h.169 
At reaction completion (TLC: silica gel, acetic acid/MeOH/water 50:20:1), the solvent was 
completely removed on a rotary evaporator. The resulting solid was washed with diethyl 
ether, collected by filtration and vacuum dried. Yield: 30.3 mg, 97%. 
 
1H NMR(dmso-d6, δ): -3.03 (br s, 2H, NH), 1.37 (s, 9H, CH3Boc), 3.04 (m, 1H, CH2 spacer), 
3.10 (m, 2H, CH2 spacer), 3.44 (t, 2H, NHCH2 spacer), 3.59 – 3.69(m, 8H, CH2 spacer), 4.71 
(s, 9H, N-CH3),6.80 (t, 1H, NHBoc), 8.35(m, 4H, mPh + oPh), 8.93 (t, 1H, NHBoc),9.02(m, 
8H, H 3,5Py+2βH), 9,06(br s, 4H, βH), 9.15 (m, 2H, βH),9.47 (d, 6H, J = 5.6 Hz, H 2,6Py). 
RP-HPLC Waters XTerra RP8 (Gradient A): 10.07 min. TLC Rf=0.26 (acetic 
acid/MeOH/water 50:20). 
 
(22) 
 
A 150µL amount of trifluoroacetic acid (TFA) was added to a solution of 21 (40mg, 
0.031mmol) dissolved in 5 mL of anhydrous CH2Cl2.  
After stirring at room temperature for 3 h in the dark, RP-HPLC (Waters XTerra RP8, 
gradient A) showed the formation of the product. 
The solvent was completely removed on a rotary evaporator to give a purple solid of the title 
porphyrins as trifluoroacetic salt.Yield: 34.8 mg, 87%. 
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1H NMR (acetone-d6, δ): -2.87 (br s, 2H, NH), 3.72 (m, 2H, CH2spacer), 3.73 – 3.78 (m, 2H, 
CH2 spacer), 3.80 (m, 4H,CH2 spacer), 3.94 (m, 2H, CH2 spacer), 4.00 (m, 2H, CH2 spacer), 
5.01 (s, 9H, N-CH3), 8.33 (d, 2H, mPh + oPh), 8.43 (d, 2H, mPh + oPh), 9.07 (m, 2H, βH), 
9.15 (d, 6H, J = 5.3 Hz, H 3,5Py), 9.28 (m, 6H, βH), 9.67 (d, 6H, J = 5.6 Hz, H 2,6Py). 
 
1H NMR (CD3OD, δ): 3.69 - 3.88 (m, 8H, CH2 spacer), 3.93 (m, 2H, CH2 spacer), 4.02 (m, 
2H,CH2 spacer), 4.98 (s , 9H, NCH3), 8.33 (d, 2H, mPh + oPh), 8.41 (d, 2H, mPh + oPh), 9.12 
(d, 6H, J = 5.3 Hz, H 3,5Py), 8.83 - 9.47 (m, 8H, βH), 9.63 (d, 6H, J = 5.6 Hz, H 2,6Py). 
RP-HPLC Waters XTerra RP8 (Gradient A): 13.70 min. TLC Rf=0.16 (acetic 
acid/MeOH/water 50:20). 
 
(23) 
 
A 4.71 mg amount of bpyAc (0.022mmol, 2 equiv.) a 4.19 mg amount of CDMT 
(0.024mmol, 2.2 equiv.) were dissolved in DMF (3 mL). After dissolution, the mixture was 
cooled at 0°C and N-methylmorpholine (2.61 µl, 0.024mmol, 2.2 equiv.) was added.  
After stirring for 4 h at 0°C, a solution of 22 (14 mg, 0.011mmol) and N-methylmorpholine 
(2.65 µl, 0.024mmol, 2.2 equiv.) in 1 mL of anhydrous DMF was added. The reaction mixture 
was stirred for 24 h at rt in the dark. At reaction completion (TLC, acetic acid/MeOH/water 
50:20:1) DMF was removed under reduced pressure. The residue was washed with diethyl 
ether, placed into a thimble of a Soxhlet apparatus and continuously extracted with 300 ml of 
anidrous CH2Cl2 for 12h. The residue on the thimble was dissolved in 5 ml of isopropanol and 
vacuum dried to obtain the title compound. Yield: 12.83 mg (85%). 
 
1H NMR (CD3OD, δ): 1.52(s, 3H, CH3), 3.66 (m, 2H, CH2 spacer), 3.79 – 3.82 (m, 10H, CH2 
spacer), 6.22 (d, J = 4.8,1H, H5' bpy), 7.33 (s, 1H, H3' bpy), 7.62 (d, J = 4.8,1H, H6' bpy), 
7.67 (dd, 1H, J =1.50, 4.96 Hz, H5), 8.24 (m, 4H, mPh + oPh), 8.33(t, 1H, NHCO bpy), 8.39 
(s, 4H, H3, bpy), 8.62 (d, 4H, J = 4.96 Hz, H6), 8.98 (d, 6H, J = 5.3 Hz, H 3,5Py), 8.89 - 9.28 
(m, 8H, βH + NHCO), 9.39 (d, 6H, J = 5.6 Hz, H 2,6Py). 
RP-HPLC Waters XTerra RP8 (Gradient A): 9.95 min; ESI-MS m/z: 1032.5 (M)+ , m/z: 
(z=2): 516.5. 
UV-vis (CH3OH) λmax, nm (ε× 10-3, dm3 mol-1cm-1): 426 (124), 518 (7.2), 555 (3.7), 591 
(2.8), 647 (1.0). 
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(24) 
 
A 10 mg amount of 23 (0.007mmol) was dissolved in a mixture of CH3OH (6 mL) and PBS 
(2 mL). 
To this solution a 7.86 mg amount of [NEt4]2[ReBr3(CO)3] (0.010mmol, 1.) dissolved in 6 mL 
of PBS (pH = 7.4) was added. After stirring at 70°C under N2 for 12h in the dark, RP-HPLC 
(Waters XTerra RP8, gradient A) showed the complete product formation. KSCN (0.011 
mmol, 1.14 mg) dissolved in little H2O, was added and the solution heated to 70 °C for 2 h to 
ensure complete formation of the product. 
The solvent was evaporated under vacuum and the residue was redissolved in 8 mL of 
methanol. 
The crude material was purified by preparative HPLC (Nucleosil RP C18 HD 100 Å, gradient 
C) to afford 8 mg (65%) of compound 24 as a purple solid. 
There are two linkage isomers with a SCN- ligand, i.e., thiocyanato conjugate Re-S-SCN 
which converts to the thermodynamically favored N-bound isothiocyanato conjugate Re-N-
NCS. The spectral and analytical data of 24 prepared in the present study were consistent with 
those previously reported. 170 
 
RP-HPLC Waters XTerra RP8 (Gradient A): 10.27 min  
ESI-MS m/z: 1359.5 (M)+ , m/z: (z=2): 680.3calcd for [M]+ Isotopic distribution: 1361,38 
(100,0%), 1362,39 (73,6%), 1359,38 (56,4%), 1360,38 (44,0%). 
1H NMR (t = 0, CD3OD, δ): 2.32 (s, 3H, CH3), 3.57 – 3.86 (m, 12H, CH2 spacer),4.82 (9H, 
N-CH3), 7.28 (d, J = 6.06, 1H, H5' bpy), 7.94 (dd, 1H, J =1.50, 4.96 Hz, H5), 8.30 (m, 5H, 
mPh + oPh + H3' bpy), 8.42 (d, J = 6.06, 1H, H6' bpy), 8.70 (d, 1H, J = 4.96 Hz, H6), 8.96 
(m, 7H, J = 5.3 Hz, H 3,5Py +H3, bpy), 8.89 - 9.28 (m, 8H, βH), 9.39 (d, 6H, J = 5.6 Hz, H 
2,6Py). 
UV-vis (CH3OH) λmax, nm (relative intensity): 427 (100), 518 (11.7), 555 (6.9), 591 (4.6), 647 
(2.0).  
 
Labelling with 99mTc 
 
Na[99mTcO4] was eluted from a 99Mo/99mTc generator(Mallinckrodt, Petten, The Netherlands) 
using 0.9% saline. 
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The solution of the precursor [99mTc(H2O)3(CO)3]+was prepared from [99mTcO4]- (1 ml eluate) 
using aborocarbonate kit containing K2CO2BH3 (4 mg, 0.029mmol), disodium tartrate 
dihydrate (7 mg, 0.030 mmol) and borax decahydrate (7 mg, 0.018 mmol) or with an Isolink 
kit®(Mallinckrodt-Tyco, Inc.), according to a previously described procedure.132 (Solutions of 
the precursor [99mTc(H2O)3(CO)3]+were prepared from [99mTcO4]– as described in the 
literature or by using the Isolink® kit) 
After stirring for 20 min at 95°C, the mixture was cooled down, neutralised with 0.1 M HCl 
and the pH was adjusted to 7.4 byadding 0.1 M phosphate buffer (100–200ml). 
Complete formation of [99mTc(H2O)3(CO)3]+ was confirmed by HPLC analysis using RP-
HPLC HPLC coupled with gamma detector after cooling to r.t. (Macherey-Nagel EC 250/3 
Nucleodur C18 Gravity, Gradient B). Rt for [99mTc(H2O)3(CO)3]+ = 5.25 min 
 
In a nitrogen-purged glass vial, 100 µl of a PBS solution of the porphyrin (10−4 M for 18 and 
10-5 for 23), was added to 900 µl of the solution of fac-[99mTc(CO)3(H2O)3]+ previously 
prepared. The mixture was allowed to heat in the dark at 50°C for 30 min. 
HPLC analysis with γ-detection was performed to verify full conversion of the 
[99mTc(H2O)3(CO)3]+(Waters XTerra RP8 , Gradient A). Rt for [99mTc(H2O)3(CO)3]+ = 3.53 
min, Rt for 19a = 11.12 min; Rt for 24a = 10.46 min. 
 
Determination of the quantum yield for singlet oxygen generation 
 
The quantum yield (Φ∆) of singlet oxygen generated by compounds 18, 19 and 23 and 24 
upon photoexcitation was measured using 9,10-dimethylanthracene (DMA) as substrate.120 
Typically, 1.5 ml of a 20 µM ethanol solution of DMA and 1.5 ml solution of the porphyrin 
(0.4 A at Soret band maximum, ≈ 10-6 M) in ethanol were placed in a quartz cuvette of 1 cm 
optical path and irradiated with 590–700 nm light for different periods of time at 20 ± 2 °C 
under gentle magnetic stirring. The fluence-rate was 100 mW/cm2. The DMA fluorescence 
emission was recorded in the 380–550 nm wavelength range with excitation at 360 nm. The 
first-order rate constant of the photo-oxidation of DMA by 1O2was obtained by plotting ln 
F0/F as a function of the irradiation time t, where F0 and F represent the fluorescence intensity 
at time 0 and at time t, respectively. The rate constant was then converted into 1O2 quantum 
yield by comparison with the rate constant for DMA photo-oxidation sensitized by 
haematoporphyrin (Hp), for which Φ∆ was shown to be 0.65.120 
 
126 
 
Photostability studies 
 
The stability of the porphyrin to red light irradiation was determined by preparing a solution 
of the appropriate compound in ethanol with an absorbance of 0.4 at the maximum absoption 
peak. This solution was placed in a quartz cuvette with a1 cm optical path and irradiated at 25 
°C for different periods of time under gentle magnetic stirring by using 590-700nm light 
(Techno Light 270, Karl Storzsource, 100 mW/cm2). After each irradiation, the absorbance 
spectrum was recorded by a Jasco V-500 UV-vis spectrophotometer equipped with a Peltier 
temperature controller using 1.0 cm path-length quartz cuvettes (3.0 mL). The value of the 
absorbance at the maximum peak at time 0 was compared with those recorded at the various 
irradiation times. 
 
Tumour cell lines for in vitro tests 
 
The human cervix epitheloid carcinoma HeLa cell line (ATCC, CCL2, Rockville, Maryland) 
was maintained in Dulbecco’s modified Eagle’s medium (EuroClone®, Devon, UK) 
supplemented with 5% fetal bovine serum (FBS, Gibco, Invitrogen™, Paisley, Scotland, UK), 
2 mM L-glutamine (EuroClone®, Devon, UK), and 100 IU/ml penicillin and 100 µg/ml 
streptomycin (EuroClone®, Devon, UK).  
The cell line was kept at 37 °C in a CO2 incubator with 5% CO2 and 100% relative humidity. 
Cells from a confluent monolayer were removed from flasks by a trypsin-EDTA solution. 
Cell viability was determined by the trypan blue dye exclusion test. For experimental 
purposes cells were “grown" in multiwell culture plates. 
All experiments were carried out in complete medium containing 5% FBS (CM-5%). 
 
In Vitro Cell Uptake of Re-Porphyrins Conjugates.  
 
HeLa cells were plated at 10000 per well in a Costar 96 well plate (Euroclone, Devon, UK) 
and allowed to grow for 24 h. Compound’s stocks were freshly prepared in dimethylsulfoxide 
(Sigma, St. Louis, MO, USA) at a concentration of 10-2 M and then diluted into medium to 
final working concentrations. Cells were exposed to variable concentrations of each 
compound (0.1-100 uM) for 0, 1, 2, 4, 8, and 24 h. At the end of the incubation time, the 
medium containing treatment was removed and cells were washed with 200 µl of PBS. Cells 
were harvested upon addition of 100 µl of 0.25% Triton X-100 (Sigma, St. Louis, MO, USA) 
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in PBS. To determine the compounds uptake, fluorescence emission was read at 430/670 nm 
(excitation/emission) using a Tecan Infinite F 200 plate reader (Tecan Austria GmbH, Grodig, 
Austria). Experiments were conducted in quadruplicate and repeated tree times. 
 
Determination of Cell Cytotoxicity.  
 
Cell growth inhibition was determined by the MTT viability test.171 Cells were sown at 10000 
per well on 96- well plates and allowed to grow 24 h. Cells were incubated for 1 h, 2h, 4h and 
24h with variable concentrations (0.1-100 µM) of the appropriate compound, obtained by 
serial dilutions in CM-5% of stocks freshly prepared in dimethylsulfoxide (Sigma, St. Louis, 
MO) at 10-2 M concentration. Maximum dmso concentration in the cell incubation medium 
was ≤ 0.3% v/v. Cell toxicity analysis was performed at the end of the incubation time. 
Briefly, MTT dissolved in PBS (5 mg mL-1) was added (10 µL per 100 µL of medium) to all 
wells and the plates were then incubated at 37 °C with 5% CO2 and 100% relative humidity 
for 4 h. After this time, the medium was discarded and 200 µL of dmso were added to each 
well according to the method of Alley et al.128 Optical density was measured at 570 nm on a 
SpectraCount Packard (Meriden, CT) instrument. IC50 values were calculated from dose-
effect curves with GraphPad Prism version 4.03 for Windows (GraphPad Software, San 
Diego, CA). Experiments were conducted in quadruplicate and repeated tree times. 
 
Determination of Cell Phototoxicity. 
 
Cells were sown at 10000 per well on 96-well plates and allowed to grow 24 h. Then, cells 
were incubated with concentrations from 0.1 to 100 µM of the appropriate compound, 
obtained by serial dilutions in CM-5% of stocks freshly prepared in dimethylsulfoxide 
(Sigma, St. Louis, MO) at a concentration of 10-2 M, for 24h. Maximum dmso concentration 
in the cell incubation medium was ≤ 0.3% v/v. Thereafter, the media containing compounds 
were replaced with drug-free medium and cells were irradiated at 590-700 nm at a fluence 
rate of 9 mW/cm2 and light doses ranging from 1 to 10 J/cm2. This wavelength interval was 
isolated from the emission of a halogen lamp (Techno Light 270, Karl Storz) by the insertion 
of broadband optical filters. Control experiments performed in the absence of any 
photosensitizer indicated that light doses up to 10 J/cm2 cause no evident cell damage. A plate 
similarly treated, but not exposed to light was used as reference for the dark cytotoxicity in 
the same experimental conditions. 
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Analysis of cell phototoxicity using the MTT assay as described above was performed after a 
further incubation of 24 h after irradiation and compared to the values of control cells without 
light irradiation. Experiments were conducted in quadruplicate and repeated tree times. 
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